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Among the three isoforms of Peroxisome Proliferator-Activated Receptors (PPARs) (-γ, -α 
and –δ), PPARγ is the isoform that is most commonly overexpressed in a plethora of cancer 
cell types. Cancer-specific overexpression of this nuclear receptor has rendered it an attractive 
therapeutic target. As such, experimental evidence have accrued in the past decade to 
demonstrate promising antineoplastic effects of PPARγ agonists, which are represented by the 
naturally-occurring ligand 15d-PGJ2 and synthetic antidiabetic agents known as the 
thiazolidinediones (TZDs). These conventional agonists, however, have been historically 
plagued with safety and potency issues. Moreover, studies using these agents to decipher 
exact mechanisms of PPARγ-induced cell cancer death are often confounded by PPARγ-
independent production of ROS. Clinical and experimental limitations of these pre-existing 
compounds underscore a critical need for identification and development of new-generation 
PPARγ activators. Here we identified a novel small molecule PPARγ activator, named Pr-
MPO, which is structurally unrelated to TZDs. Pr-MPO-triggered PPARγ transcriptional 
activity was confirmed not only by transfection of reporter constructs containing peroxisome 
proliferator-response element (PPRE), but also functionally validated by transcriptional 
modulations of a panel of PPARγ bona fide gene targets in cancer cells. Pr-MPO was 
dependent upon PPARγ expression and transactivation for its antineoplastic effects, and was 
demonstrated to induce effective cell kill only in PPARγ-overexpressing cancer cells while 
exerting minimal effect on their non-PPARγ-expressing normal counterparts. Even though 
pre-existing agonists were also shown to exert such anticancer functions, Pr-MPO possesses 
numerous advantages over these compounds, namely, a prominent improvement in potency, 
lack of off-target ROS/RNS production, consistent efficacy in different serum conditions, and 
lastly, the ability to engage a novel death pathway that is not mediated solely by classical 
apoptosis, but rather dependent on autophagic induction. Indeed, autophagy inhibition by both 
pharmacological inhibitor 3-methyl-adenine (3-MA) and silencing of autophagy related genes 
(Atg) restored cancer cell viability, long-term clonogenic abilities and abrogated biochemical 
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hallmarks of apoptosis. Our findings thus support the notion of an alternative death paradigm 
where autophagy precedes and is casually linked to the subsequent onset of programmed cell 
death with apoptotic features. The discovery of this physiological effect of Pr-MPO in cancer 
cells sparked further investigations to delineate a previously unestablished regulatory role of 
PPARγ in mounting a coordinated autophagic response that is responsible for cellular demise. 
In this model, we demonstrate that PPARγ can act as an integral mediator of autophagy, as 
evidenced by the dependence of Pr-MPO-induced autophagic cell death upon PPARγ 
transcriptional activity. Further studies identified BNIP3, NHE-1 and MnSOD as PPARγ 
transcriptional targets acting as molecular links between PPARγ activation and autophagy 
induction. Overall, data from our study provide a compelling rationale for Pr-MPO to be 
developed as a drug candidate or lead compound in cancer therapeutics. Moreover, utilization 
of Pr-MPO as an experimental tool also reveals a novel approach of cancer-specific 
autophagy induction, whereby a transcription factor that is selectively overexpressed in 
cancer is targeted to orchestrate autophagic cell death, in order to circumvent the potential 
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1 Peroxisome proliferator-activated receptors (PPARs) 
1.1 From peroxisomes to peroxisome proliferators (PP) to peroxisome 
proliferator-activated receptors (PPARs) 
Peroxisomes, also known as glyoxysomes or microbodies in plants, are organelles 
ubiquitously present in eukaryotes that perform diverse metabolic functions. A majority of 
these functions are related to lipid metabolism, such as β-oxidative degradation of fatty acid, 
synthesis of cholesterol and other isoprenoids, and synthesis of glycerolipid (plasmalogen) 
(Bjornsson and Olsson, 2006; Wanders and Tager, 1998). Peroxisomes are also involved in 
detoxification of hydrogen peroxide, alcohol oxidation, transaminations, purine and 
polyamine catabolism (Tolbert, 1981), as well as gluconeogenesis in liver and kidney. The 
morphology of peroxisomes also varies depending on cell type, but typically, they are 
spherical, 0.5-1.5µm in diameter (in a human cell) and possess a single boundary lipid bilayer 
membrane enclosing a granular matrix of soluble proteins (Eckert and Erdmann, 2003).  
 
Remarkably, peroxisomes can be induced to increase both in size and number in response to a 
group of structurally unrelated compounds. This category of compounds, termed peroxisome 
proliferators (PP) , includes the fibrate class of hypolipidemic agents, phthalate plasticizers 
and herbicides (Reddy et al., 1982). The first identified peroxisome proliferator is chlofibrate, 
which was observed to cause hepatomegaly in rats, accompanied by proliferation (increase in 
size and number) of peroxisomes with an enhanced capacity for fatty acid metabolism (Hess 
et al., 1965; Svoboda and Azarnoff, 1966). In addition, dietary or physiological conditions 
such as high-fat diet and cold acclimatization can also induce proliferation of peroxisomes 
(Kliewer et al., 1994).  
 
Interestingly, administration of peroxisome proliferators has also been associated with an 
increased transcription of genes implicated in peroxisomal β-oxidation of long-chain fatty 
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acids and genes of the cytochrome P450 IV family (Hardwick et al., 1987; Kimura et al., 
1989; Lalwani et al., 1983; Sharma et al., 1989). Taken together with a study revealing a 
peroxisome proliferator binding protein in rat liver (Lalwani et al., 1983), the ability of 
peroxisome proliferators to regulate gene transcription led to the hypothesis that they function 
similarly as steroid hormones. Finally, a breakthrough in mechanistic understanding of 
peroxisome proliferation was achieved when the first mammalian receptor activated by 
peroxisome proliferators was cloned in 1990 (Issemann and Green, 1990). This receptor, 
named peroxisome proliferator-activated receptor-α (PPARα), belongs to the nuclear receptor 
(NR) superfamily, other members of which include receptors for estrogen, thyroid hormone, 
vitamin D3, retinoids and glucocorticoid (Wahli et al., 1995). Shortly after the identification 
of PPARα, two additional isoforms of the receptor were cloned and characterized, designated 
as PPARγ and PPARδ (Dreyer et al., 1992; Kliewer et al., 1994). Paradoxically however, 
neither is PPARγ nor PPARδ (otherwise known as PPARβ) implicated in peroxisome 
proliferation. Despite the misnomer in nomenclature, these three receptor isoforms represent 
the PPARs.  
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1.2 Structural domains and mechanism of action of PPARs 
Akin to other members of the NR superfamily, PPARs are ligand-activated transcription 
factors responsible for modulation of target gene expression. PPAR proteins display a typical 
modular NR structure composed of four functional domains, namely A/B, C, D and E/F 
(Figure A). The amino-terminal A/B domain includes a ligand-independent transactivation 
function-1 (AF-1) that is amenable to phosphorylation by MAPKs (Werman et al., 1997), 
while the C region represents a DNA binding domain (DBD) (Kliewer et al., 1992) . The D 
domain is the docking site of cofactors, whereas the E/F domain constitutes the ligand-
binding domain (LBD), where a ligand-dependent activation function 2 (AF-2) is located 
(Berger and Moller, 2002). Among these domains, the DBD containing two zinc fingers is the 
most conserved across the three receptor isoforms (Berger and Moller, 2002), while the LBD 
is poorly conserved between them. The LBD of PPAR consists of 11-13 α-helices that fold to 
form a hydrophobic ligand-binding “pocket”; the relatively large size of this “pocket” as 
compared to that of other NRs may account for diversity of structurally dissimilar ligands 
(Nolte et al., 1998). Importantly, ligand-dependent activation of PPAR constitutes the primary 
mode of gene transcription modulation by this NR (Figure B). Upon ligand-binding at the 
LBD of a PPAR, a conformational change in the AF-2 helix is induced, which in turn 
facilitates heterodimerization of the receptor with its binding partner, retinoid X receptor 








1.2.1 Heterodimerization with RXR 
The strict requirement of PPARs to operate as heterodimers with RXR (Miyata et al., 1994) 
sets them apart from the steroid hormone receptors, which function as homodimers. Similar to 
the PPARs, there are three distinct subtypes of RXRs, namely, RXRα, β and γ, all of which 
are activated by the vitamin A derivative, 9-cis-retinoic acid. Even though all three RXR 
subtypes are capable of binding PPARs (Mangelsdorf et al., 1992), they may modulate DNA-
binding activity of PPARs differently. Specifically, when RXRγ is the heterodimeric partner 
of PPAR, binding to target sequences with strong affinity is favoured. Meanwhile, 
heterodimerization with RXRα facilitates binding to weak affinity response elements 
(Desvergne and Wahli, 1999).  
 
Notably, RXR binding to RXR-specific synthetic ligands “rexinoids” can also activate the 
heterodimeric complex, exerting anti-diabetic effects in mouse models of Type II diabetes in 
a way that resembles activation by PPAR agonists (Mukherjee et al., 1997a). In addition, 
concurrent administration of PPARγ ligands and RXR cognate ligands was reported to elicit 
synergistic transcriptional effect (Schulman et al., 1998). Thus, the PPAR:RXR complex 
functions in response to ligands specific for either subunit of the heterodimer. Patently, the 
intricate interplay between RXR and PPAR further complicates the biological landscape of 
PPAR activation and functions.  
 
1.2.2 Peroxisome Proliferator Response Element (PPRE) 
PPARs bind to DNA by recognition of target sequences known as core recognition motifs. 
The motif recognized by PPARs and other members of the thyroid hormone receptor/retinoic 
acid receptor (TR/RAR) family is composed of the degenerate hexamer AGGTCA sequence. 
Since PPAR:RXR bind to DNA as a heterodimer whereby both subunits interact with the 
DNA (Figure B), two copies of the core motif are required to constitute a functional 
peroxisome proliferator response element (PPRE) (Lemberger et al., 1996). Hence, PPREs are 
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defined as a direct repeat of two core recognition motifs AGGTCA separated by one 
nucleotide, hence named DR-1 (“1” denoting one spacer nucleotide between the hexamers) 
(Kliewer et al., 1992). PPAR binds to the upstream (5’) core motif, while RXR interacts with 
the downstream (3’) motif (A et al., 1997). The first physiologically occurring PPRE was 
identified in the promoter of the acyl-CoA oxidase gene (ACO) (Tugwood et al., 1992), and 
subsequently found in other PPAR-inducible genes such as adipocyte fatty acid-binding 
protein (Wahli et al., 1995). In recent years, numerous studies have reported that DR-2 is also 
a PPRE (Fontaine et al., 2003; Gervois et al., 1999; Kumar et al., 2004; Kumar et al., 2009; 
Venkatachalam et al., 2009). PPREs are thus distinguished from the direct repeat response 
elements recognized by other members of the TR/RAR class, such as that targeted by vitamin 
D receptor (DR-3), thyroid hormone receptor (DR-4), and retinoic acid receptor (DR-5) 
(Lemberger et al., 1996). Moreover, 5’ flanking nucleotides of PPREs also determine binding 
affinity between the heterodimer and the target sequences (Hsu et al., 1998). Interestingly 
however, PPARγ binds more strongly than PPARα and PPARδ at most PPREs, allowing this 
receptor isotype to be less reliant on a well-conserved 5’-flanking extension (Desvergne and 
Wahli, 1999).  
 
 
Figure B: Schematic representation of PPAR gene transcription.  
Upon ligation with endogenous or exogenous ligands, PPAR heterodimerizes with its obligate 
partner RXR. The heterodimer recognizes and binds to PPRE located in the promoter region 
of a target gene. Regulation of target gene transcription is modulated by interactions with 
cofactors, either coactivators or corepressors.  Recruitment of corepressors inhibits gene 
transcription, while interaction with coactivators releases corepressors and activates gene 
transcription. (Kota et al., 2005) 
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1.2.3 Involvement of cofactors 
Several cofactor proteins, acting as coactivators or corepressors, play a pivotal role in 
modulating the ability of NRs to initiate or repress transcription of target genes. Interactions 
between cofactors and NRs are ligand-dependent. In the absence of ligand-binding, 
PPAR:RXR heterodimer recruits a corepressor complex comprised of NCoR and SMRT, 
which harbor histone deacetylase activity (HDAC), thus repressing transcription by the 
deacetylated histones (Chen and Evans, 1995; Horlein et al., 1995; Xu et al., 1999). In the 
presence of PPAR ligands, this repressed state of gene transcription is reverted. Ligand-
binding triggers the formation of a “charge clamp” between the AF-2 and the core LBD. This 
ligand-dependent conformational alteration of the receptor enables derepression of 
transcription to occur that is characterized by dissociation from corepressors, followed by 
transactivation of target promoters by recruitment of coactivators. Generally, coactivators 
interact with nuclear receptors via the conserved LXXLL (where X is any amino acid) motif 
(Heery et al., 1997). In accordance with the classical paradigm of NR-mediated 
transactivation, coactivators such as CBP/p300 and steroid receptor coactivator (SRC)-1 are 
first recruited to liganded and PPRE-bound PPAR:RXR heterodimer(Torchia et al., 1997; Zhu 
et al., 1996). Armed with histone acetylase activity, this group of coactivators is capable of 
chromatin decondensation. A second group of coactivator complex is then recruited and 
assembled, comprising of members of the DRIP/TRAP family such as PPAR binding protein 
(PBP)/TRAP220 (Zhu et al., 1997); this additional coactivator complex forms a connecting 
bridge between the NR and the basal transcription initiation machinery, hence kickstarting the 
transcription process. Of note, binding of different ligands at the same receptor may result in 
differential recruitment of coactivators(Oberfield et al., 1999). Henceforth, distinctive 
interactions between PPAR and coactivators serve as an important mechanism to fine-tune 




1.3 PPAR subtypes 
1.3.1 Differential expression of PPARs 
An understanding of distinct expression patterns of PPAR subtypes yields insights into their 
different physiological functions. In the human cells, PPARα is well-expressed in the heart, 
kidney, skeletal muscle and large intestines (Auboeuf et al., 1997), but expression of this 
receptor is lower in human than in rodents’ liver (Palmer et al., 1998). Generally, PPARα 
expression is concentrated in tissues with high rates of fatty acid oxidation, such as in 
cardiomyocytes and cells of the kidney proximal tubules, where fatty acids are used as the 
primary energy source. The expression of PPARα is downregulated by insulin (Steineger et 
al., 1994), but upregulated by glucocorticoids (Lemberger et al., 1994). On the other hand, 
human PPARδ (hPPARδ) is ubiquitously present in a wide range of tissues, with relatively 
higher expressions in the placenta and the large intestine (Rodie et al., 2005). Unlike its -α 
and -γ counterparts, PPARδ subtype receives the least attention in research efforts. As such, 
regulation of PPARδ remains undetermined to date.  
 
In both mouse and human, the single PPARγ gene is subjected to alternative splicing and 
different promoters’ usage to produce two PPARγ protein isoforms, PPARγ-1 and PPARγ-2 
(Elbrecht et al., 1996). PPARγ-1 protein can be translated from three mRNA transcript 
variants (PPARγ1, γ3, γ4 mRNA), while PPARγ-2 protein is encoded by PPARγ2 mRNA 
transcript(Rumi et al., 2004) (Figure C). The structural difference between these two protein 
isoforms lies in the 30 extra amino acids in the amino-terminus of PPARγ-2 (Fajas et al., 
1997). In contrast to PPARα and δ, hPPARγ displays a confined pattern of expression. Both 
hPPARγ-2 and hPPARγ-1 are abundantly expressed in the adipose tissue, which is reflective 
of PPARγ’s critical role in adipogenesis and storage of fatty acid (Tontonoz et al., 1994a). In 
addition, hPPARγ-1 is present in low levels in skeletal muscle, liver, which are representative 
of tissues that are insulin-responsive, and heart (Mukherjee et al., 1997b). On the other hand, 
deviating from the expression pattern in rodents, hPPARγ is detectable neither in spleen nor 
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in circulating T lymphocytes; it is, however, overexpressed in several transformed human B 
lymphocyte and myeloid cell lines (Greene et al., 1995). Pertaining to the regulation of 
PPARγ expression, administration of insulin and corticosteroids synergistically increases 
mRNA of this NR in human adipocytes (Vidal-Puig et al., 1997). Conversely, tumor necrosis 
factor-α (TNFα) is able to downregulate PPARγ, and correspondingly revert PPARγ-mediated 




Figure C: PPARγ mRNA transcript variants and protein isoforms.  
Three PPARγ mRNA transcript variants (PPARγ1, γ3, γ4 mRNA) encode a single protein 
PPARγ-1, while PPARγ2 mRNA transcript encodes PPARγ-2 protein, which has 30 
additional amino acids in the amino terminal. (Rumi et al., 2004) 
 
1.3.2 Ligands and biological functions of PPARα and PPARδ 
1.3.2.1 PPARα 
The most well-known synthetic activators of PPARα are the hypolipidemic fibrates (Issemann 
and Green, 1990), whereas physiological ligands of this receptor are primarily unsaturated 
fatty acids and phytanic acids (Desvergne and Wahli, 1999). Strikingly, even though PPARα 
activation triggers hepatic peroxisome proliferation, hepatomegaly and hepatocarcinogenesis 
in rodents, humans are spared from these adverse therapeutic events (Cattley et al., 1998). 
One possible explanation for this disparity is that human hepatocytes express PPARα at levels 
ten-fold lower than rodent hepatocytes (Palmer et al., 1998).  
 
PPARα is an essential regulator of cellular uptake, activation and β-oxidation of fatty acids. 
Activation of this receptor promotes cellular uptake of fatty acids by inducing expression of 
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proteins responsible for fatty acids transport across the cell membrane, such as fatty acid 
transport protein (FATP) (Martin et al., 1997) and fatty acid translocase (FAT) (Motojima et 
al., 1998). On the other hand, β-oxidation of fatty acids is mediated by transcriptional 
upregulation of several PPARα-responsive genes, including acyl-CoA oxidase (ACO) 
(Schoonjans et al., 1995) and keto-acyl-CoA thiolase enzymes (Zhang et al., 1993). In 
addition, PPARα activation is beneficial for reducing triglycerides and raising HDL in the 
clinical setting (Linton and Fazio, 2000). Reduction of triglycerides by PPARα is attributed in 
part to induced expression of lipoprotein lipase (LPL) and repressed expression of hepatic 
apolipoprotein (apo) C-III (Schoonjans et al., 1996; Staels et al., 1995). In fact, trial results 
provide strong proof that gemfibrozil, a PPARα agonist, reduced cardiovascular events or 
death by 22% (Linton and Fazio, 2000). In sum, the net effect of PPARα activation in 
improving cardiovascular outcomes presents a promising strategy for the treatment of 
dyslipidemia and metabolic syndrome, alone or in synergy with PPARγ activation.  
 
1.3.2.2 PPARδ 
Curiously, screenings of natural and synthetic ligands have been much less fruitful in 
unearthing PPARδ-specific agonists. Most studies on PPARδ utilize fatty acid α-
bromopalmitate and L-165041 as relatively selective agonists of this receptor subtype. So far, 
no PPARδ-specific target genes have been discovered. Nevertheless, PPARδ is implicated in 
numerous physiological processes exemplified by the regulation of lipids, insulin resistance, 
fertility, axon myelination and lipid metabolism in the brain. Similar to PPARα, activation of 
PPARδ may have therapeutic utility in the treatment of hyperlipidemia, atherosclerosis and 
obesity by regulating genes responsible for lipid catabolism, cholesterol efflux and energy 
expenditure in muscles (Dressel et al., 2003; Tanaka et al., 2003). Biological functions more 
specific to this receptor subtype are associated with fertility and the central nervous system 
(CNS). Future identification and development of specific PPARδ agonists are required to 
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provide useful experimental tools for delineating functionality of this obscure receptor 
subtype.  
 
1.3.3 Ligands of PPARγ 
In terms of endogenous ligands, polyunsaturated fatty acids including linoleic acid, linolenic 
acid, arachidonic acid and eicosapentaenoic acid bind and activate PPARγ at micromolar 
concentrations, which correspond to their physiological serum levels (Berger and Moller, 
2002; Kota et al., 2005). In addition, 9-HODE and 13-HODE, which are conversion products 
of linoleic acid, may also serve as PPARγ ligands (Nagy et al., 1998). Thus far, 15-deoxy-
Δ12,14-prostaglandin J2 (15d-PGJ2), a metabolite of the eicosanoid prostaglandin D2, is the 
most potent endogenous ligand identified, with reported Kds ranging from 325nM to 2.5µM 
(Boitier et al., 2003). Prostaglandins (PGs) are a class of fatty acid metabolites derived from 
arachidonic acid (AA) via the cyclooxygenase pathway. The pathway leading to 15d-PGJ2 
formation is illustrated in Figure D (Scher and Pillinger, 2005), while Figure E depicts the 
chemical structure of 15d-PGJ2 (a cyclopentenone). Given the critical involvement of COX in 
Δ12-PGJ2  and 15d-PGJ2 production, COX induction may increase PPARγ activation by 
elevating physiological levels of endogenous ligands (Birnbaum et al., 2005; Yano et al., 
2007). 
 
The discovery that thiazolidinedione (TZD) antidiabetic agents are in fact synthetic PPARγ 
agonist ligands sparked off renewed research interest in this receptor subtype(Lehmann et al., 
1995; Willson et al., 1996). Chemical structures of TZD compounds are shown in Figure E. 
Among the TZDs, rosiglitazone was demonstrated to possess the highest affinity for PPARγ 
(Kd of ~ 40nM), followed by pioglitazone, troglitazone and lastly ciglitazone (Berger and 
Moller, 2002). Initially, these compounds were used for treating patients with type II diabetes 
or impaired glucose tolerance without mechanistic understanding of their molecular targets. 
Further studies later revealed that in vivo antihyperglycemic efficacy of these agents correlate 
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well with in vivo PPARγ agonism (Berger et al., 1996), demonstrating a functional 
association between PPARγ activation and insulin sensitization.  
 
It is also worth highlighting that in 2002, Leesnitzer et al. identified a selective and potent 
antagonist of PPARγ in a high throughput screen for PPARγ ligands. This compound, 
GW9662 (Figure E), binds irreversibly to PPARγ through covalent modification of a cysteine 
residue in the LBD, and functional antagonism was experimentally validated in adipocyte 
differentiation (Leesnitzer et al., 2002). PPARγ-targeted antagonism mediated by this 




Figure D: Schematic diagram of 15d-PGJ2 synthesis.  
COX-1 and COX-2 enzymes catalyze the oxidative conversion of AA to prostaglandin H2 
(PGH2). This is followed by generation of PGD2 mediated by hematopoietic and/or lipocaline 
PGD2 synthases (H-PDGS, L-PDGS). Non-enzymatic chemical dehydration of PGD2 then 
produces prostaglandin PGJ2. Albumin accelerates these conversions and catalyzes the 
subsequent isomerization of PGJ2 to Δ
12
-PGJ2, which can be further converted to 15d-PGJ2. 





Figure E: Chemical structures of PPARγ agonists and antagonist. 
(I) 15d-PGJ2, an oxidized metabolite of polyunsaturated fatty acids, is a natural ligand of 
PPARγ. (II) Thiazolidinediones, including Troglitazone, Ciglitazone, Rosiglitazone and 
Pioglitazone, are synthetic agonists of PPARγ. (III) GW9662 is an irreversible antagonist 
specific towards PPARγ. (Chou et al., 2007) 
 
1.3.4 Biological functions of PPARγ activation 
1.3.4.1 PPARγ and adipogenesis 
The first seminal observation that PPARγ is primarily expressed in adipose tissue incited 
subsequent studies to rigorously prove that PPARγ is necessary and sufficient (alone) to 
differentiate adipocytes. Enforced PPARγ expression combined with administration of weak 
PPAR ligands induced differentiation of NIH-3T3 fibroblasts to adipocytes (Tontonoz et al., 
1994b). Also, direct genetic evidence is derived from the observation that PPARγ 
heterozygous null mice had reduced amounts of adipose tissue (Rosen et al., 1999). PPARγ-
induced adipogenesis is mediated by direct up-regulation of an array of adipose target genes, 
established examples being adipocyte fatty acid-binding protein aP-2 (Tontonoz et al., 
1994a), fatty acid transport protein (FATP) (Martin et al., 1997), acyl-CoA oxidase gene 
(ACO) (Schoonjans et al., 1995), phosphoenolpyruvate carboxy kinase (PEPCK) (Tontonoz 
et al., 1995)and malic enzyme (ME)(Castelein et al., 1994). These well-documented bona fide 
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targets of PPARγ are required at critical stages of lipid accumulation, such as release of fatty 
acid from lipoprotein-bound triglycerides (LPL), cellular uptake of fatty acid into adipocytes 
(FATP, aP2), fatty acid and triglycerides syntheses (ME), glyceroneogenesis (PEPCK), and 
fatty acid esterification (ACO). Contrasting the role of PPARα in fatty acid oxidation and 
catabolism, PPARγ appears to regulate an opposite arm in lipid homeostasis by promoting 
fatty acid storage and lipid accumulation in adipocytes. Currently, speculations abound to 
propose that weight gain in patients receiving TZDs treatment is associated with PPARγ-
promoted adipose differentiation and triglyceride accumulation, a side-effect particularly 
detrimental to diabetic patients who are already associated with increased cardiovascular risk. 
Hence, it is tempting to consider innovative approaches of combined PPARγ/α activation to 
synergistically combat hyperglycemia, obesity, dyslipidemia and adverse cardiovascular 
events.  
1.3.4.2 PPARγ in insulin sensitization 
Spurred by the identification of TZDs as high-affinity PPARγ ligands, mounting experimental 
data surfaced in the last decade to prove PPARγ regulation of genes associated with insulin 
action. Based on PPARγ’s predominant expression in adipose tissue, the prevailing view 
holds adipose cells as the major direct targets of TZDs, with secondary effects exerted on 
other insulin-responsive tissues such as skeletal muscle and liver, where PPARγ expression is 
low (in skeletal muscle) or almost absent (in liver). PPARγ activation is shown to upregulate 
c-CBL-associated protein (CAP) (Ribon et al., 1998) and insulin receptor substrate-2 (IRS-2) 
(Smith et al., 2001) in cultured adipocytes, genes implicated in positive regulation of insulin-
signaling pathway. On the other hand, expression of 11 β-hydroxysteroid dehydrogenase 1 
(11β-HSD-1) is suppressed by PPARγ activation, a protein known to exacerbate insulin 
resistance (Berger et al., 2001). In vivo, human subjects receiving rosiglitazone had elevated 
plasma levels of adipocyte-related complement protein (Acrp)30 (Combs et al., 2002), a 
secreted adipocyte-specific protein responsible for decreasing glucose, triglycerides and free 
fatty acids(Berg et al., 2001). Hence, PPARγ-induced Acrp30 may represent an important 
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mechanism through which TZDs improve clinical outcomes of patients with metabolic 
syndrome. Lastly, TZDs-mediated insulin sensitization is also achieved by complex 
antagonism between PPARγ and tumor necrosis factor-α (TNFα). TNFα, a pro-inflammatory 
cytokine secreted by lipid-laden adipocytes, has been shown to impair insulin signal 
transduction (Hotamisligil et al., 1994) and increase insulin resistance (Hotamisligil et al., 
1993). PPARγ ligands restored insulin sensitivity by inhibiting TNFα expression in white 
adipose tissue (Hofmann et al., 1994), reversing TNFα-suppressed phosphorylation of the 
insulin receptor and IRS-1 (Peraldi et al., 1997), and abrogating TNFα-mediated lipolysis 
(Souza et al., 1998). On the other hand, TNFα downregulates PPARγ expression (Zhang et 
al., 1996) and inhibits PPARγ transcriptional function (Gao et al., 2006). Hence, 
multifactorial antagonism between these two major players holds the key to overall regulation 
of lipid metabolism and contributes to pathogenesis of lipid and glucose disorders.  
15 
 
1.4 PPAR activators against cancer 
Systemic lipid metabolism is no doubt the stronghold of PPAR biology research, thus the 
search and identification of PPAR target genes have traditionally been devoted to genes 
related to lipid homeostasis. Whether this biased slant in research focus reflects a true 
physiological exclusiveness of PPAR function in lipids regulation appears highly contentious. 
In fact, recent studies show that PPARs are also able to regulate cell proliferation, 
differentiation, and apoptosis; modulation of their functions is henceforth a potential 
chemotherapeutic strategy (Sertznig et al., 2007). Of the three receptor subtypes, PPARγ is 
the most established with regards to antineoplastic effects. As for PPARα, even though more 
experimental data are now emerging to support its antiangiogenic and antitumorigenic 
functions, research interest in this isoform is still hampered by at least two reasons. Firstly, 
unlike PPARγ overexpression in a cornucopia of wide-ranging cancer types, overexpression 
of PPARα in transformed relative to normal cells is at best sporadic (Sertznig et al., 2007) 
(Table 1). Secondly, it is now known that transactivation status of PPARα in rodent liver is 
irrelevant to human systems (Palmer et al., 1998), severely limiting usefulness of in vivo 
models for determining anticancer efficacy or toxicity of PPARα agonists. On the other hand, 
activation of PPARδ appears to aggravate rather than inhibit tumor progression. Here we 
briefly review the current status of PPARα and δ research in cancer, with more details 











Cancer types PPARα PPAR PPARγ 
Colon adenocarcinoma cells/stromal myofibroblasts(IHC)   77.70% 
Human gastric carcinoma cells (IHC)   ↑ 
Human renal carcinoma cells (IHC, WB, RNA)   ↑ 
Gastric carcinoma cells in mice (WB)   ↑ 
Hepatocellular carcinoma cells (IHC)   ↑ 
Human prostatic carcinoma cells (NB and RNA)   ↑ 
Colon adenocarcinoma cells   ↑ 
Colorectal carcinoma (cells with inactivating mutation of APC)  ↑  
Human breast adeno carcinoma cells   ↑ 
Human liposarcoma cells   ↑ 
Human prostate cancer cells   ↑ 
Human colorectal cancer cells   ↑ 
Non-small cell lung cancer   ↑ 
Human pancreatic carcinoma cells   ↑ 
Human transitional bladder cancer   ↑ 
Human gastric cancer cells (NB, WB, RNA)   ↑ 
Human pituitary adenomas (IHC)   ↑ 
Human squamous cell carcinoma (IHC) ↓ ↑ → 
Human melanoma cells (IHC, WB, RNA) + + + 
↑, higher expressed; →, no change; ↓, lower expressed; +, presence demonstrated; IHC, immunohistochemistry; 
WB, Western blot; RNA, polymerase chain reaction quantification; NB, Northern Blot 
 
Table 1: Summary of PPAR expression in various cancers. 
(Sertznig et al., 2007) 
 
1.4.1 PPARδ and cancer 
The role of PPARδ in cancer remains largely an enigma, but data derived from a majority of 
studies are leaning towards the notion that antagonism, instead of agonism,of PPARδ would 
be beneficial for chemotherapeutics. The first evidence suggesting that PPARδ potentiates 
colon cancer came from the observation that PPARδ expression was upregulated as a result of 
inactivation mutations of adenomatous polyposis colitis (APC) tumor suppressor gene in 
colorectal carcinoma cells (He et al., 1999). In addition, PPARδ+/- colorectal cancer cell line 
had enhanced propensity to form tumors in nude mice as compared to PPARδ-/- cancer cells 
(Park et al., 2001), and treatment of APC
min
 mice with the PPARδ agonist GW1516 
augmented small intestine tumorigenesis (Gupta et al., 2004). Consistent with the prosurvival 
role of PPARδ activation, Wang et al. reported that ligand activation of PPARδ confers 
colorectal cancer cells resistance to PPARγ-mediated apoptosis (Wang et al., 2011). Even 
though new evidence is arising to challenge the original link of PPARδ to carcinogenesis by 
showing that PPARδ attenuates colon and skin carcinogenesis (Harman et al., 2004; Kim et 
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al., 2004) , insufficient and conflicting results render it premature to advocate the use of 
PPARδ agonists for cancer therapeutics.  
 
1.4.2 PPARα and cancer 
Paradoxically, the link between PPARα and cancer was first drawn when it was observed that 
peroxisome proliferators (PP) induced hepatocarcinogenesis in rodents (Reddy and Rao, 
1992). Owing to marked interspecies difference in PPARα expression (Palmer et al., 1998), 
long-term exposure of human patients to gemfibrozil and clofibrate, hypolipidemic drugs 
which are also potent PPs, has fortunately not been associated with increased incidences of 
liver or other cancers (1992). These species differences highlight potential pitfalls of 
extrapolating data from standard therapeutic effectiveness and toxicological testing of PPARα 
ligands in rodents to human conditions. Despite this limitation, there are experimental data to 
suggest potential of PPARα activation in cancer therapeutics. Though far from being a 
common occurrence, there are reports showing overexpression of PPARα in prostate 
adenocarcinoma(Collett et al., 2000), breast carcinoma (Suchanek et al., 2002) and 
lymphocytic leukemic cells(Liu et al., 2006). Fibrates exert antiproliferative and apoptotic 
effects in normal and hyperproliferating mouse epidermis, which are abrogated in PPARα-
deficient mice (Komuves et al., 2000). In addition, PPARα ligands are demonstrated to inhibit 
growth of numerous human cancer cell lines including colon, liver, breast, endometrial and 
skin, even though it is unclear whether these anticancer effects are truly a function of PPARα 
activation (Komuves et al., 2000; Maggiora et al., 2004; Muzio et al., 2007; Saidi et al., 2006; 
Tanaka et al., 2003; Thuillier et al., 2000). In vivo, topical PPARα agonists have a mild 
protective effect against skin cancer (Thuillier et al., 2000) and metastasis of melanoma cells 
(Grabacka et al., 2004). Recent findings extend the repertoire of PPARα target genes to those 
regulating angiogenesis, suggesting that PPARα ligands suppress tumor progression by 
inhibiting angiogenesis in the tumor microenvironment(Panigrahy et al., 2008). Further 
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studies are required to clarify receptor-dependent and independent mechanisms of PPARα 
ligands in cancer treatment.  
 
1.4.3 PPARγ and cancer 
The concept that PPARγ activation represents an attractive antineoplastic strategy stems in 
part from the observation that PPARγ expression is generally higher in neoplastic tissues than 
their normal counterparts. Evidence accumulates to demonstrate overexpression of PPARγ in 
tumors of breast, prostate, colorectal, stomach, salivary gland, cervix, ovary, bladder, lung, 
testes, as well as leukemia and neuroblastoma (Krishnan et al., 2007). Considering the 
fundamental physiological role of PPARγ in cell metabolism, its elevated levels in 
transformed cells may be the result of secondary metabolic changes, rather than a case of 
oncogene overexpression. Another proposed mechanism of PPARγ upregulation in cancer 
cells is the recruitment of a powerful tumor-specific PPARγ promoter by myc-associated zinc 
finger protein (MAZ), as demonstrated in MCF7 cells (Wang et al., 2008). Despite the high 
expression of PPARγ in cancerous cells, there is no significant PPARγ activity without the 
addition of exogenous ligand (Keshamouni et al., 2004). In general, NRs undergo 
ubiquitination and proteasomal degradation upon activation by their ligands and after 
mediation of target-gene transcription (Hauser et al., 2000). Hence, an alternative mechanism 
proposed to explain accumulation of PPARγ receptor in tumors is a lack of receptor activation 
due to deficient endogenous ligand. Remarkably, a large body of experimental data 
corroboratively demonstrates that PPARγ activators exert antiproliferative effects in a 
plethora of malignant cell types, including but not restricted to neuroblastoma, colon cancer, 
breast cancer, pituitary adenomas, gastric cancer, bladder cancer, liposarcoma, prostate cancer 
and melanoma (Sertznig et al., 2007). Tumor suppressive effects of PPARγ have been linked 
to its ability to induce differentiation (Tontonoz et al., 1997), cell cycle arrest (Morrison and 




1.4.3.1 PPARγ in Neuroblastoma  
Neuroblastoma (NB), a cancer of the sympathetic peripheral nervous system originating in 
cells derived from the neural crest, is the most common extracranial childhood malignancy. 
Current treatment of NB includes surgery, radiotherapy and chemotherapy with platinum 
drugs, etoposide, doxorubicin, cyclophosphamide and vincristine. Even with intensive 
therapy, more than 60% of patients with advanced disease have a poor prognosis. In an effort 
to identify more effective therapies for these inflicted children, PPARγ activators have been 
proposed as a possible therapeutic option. In the first study demonstrating PPARγ expression 
in NB cells, Han et al. utilized RT-PCR to show that NB cell line LA-N-5 express PPARγ and 
PPARδ, but not PPARα (Han et al., 2001b). Another independent study published by Isaac et 
al. also reiterated the fact that PPARγ and δ proteins are highly expressed, while PPARα 
protein is almost undetectable (Isaac et al., 2006) in SK-N-SH NB cell line, of which SHEP-1 
cell line is an epitheloid subclone (Biedler et al., 1973).  
 
Among the two receptor subtypes expressed in NB cells (γ and δ), only PPARγ has been 
proven to be beneficial for the control of malignancy. Encouraging results were obtained from 
an investigation based on NB patient samples, showing that PPARγ expression correlates with 
the clinical course of NB; patients with decreased urinary vanillyl mandelic acid (VMA) level 
(marker for NB regression) tended to have high PPARγ mRNA expression, while those with 
elevated urinary VMA (indicative of NB progression) harbored low levels of PPARγ mRNA 
(Sato et al., 2003). A role of PPARγ activation in the regression of NB is reinforced by 
several studies using endogenous or synthetic PPARγ ligands. 15d-PGJ2, the endogenous 
ligand of PPARγ, counteracted growth of various NB cell lines by induction of apoptosis, 
which was inhibited by the PPARγ antagonist GW9662 (Kim et al., 2003; Rohn et al., 2001). 
Chemotherapeutic potential of synthetic PPARγ ligands was also addressed by other studies. 
To date, no study has been published to show antitumor effects of TZDs in vivo. 
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Nevertheless, unpublished data by Cellai et al. (Peri et al., 2008) revealed that 150mg/kg/day 
of oral rosiglitazone pronouncedly reduced growth of SK-N-AS xenografts in nude mice.  
 
Surprisingly, even though most cases of ligand-mediated NB growth inhibition are dependent 
upon PPARγ activation (Emmans et al., 2004; Han et al., 2001a; Kato et al., 2002; Valentiner 
et al., 2005), total wildtype PPARγ expression levels alone in NB cells are not predictive of 
their sensitivity towards PPARγ ligands(Valentiner et al., 2005). Currently, a few papers have 
suggested that additional intra- or extracellular factors may modulate NB cell lines’ response 
to PPARγ activators. For example, 15d-PGJ2-mediated PPARγ activation of NB cell line 
IMR-32 is limited by the presence of lipids in culture medium (Rodway et al., 2004). 
Meanwhile, Servidei et al. suggested that therapeutic efficacy of PPARγ ligands is, at least in 
part, dependent upon NB cell phenotype, with neuroblastic (N) type cells being most sensitive 
to treatment (Servidei et al., 2004). To further complicate the picture, Cellai et al. challenged 
these previous findings by showing that stromal (S) type cell line SK-N-AS is significantly 
more amenable to rosiglitazone-induced PPARγ activation and resultant apoptotic effects than 
N type SHSY5Y, even though PPARγ in SHSY5Y has no inactivation mutations(Cellai et al., 
2006). Significantly, it was suggested in that report that phosphorylation status of PPARγ in 
NB cells plays a determinant role in their response to PPARγ agonists because SHSY5Y 
harbored elevated levels of phosphorylated-PPARγ relative to SK-N-AS. Clearly, further 
studies are required to decipher exact mechanisms of PPARγ-associated antineoplastic effects 
in NB cells, as well as unravel the exact factors influencing transactivation status of the 
receptor. Nonetheless, the prevalent efficacy of PPARγ agonists in NB cell lines, patient 
samples and mouse model is likely to have clinical resonance.  
 
1.4.3.2 PPARγ in breast carcinoma 
Breast carcinoma ranks as the top malignancy identified in woman world-wide. One of the 
key treatment options for advanced breast cancer is anti-estrogenic therapy, through which 
21 
 
systemic estrogen levels are reduced and hormone receptors are blocked (Yager and 
Davidson, 2006). Unfortunately, anti-estrogens are futile against ERα-negative tumors, which 
are often aggressive and metastatic. Hence, there is an impetus to identify novel cancer-
specific molecular targets. In the past decade, considerable research attention has been paid to 
therapeutically exploit tumor-specific overexpression of PPARγ in breast cancer. Both human 
cancer cell lines (MCF7, BT474, T47D, and MDA-MB-231) and human primary metastatic 
breast adenocarcinoma samples express elevated amounts of PPARγ relative to normal 
mammary epithelial cells (Clay et al., 1999; Elstner et al., 1998; Mueller et al., 1998; Suzuki 
et al., 2006). Suzuki et al. reported that PPARγ immunoreactivity was an independent 
prognostic factor for improved clinical outcome and survival of ERα-positive breast 
carcinoma patients (Suzuki et al., 2006). With a few exceptions, a growing body of evidence 
indicates that expression and transactivation of PPARγ are protective against breast cancer 
progression. Ligand-mediated activation of PPARγ in breast cancer cell line induced 
inhibition of growth and clonogenic capacity, and alterations in gene signature associated 
with a more differentiated and less malignant state (Mueller et al., 1998). Data acquired from 
in vivo models corroborate antineoplastic potential of PPARγ activators. For an instance, 
troglitazone significantly reduced tumor and size and weight of injected breast cancer in 
immunodeficient mice (Elstner et al., 1998). More recently, both PPARγ and PPARδ 
activators are tested on progestin- and carcinogen-induced mouse mammary tumors (Yin et 
al., 2005). Interestingly, PPARγ activator GW7875 inhibited tumorigenesis, while PPARδ 
activator GW501516 actually increased tumor incidence over baseline.  
 
Although mechanisms of PPARγ-mediated antineoplastic effects are far from clear, research 
efforts have been made to identify effector targets of PPARγ in breast carcinoma. Elstner et 
al. showed that troglitazone, combined with either all-trans-retinoic acid or 9-cis-retinoic acid, 
triggered apoptosis in Bcl-2 overexpressing cell lines (MCF7, MDA-MB-231, ZR-75-1), but 
suppressed Bcl-2 expression only in MCF7 cells (Elstner et al., 2002). Others have shown that 
treatment of breast carcinoma cell lines with PPARγ agonists upregulated p21, with 
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concomitant downregulation of CDK2, CDK4, cyclin D1, and decreased phosphorylation of 
retinoblastoma, which concertedly resulted in cell cycle arrest(Samid et al., 2000; Yin et al., 
2001). These targets however, are not direct transcriptional targets of PPARγ, and there are 
suggestions that PPARγ agonists may act partially through receptor-independent pathways to 
modulate these proteins. In recent years, some advances are made in identifying bona fide 
transcriptional targets of PPARγ in breast carcinoma (Kumar et al., 2009; Patel et al., 2001; 
Venkatachalam et al., 2009; Zhou et al., 2009) (described in the later section). PTEN is 
perhaps the most well-known transcriptional target of PPARγ in MCF7 breast cancer cells 
(Patel et al., 2001; Teresi et al., 2006), due to its established role as a tumor suppressor. 
Members of our laboratory have also published their findings with regards to transcriptional 
downregulation of NHE-1 by PPARγ activation, which is required for tumor-selective effect 
of the receptor ligands (Kumar et al., 2009).  
 
On grounds of promising in vitro and in vivo data, a phase II study was conducted to assess 
the effect of troglitazone on refractory breast cancer patients(Burstein et al., 2003). 
Intriguingly, PPARγ activation appears to have little clinical value in these patients. However, 
several factors account for the failure of this clinical trial that may not be related to inefficacy 
of the PPARγ activator. The study was halted prematurely due to withdrawal of troglitazone 
from the market upon FDA warnings of hepatotoxicity, and hence no patients were on trial 
for more than 20 weeks. In addition, it is known that clinical benefits of any kind of therapy 
are severely limited in heavily treated refractory breast carcinoma patients. Thus, assessment 
of compound efficacy in such patients may obscure any potential clinical effect. Furthermore, 
patients were enrolled into the study with no prior evaluation of hormone receptor status (ER, 
PR, HER-2) and PPARγ expression in tumors. To fully realize therapeutic efficacy of PPARγ 
agonistic compounds in future trials, more tailored patient selection criteria are warranted. 
Lastly, the lack of overt clinical activity of troglitazone does not preclude the possibility that 
next generation PPARγ agonists, especially non-TZDs, may have improved efficacy and 
reduced toxicity.  
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1.5 PPARγ target genes in cancer 
1.5.1 Bcl-2 and adenovirus E1B 19kDa-interacting protein 3 (BNIP3) 
BNIP3 is a pro-death BH3-only protein of the Bcl-2 family (Boyd et al., 1994). This protein 
has captivated the attention of researchers because of its unique ability to induce both 
apoptotic and autophagic cell death. Enforced expression of BNIP3 was reported to mediate 
apoptosis via MOMP, opening of the mitochondrial permeability pore and loss of 
mitochondrial membrane potential, with or without cytochrome c release and caspase 
activation(Chen et al., 1997; Prabhakaran et al., 2007; Vande Velde et al., 2000). Apoptotic 
activity of BNIP3 is indirectly regulated by transcriptional upregulation of this protein under 
hypoxic conditions through a hypoxia-inducible factor (HIF) response element in its proximal 
promoter (Bruick, 2000). In addition to induction of hypoxia-induced apoptosis, recent 
evidence showed that BNIP3 is also responsible for mediating autophagic cell death (Zhang 
and Ney, 2009). Though mechanistic insights of BNIP3-induced autophagy are still lacking, 
there are speculations that BNIP3 may interact with Bcl-2/Bcl-XL, hence releasing Beclin 1 to 
activate Vps34 in a class I PI-3K kinase complex (Bellot et al., 2009). Recently, BNIP3 was 
identified as a direct target of PPARγ in a genome-wide microarray analysis of primary 
murine mammary epithelial cells transduced with active PPARγ (Zhou et al., 2009). This was 
validated by troglitazone-stimulated luciferase reporter activity of MDA-MB-231 cells 
transfected with the BNIP3 promoter (Zhou et al., 2009). Even though this paper did not 
reveal any identified PPRE sites on the BNIP3 promoter, their experimental data strongly 
suggest that BNIP3 is a transcriptional target of PPARγ.  
 
1.5.2 Hypoxia-inducible factor 1 (HIF1α) 
In the same study which uncovered BNIP3 as a PPARγ target in carcinoma cells, HIF1-α was 
also observed to be transcriptionally upregulated in a PPARγ-dependent way (Zhou et al., 
2009). HIF-1 is a heterodimer comprised of constitutively expressed HIF-1β and HIF1-α 
subunits. Steady-state expression of HIF1-α is modulated in an oxygen-dependent way 
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(Mazure and Pouyssegur, 2010); under normoxic conditions, HIF1-α is degraded by the Von 
Hippel–Lindau (VHL) tumor suppressor gene, but can be stabilized in hypoxic or anoxic 
conditions (Maxwell et al., 1999). HIF1-α is reported to induce a plethora of genes regulating 
angiogenesis, proliferation, survival and glucose metabolism (Semenza, 2003), and is thus 
incriminated to promote solid tumor growth by facilitating adaptation to oxygen limitation. 
This tumorigenic role of HIF1-α is however challenged by a number of studies demonstrating 
a pro-apoptotic role of this transcription factor in some instances. Gene expression profiling 
revealed that hypoxia-induced HIF1-α upregulates numerous pro-apoptotic and anti-
proliferative genes, such as BNIP3, Noxa, IFGBP-3 and BIK (Bacon and Harris, 2004). In 
colorectal and mammary carcinoma cell lines, HIF-1α was cancer-selectively upregulated by 
a compound rimcazole under normoxic conditions to execute apoptosis (Achison et al., 2007). 
Moreover, HIF1-α also triggers autophagic cell death in hypoxia via induction of BNIP3 
(Tracy et al., 2007). It is thus apparent that HIF1-α is capable of engaging a myriad of 
molecular pathways which can be pro-death or pro-survival depending on cellular contexts.  
 
1.5.3 Ras homolog gene family, member B (RhoB) 
RhoB is a member of the Ras superfamily of small GTP-binding proteins with a role in 
regulating cytoskeletal actin organization and vesicle transport (Wennerberg and Der, 2004). 
Unlike RhoA and RhoC which have been implicated in oncogenesis, invasion and metastasis 
(Khosravi-Far et al., 1995; van Golen et al., 2000), RhoB is shown to exert antiproliferative 
and proapoptotic effects (Liu et al., 2001). Research interest in RhoB was spurred by the 
discovery of this protein being the effector target of farnesyltransferase inhibitor (FTI) in 
blocking neoplastic transformation (Lebowitz and Prendergast, 1998). In this regard, one 
important finding is that any modulation of RhoB activity in normal cells is inconsequential, 
whereas its gain of function drastically dampened growth of oncogenic Ras-transformed 
cancer cells (Liu et al., 2001; Prendergast and Oliff, 2000). Other studies corroborate the 
antineoplastic role of RhoB by demonstrating that its overexpression inhibits cell migration, 
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cancer invasion and metastasis (Jiang et al., 2004). Hence, compounds that upregulate RhoB 
in transformed cells could have therapeutic potential. Joining the ranks of HMG CoA 
reductase inhibitors (statins) (Holstein and Hohl, 2001), prenylation inhibitors (FTI, GGTI) 
(Huang and Prendergast, 2006) and HDAC inhibitors (FK288) (Marlow et al., 2009), PPARγ 
agonists (TZDs and RS5444) are now demonstrated to transcriptionally upregulate RhoB in a 
PPARγ-dependent manner in anaplastic thyroid carcinoma cell lines (Marlow et al., 2009). In 
fact, two putative PPREs have been identified in the RhoB promoter, suggesting that it is a 
bona fide PPARγ target (Marlow et al., 2009). 
 
1.5.4 Phosphatase and tensin homolog located on chromosome ten (PTEN) 
PTEN is an extensively studied tumor suppressor that is often lost in advanced human tumors 
(Li et al., 1997). It is a dual specificity phosphatase that displays both lipid and protein 
phosphatase activity (Myers et al., 1997). The lipid phosphatase activity of PTEN 
dephosphorylates the 3’ position of the class I PI-3K product phosphatidylinositide (3,4,5)-
triphosphate (PIP3) to PIP2. Since PIP3 is required for Akt phosphorylation, active PTEN 
negatively regulates the PKB/Akt proliferative pathway (Maehama and Dixon, 1998). On the 
other hand, the protein phosphatase aspect of PTEN inhibits the Shc/Grb2/Sos and mitogen-
activated protein kinase (MAPK) pathways, thereby limiting cell division and sensitizing 
tumors to apoptosis (Gu et al., 1998). New insights into the tumor suppressor role of PTEN 
are yielded by the discovery that PTEN promotes autophagy by antagonizing the Akt/PKB 
pathway (Arico et al., 2001). Hence, it is conceivable that loss of PTEN contributes to 
malignant transformation by paralleled inhibition of apoptotic and autophagic cell death. 
Earlier groups have shown that PTEN transcription can be increased by Early growth 
response-1 (Egr-1), p53 and Sp1 (Han et al., 2003; Stambolic et al., 2001; Virolle et al., 
2001). Conversely, NF-κB inhibits PTEN transcription. In the last decade, two putative 
PPREs were identified upstream of the minimal promoter region of PTEN, which were 
experimentally demonstrated to be recognized and bound by PPARγ (Patel et al., 2001). A 
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follow-up study conducted by another group confirmed that PTEN is indeed transcriptionally 
upregulated by Rosiglitazone and Lovastatin in a PPARγ-dependent manner (Teresi et al., 
2006) which may contribute to tumor regression. 
 
1.5.5 Na+/H+ exchanger-1 (NHE-1) 
Localized at the plasma membrane, NHE-1 is a major regulator of intracellular pH (pHi) and 




 across the plasma membrane (Pedersen, 
2006). Though it is a ubiquitous protein, overexpression NHE-1 is an oncogenic signal 
contributing to the development and maintenance of a transformed phenotype (McLean et al., 
2000; Reshkin et al., 2000). Since an acidic intracellular milieu acts as an early and important 
event in programmed cell death (PCD), NHE-1 is implicated in mitigating PCD in cancer 
cells by alleviating acidification (Akram et al., 2006; Matsuyama et al., 2000; Rich et al., 
2000). As a result, downregulation of NHE-1 expression in cancers resulted in intracellular 
acidification, growth reduction and sensitization to death stimuli (Akram et al., 2006; Kumar 
et al., 2007). Independent of its function in mediating ion translocation, NHE-1 is also a 
scaffold protein, interacting directly with the plasma membrane-cytoskeleton linker ezrin 
(member of the ezrin/radixin/moesin ERM family proteins) (Baumgartner et al., 2004). Both 
ERM binding and ion translocating activities of NHE-1 are proposed to activate Akt/PKB, 
thus antagonizing death induction in cancers (Wu et al., 2004). NHE-1 activity was first 
shown to be inhibited by troglitazone in breast carcinoma cell lines (Turturro et al., 2004), but 
it was not until recent publications that putative PPREs were identified on the NHE-1 
promoter, which were later experimentally validated (Kumar et al., 2009; Venkatachalam et 
al., 2009). Unlike other inducible genes of PPARγ, NHE-1 is transcriptionally downregulated 
by PPARγ activation. Corroborating other studies that revealed encouraging results with 
antisense therapy targeting NHE-1 gene in gastric cancer xenografts (Liu et al., 2008), tumor-
selective modulation of NHE-1 expression is a mechanism responsible for TZDs and 15d-
PGJ2-induced cancer inhibitory effects. 
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1.5.6 Managanese superoxide dismutase (MnSOD) 
MnSOD is a resident protein of the mitochondrial matrix that catalyses the dismutation of 
superoxide radicals into hydrogen peroxide and molecular oxygen (Fridovich, 1995). This is 
an enzyme that is janus-faced in oncogenesis. On one hand MnSOD has been shown to be 
tumor-suppressive because its overexpression inhibits tumor growth (Behrend et al., 2005; 
Lam et al., 1997), while on the other hand it is linked to cancer invasion and metastasis 
(Malafa et al., 2000; Nozoe et al., 2003; Toh et al., 2000). Studies have shown that MnSOD is 
overexpressed in colorectal carcinomas and liver metastases as compared to normal mucosa 
(Toh et al., 2000), which is corroborated in other cancer types (Izutani et al., 1998; Malafa et 
al., 2000). Consistent with this, increased expression of MnSOD protects cells from numerous 
antineoplastic modalities, such as TRAIL, TNFα and ionizing radiation (Hirose et al., 1993; 
Mohr et al., 2008; Motoori et al., 2001). In contrast, downregulation of MnSOD sensitizes 
colon cancer cells to apoptotic effects of radiation, hyperthermia and doxorubicin (Kuninaka 
et al., 2000). It was proposed that MnSOD suppression allows accumulation of superoxide, 
which augments the effect of treatment modalities dependent upon ROS for lethality (Sinha 
and Mimnaugh, 1990). Another explanation is that MnSOD upregulates matrix-degrading 
metalloproteinases to increase aggressiveness of tumors (Wenk et al., 1999). 
Transcriptionally, MnSOD is found to be positively regulated by NF-κB, which is 
intrinsically connected to tumor progression (Allen and Tresini, 2000). It was first shown in 
mouse cardiomyocyte that MnSOD is a PPARγ target gene (Ding et al., 2007). This was 
confirmed by another study conducted by Venkatachlam et al., which showed that 
interestingly, MnSOD is transcriptionally repressed by PPARγ activation (Venkatachalam et 
al., 2009). Importantly, PPARγ-induced MnSOD downregulation was observed to be critical 
for mediating antitumor effects (Kumar et al., manuscript under review). 
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1.6 Problems posed by current PPARγ agonists 
One major caveat that demands attention in PPARγ research is the toxicity issue associated 
with these compounds. Troglitazone (Rezulin) was the first TZD approved for treatment of 
diabetic patients, followed by rosiglitazone (Avandia) and pioglitazone (Actos). However, in 
March 2000, troglitazone was removed from commercial availability due to severe drug-
induced hepatotoxicity (Graham et al., 2003). In fact, troglitazone was ranked as the second 
most common cause of fatality related to acute liver failure worldwide between 1970 and 
2004 (Bjornsson and Olsson, 2006), causing serious concerns about the safety of other TZD 
counterparts. For rosiglitazone and pioglitazone treatment regimes, a low incidence of 
elevated alanine transaminase (ALT) levels is observed, although there are a few rare 
exceptions of severe hepatotoxicity (Al-Salman et al., 2000; Forman et al., 2000). The full 
nature and mechanism of PPARγ ligands-induced hepatoxicity are poorly understood, but 
general scholarly consensus acknowledges that it is likely be a PPARγ-independent event, 
especially since PPARγ is not expressed at a functionally relevant level in normal liver 
(Peraza et al., 2006). Also, there are strong indications that PPARγ-independent oxidative 
stress-induced mitochondrial dysfunction is the underlying factor of troglitazone-triggered 
liver injury (Julie et al., 2008). It has been suggested that currently prescribed glitazones have 
lesser effect in inducing ROS production than troglitazone, hence less likely to induce liver 
fibrosis/cirrhosis (Deng et al., 2009; Narayanan et al., 2003). Worthy to note, dose exposure 
of troglitazone is also the highest among the clinical TZDs (rosiglitazone 4-8mg, pioglitazone 
15-45mg, troglitazone 200-600mg) (Julie et al., 2008) , which possibly accounts for 
intensification of toxicity. Taken together, these findings suggest that PPARγ activator 
compounds that are more potent and less likely to produce ROS will be beneficial. 
 
Though safer than troglitazone, the remaining TZDs in clinics are known to cause other 
adverse drug-related events. Rosiglitazone treatment is associated with increased risks of 
myocardial infarction and cardiovascular deaths (Nissen and Wolski, 2007). Again, cardiac 
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toxicity may be mediated, at least in part, by effects independent of PPARγ. Duan et al. 
reported that cardiac hypertrophy was induced by rosiglitazone in both wild-type and cardiac 
myocyte-specific PPARγ-null mice(Duan et al., 2005). On the other hand, increased 
cardiovascular risks may also be related to TZD-induced weight gain and peripheral edema 
(Nesto et al., 2003). As PPARγ activation promotes adipocyte differentiation and lipid 
accumulation, increased adiposity is proposed as a primary cause of drug-induced weight gain 
(Larsen et al., 2003). Moreover, weight gain is possibly exacerbated by TZD-triggered fluid 
retention, with contradictory results pertaining to whether this is a PPARγ receptor-dependent 
effect (Zhang et al., 1994; Zhang et al., 2005). Given that 90% of type II diabetic patients are 
obese and have high risk for congestive heart failure, TZDs-exacerbated weight gain and 
cardiotoxicity are clearly suboptimal. Hence, the development of multimodal drugs capable of 
reducing hyperglycemia or mediating cancer regression while simultaneously inhibit 
progression of secondary cardiovascular complications may prove valuable.  
 
Efforts to achieve these therapeutic goals lead to the emergence of two novel classes of 
compounds, namely, the dual PPARγ/α agonists and the selective modulators of PPARγ 
(SPPARγMs). Identification and development of dual PPARγ/α agonists are premised on the 
concept of simultaneously reaping PPARγ-mediated therapeutic benefits (insulin sensitization 
or antineoplastic effects) and curbing its unwanted side effects by PPARα activation, which is 
known to regulate lipid catabolism and confer cardiovascular protection (Pourcet et al., 2006). 
The other compounds, known as SPPARγMs, are in fact partial agonists of PPARγ. 
Proponents of SPPARγMs claim that partial agonism restricts expression of PPARγ target 
genes to the “beneficial” cluster responsible for insulin-sensitization, without upregulating 
proadipogenic genes inadvertently activated by full agonists(Burgermeister et al., 2006; 
Oberfield et al., 1999; Rangwala and Lazar, 2002), thereby avoiding weight gain. Despite the 
heightened interest in these two categories of new agonists for the treatment of diabetes, their 
potential applications in cancer therapeutics remain to be explored.  
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2 Programmed cell death 
Programmed cell death (PCD) is a genetically determined natural process of eliminating 
unwanted cells that may be redundant, ectopic, damaged or mutated. Deregulation of this 
process perturbs the delicate balance between cell proliferation and cell death, leading to 
pathological consequences including the development of cancer. For a long time, PCD was 
considered to be tantamount to apoptosis, until latter findings proved that there may be other 
legitimate forms of PCD, such as autophagic cell death and necroptosis. Drugs that are able to 
achieve selective killing of tumors via restoration of functional PCD through one or a 
combination of pathways form the fundamental cornerstone of cancer chemotherapeutics.  
 
2.1 Necrosis 
Conventionally, necrosis is conceptualized as a nonregulated process where the cell is a 
passive victim that undergoes an energy-independent type of cell death. Whether the cell dies 
by “accidental” necrosis or highly regulated apoptosis depends on the tissue type, the 
developmental stage of the tissue, the physiologic milieu, and the type and degree of stimuli 
(Fiers et al., 1999). For example, certain cytotoxic drugs or chemicals may induce apoptosis 
at low doses, while culminating in necrosis at high doses. In terms of morphology, some of 
the key features of a necrotic cell include cell swelling (oncosis), swelling of intracellular 
organelles, and finally plasma membrane rupture as well as unsystematic breakdown and 
discharge of organelles (Majno and Joris, 1995). Hence, necrosis is often thought to be 
detrimental because the eventual release of cytoplasmic contents prompts an inflammatory 
reaction that may support tumor growth (Vakkila and Lotze, 2004). Previously, being 
entrenched in the notion that necrosis is an “accidental” and passive response, the research 
field saw little effort in targeting this mode of cell death. This pedagogic paradigm is now 
challenged by molecular insights revealing critical involvement of cellular effectors in 
necrosis. Moubarak et al. reported that poly (ADP-ribose) polymerases-1 (PARP-1) and 
apoptosis inducing factor (AIF) are required in necrosis induced by alkylating DNA damage, 
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with calpains and Bax acting as intermediate molecular links(Moubarak et al., 2007). 
Ablation of Bax or AIF inhibited necrosis in this model, strongly suggesting that cellular 
susceptibility to necrosis may be genetically determined. Another study observed that kinase 
RIP (receptor interacting protein) is critical for mediating tumor necrosis factor (TNF)-
induced necrosis; RIP can inhibit ATP/ADP exchange on mitochondrial membranes by direct 
association with adenine nucleotide translocase (ANT), hence impairing mitochondrial 
function, with cell death as a consequence (Temkin et al., 2006). Currently, a small molecule 
necrostatin-1 (Nec-1) is used to specifically block necroptosis, a non-apoptotic mode of active 
cell death triggered by death receptor signaling in the presence of caspase inhibition, and 
which shares morphological appearances with typical necrosis (Degterev et al., 2005). The 
availability of tools such as Nec-1 presents an opportunity to examine the necrotic or 






Apoptosis was first described in 1972 in a landmark paper by Kerr et al as a novel form of 
cell death that is distinct from necrosis (Kerr et al., 1972). Morphological hallmarks that 
define apoptosis are nuclear condensation (pyknosis), nuclear fragmentation (karyorrhexis), 
membrane blebbing and cellular shrinkage(Wyllie et al., 1980). Eventually, the cell is broken 
into membrane-bound fragments known as apoptotic bodies, which contain intact organelles 
enclosed within plasma membrane. These bodies are rapidly engulfed by resident phagocytic 
cells. Unlike necrotic cells, cells dying by apoptosis do not release their cellular contents into 
the surroundings and therefore do not trigger inflammatory responses (Kurosaka et al., 2003).  
 
Apoptosis is central to a cornucopia of physiologic processes. During developmental stages, 
apoptosis mediates formation of inter-digit spaces required for proper separation of fingers 
(Jacobson et al., 1997). Apoptosis is also essential to dispense of pathogen-invaded cells in 
order to facilitate wound-healing(Greenhalgh, 1998), or remove auto-aggressive immune cells 
during maturation of the central lymphoid organs or peripheral tissues(Osborne, 1996). 
Clearly, dysfunctions in the apoptotic pathways resulting in either excessive or insufficient 
apoptosis can cause various diseases, for example, cancer, and neurodegenerative diseases 
such as Parkinson’s and Alzheimer’s disease (Elmore, 2007).  
 
2.2.1 Molecular mechanisms in apoptosis 
Apoptosis is a highly regulated process involving complex molecular circuitries that 
coordinately bring about cellular demise in an energy-driven cascade of biochemical events. 
Two prominent initiator pathways of apoptosis have been characterized in great detail, 
namely, the extrinsic or death receptor pathway, and the intrinsic or mitochondrial pathway 
(Figure F). Regardless of the initiating stimulus, both pathways converge on the execution or 
degradation phase, orchestrating morphological and biochemical alterations such as DNA 
fragmentation, breakdown of cytoskeletal and nuclear proteins, formation of apoptotic bodies, 
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and expression of ligands for phagocytic uptake. It is now known that activation of a 




Figure F: Two major pathways to caspase-dependent apoptosis, namely, the extrinsic 
and the intrinsic death pathways.  
The extrinsic pathway, exemplified here by stimulation of CD95 death receptor by CD95 
ligand, results in the recruitment and activation of caspase 8 by the adaptor protein FADD. 
This can in turn amplify death signals in two ways: by cleavage of Bid, with resultant 
translocation of t-Bid to mitochondria and MOMP, or by direct proteolytic activation of 
downstream effector caspases. On the other hand, the intrinsic pathway is triggered by 
cellular insults, damage or infection, in response to which BH3-only proteins such as Bax are 
mobilized to initiate MOMP. Subsequent formation of apoptosome from cytochrome c 
released from the mitochondria and Apaf-1 stimulates activation of caspase 9 and 
downstream effector caspases. (Hengartner, 2000) 
 
2.2.1.1 Caspases 
It was first discovered in the nematode Caenorhabditis elegans that a cysteine protease CED-
3 is critically involved in apoptosis, an evolutionarily conserved process (Yuan et al., 1993). 
Ever since, the role of caspases in the execution of apoptosis has been elucidated with 
astounding celerity. The name “caspase(s)” came from the ability of this family of cysteine 
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proteases to cleave after an Asp residue in their substrates (Alnemri et al., 1996), even though 
different caspases have different specificities based on recognition of neighboring amino 
acids. In humans, 13 caspases have been identified, out of which at least seven (caspase-2, -3, 
-6, -7, -8, -9, and -10) are implicated in apoptosis (Cohen, 1997). Caspase -1, -4 and -5 are 
identified to be inflammatory caspases regulating cytokine activation (Martinon and Tschopp, 
2007), while the functions of caspase-11, -12 and -13 are less established. Caspases that 
participate in apoptosis can be further categorized as initiator caspases, including caspase-2, -
8, -9 and -10, or effector caspases, which are caspase-3, -6 and -7. All caspases are expressed 
in cells as catalytically inactive zymogens (procaspases). During apoptosis, activation of 
caspases requires proteolytic maturation via cleavage by other caspases, or interaction with an 
allosteric activator in the form of a recruitment platform. For initiator caspases, their 
activation depend on the formation of recruitment platforms, which are polyprotein 
complexes such as the death-inducing signaling complex (DISC) for caspase-8 and -10 , the 
apoptosome for caspase-9, and the PIDDosome (consisting of RAIDD and p53-induced 
protein with a death domain, PIDD) for caspase-2 (Peter and Krammer, 2003; Shi, 2008; 
Tinel and Tschopp, 2004). Activation of effector caspases, on the other hand, is achieved 
through cleavage mediated by an initiator caspase. Once activated, caspases can in turn cleave 
and activate other procaspases, kickstarting a proteolytic cascade that amplifies the apoptotic 
signal and commits the cell to eventual death. 
 
Biochemical and morphological hallmarks of apoptosis are an obligatory result of effector 
caspases cleaving a variety of key cellular proteins. One of the earliest substrates of caspase-3 
targeted for cleavage is PARP (Casciola-Rosen et al., 1996), a nuclear protein required for 
DNA repair. Other cellular substrates of caspases include proteins involved in membrane 
blebbing (Rho-associated kinase 1, ROCK1, p-21 activated kinase, PAK, and gelsolin), 
maintenance of cellular structures (cytokeratin-18, fodrin, actin), and modulation of nuclear 
architecture (lamin) (Fischer et al., 2003). 
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2.2.1.2 Extrinsic pathway 
The extrinsic pathway initiates apoptosis by engaging stimulated death receptors to transduce 
death signals from the cell surface to the intracellular molecular circuitry. Cell surface death 
receptors are members of the TNF receptor gene superfamily; the best-characterized death 
receptors and cognate ligands include FasR/FasL (CD95/APO-1), TNFR1/TNFα, 
DR3/Apo3L, DR4/TRAIL-R1, and DR5/TRAIL-R2 (Elmore, 2007). Ligation triggers death 
receptor oligomerization and binding of cytoplasmic adapter proteins, such as Fas-associated 
death domain (FADD) and tumor necrosis factor receptor type 1-associated death domain 
protein (TRADD) (Hsu et al., 1995; Wajant, 2002). These molecules form a multiprotein 
platform known as the death-inducing signaling complex (DISC) that recruits procaspase-8 
(via association of its death effector domain with FADD) and triggers its auto-catalytic 
activation (Kischkel et al., 1995). Subsequent to caspase 8 activation, death signals can be 
propagated in two distinct manners, depending on whether the events are occurring in a type I 
or type II cell (Ozoren and El-Deiry, 2002). In type I cells, activation of caspase 8 alone 
suffices to trigger direct proteolysis of downstream effector caspases (caspase-3, -6, -7), thus 
executing cell death. In contrast, caspase 8 activation is not sufficiently robust in type II cells 
to directly elicit downstream caspase cascade; instead, an extra amplification step is required 
where Bid, a member of the BH3 domain-only subgroup of Bcl-2 family, is proteolytically 
cleaved by activated caspase 8. Cleaved bid (t-Bid) then translocates to the mitochondria and 
provokes mitochondrial outer membrane permeabilization (MOMP) and cytochrome c-
dependent caspase-3 activation (Scaffidi et al., 1998).  
 
2.2.1.3 Intrinsic pathway 
In the intrinsic pathway of initiating apoptosis, a wide range of non-receptor-mediated stimuli 
such as UV irradiation, cytotoxic drugs and growth factors withdrawal produce intracellular 
signals that perturb the integrity of mitochondrial membrane. Mitochondrial membrane 
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permeabilization (MMP) is the decisive event, the condition sine qua non for cell death 
induction in this pathway (Kroemer et al., 2007).  
 
The propensity to MMP is tightly regulated as an integrated response from the power balance 
of pro- and anti-apoptotic members of the Bcl-2 family, a family of proteins containing at 
least one Bcl-2 homology (BH) region. This family may be sub-classified into anti-apoptotic 
multidomain (containing four BH domains) proteins (prototypic representatives: Bcl-2, Bcl-
XL), pro-apoptotic three BH domains-containing proteins (Bax, Bak), and pro-apoptotic BH3-
only proteins (Bid, Bad) (Letai et al., 2002). Several mechanisms of inducing mitochondrial 
outer membrane permeabilization (MOMP) have been proposed (Kroemer et al., 2007), 
among which the involvement of Bax/Bak is frequently cited. Under normal physiologic 
conditions, Bax resides in the cytosol; upon an apoptotic stimulus, Bax translocates to and 
inserts itself into the outer mitochondrial membrane (OM) (Wolter et al., 1997), either alone 
or in association with other proapoptotic members such as Bak or tBid (Kuwana et al., 2002). 
On the other hand, Bak is normally associated with the OM, and changes its conformation 
during apoptosis to form larger aggregates. Hence, MOMP is achieved by supramolecular 
openings formed from homooligomeric Bax-containing pores or from the destabilization of 
the lipid bilayer (Basanez et al., 2002; Kuwana et al., 2002). The BH3-only pro-apoptotic 
proteins either directly stimulate opening of the Bax/Bak channel by binding and activating 
Bax/Bak (for example, tBid), or, like Bad, neutralize anti-apoptotic members by interacting 
with them and hence sensitize cells to MOMP (Letai et al., 2002). Contrariwise, the anti-
apoptotic members are well-known sentinels guarding the integrity of the mitochondrial 
membrane by associating with and antagonizing pore-forming Bax/Bak, or by interacting 
with BH3-only proteins (Letai et al., 2002) . In accordance with its role in suppressing 
MOMP, overexpression of Bcl-2 protein blocks apoptosis in the aforementioned type II cells 




MMP commits the cell to death by releasing other sequestered pro-death proteins from the 
intermembrance space (IMS) into the cytosol. In particular, the release of cytochrome c, 
which normally functions as an electron shuttle in the mitochondrial respiratory chain, causes 
the formation of an “apoptosome” in a nucleotide dATP/ATP dependent manner (Chinnaiyan, 
1999). The apoptosome, comprised of cytochrome c and apoptotic protease activating factor-1 
(Apaf-1), recruits and activates caspase-9. Subsequent activation of executioner caspases 
ensues to effect cell death. Other pro-death proteins released from the IMS include 
Smac/DIABLO and HtrA2/Omi, which are shown to exert pro-apoptotic functions by 
antagonizing inhibitors of apoptosis proteins (IAP), a family of caspase inhibitory proteins 
(XIAP, c-IAP1, c-IAP2, survivin) (Schimmer, 2004; van Loo et al., 2002). 
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2.3 Caspase-independent cell death 
Although caspases are frequently and massively activated in classical apoptosis, evidence is 
now accumulating to refute the obligatory involvement of caspases in cell death. In vivo, 
genetic invalidation of Apaf-1 delays but does not inhibit apoptosis-dependent process of 
interdigital web loss (Yoshida et al., 1998). Even in C. elegans, some cells are susceptible to 
cell death without requiring caspases (Abraham and Shaham, 2004). Data derived from cell 
lines have reported that in several instances, caspase inhibition is often not sufficient to avoid 
cell death (Hirsch et al., 1997; Sarin et al., 1997). In certain contexts, caspases are activated 
only at a late stage of the cell death process, for an instance after MOMP (Kroemer and Reed, 
2000). Hence, caspase activation at this point merely represents a hallmark of cell death rather 
than the decisive event committing cells to cellular demise. Once MOMP has occurred, other 
mitochondrial constituents may play a functional role to exert cell death even if caspase 
activation is weak or absent. For example, studies have shown that the apoptosis-inducing 
factor (AIF), a resident protein of the IMS, can be released into the cytosol in a caspase-
independent manner. Subsequent to its release, AIF translocates to the nucleus where it 
mediates chromatin condensation and caspase-independent cell death (Lorenzo et al., 1999). 
Other non-caspase proteases including calpains and cathepsins can also mediate cell death 
and engender apoptosis-associated morphological alterations. One example is cysteine 
protease cathepsin B, which acts potentially as a molecular link between lysosomal damage 
and MOMP induction (Johnson, 2000). In fact, cathepsin B is capable of exerting lethal 
effects independent of the classical apoptotic machinery (Broker et al., 2004). Another 
proposed mechanism of caspase-independent cell death is that through necroptosis (Degterev 
et al., 2005). Necroptosis typically occurs in response to death receptor stimulation in the 
presence of caspase inhibition. One of the key mediators in necroptosis is RIP-1, loss of 
expression or kinase function of which renders cells refractory to necroptosis (Holler et al., 
2000). A study conducted by Yu et al. demonstrated that necroptosis induction is dependent 
on RIP-1 and JNK function and is induced through macroautophagy (Yu et al., 2004). 
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Involvement of macroautophagy in other caspase-independent contexts have also been 
documented, for an instance in oncogenic Ras-induced cellular suicide (Chi et al., 1999). In 
that model, overexpression of oncogenic Ras in human carcinoma cell lines triggers 
autophagic cell death in the absence of caspase activation and survival is not restored by 
overexpression of Bcl-2. Though mechanisms of caspase-independent cell death are far from 
lucid, the expanding knowledge of alternative death paradigms will no doubt contribute to 
therapeutic strategies in combating cancers with inherently silenced/defective caspases or 




It is now clear that the apoptosis-necrosis dichotomy is an oversimplified representation of 
PCD, related to which alternative models of cell death may well be legitimate means to guard 
against unbridled cellular proliferation. Interestingly, when Richard Lockshin first coined the 
expression ‘PCD’, he was actually inspired by a study on developmental cell death in the 
intersegmental muscles of silk worms that, in fact, bore morphological hallmarks of 
autophagic induction (Lockshin and Zakeri, 2001). Autophagy, which literally means “self-
eating” in Greek, is a highly dynamic and regulated process in which intracellular membrane-
enclosed vesicles engulf and consume cellular components, enabling degradation and turn-
over of proteins and organelles. In the following sections, we explain the molecular basis of 
autophagy, examine its role in PCD and review the abundant data about its implication in 
cancer which ultimately highlight the attractive prospect of manipulating autophagy as a new 
anti-cancer modality.  
 
2.4.1 Different forms of autophagy 
For the purpose of classification, there are at least three documented forms of autophagy – 
chaperone-mediated autophagy (CMA), microautophagy and macroautophagy. CMA is 
characterized by particular selectivity in targeting a subset of proteins bearing specific 
pentapeptide motif (Dice, 1990). Since this process involves the translocation of unfolded 
substrates across the lysosome membrane, it is unable to cater for large protein or organelles. 
Microautophagy alludes to the transfer of cytoplasmic contents into the lysosome via direct 
inward invagination of the lysosomal membrane followed by vesicular budding into the 
lysosomal lumen (Marzella et al., 1981). In constrast, macroautophagy, the most studied form 
of autophagy, involves de novo formation of double-membrane cytosolic vesicles, termed 
autophagosomes, which deliver sequestered cytoplasmic cargo to the lysosome for 
degradation (Yorimitsu and Klionsky, 2005). Even though macroautophagy is generally 
considered as a bulk sequestration process, there is increasing evidence for organelle-specific 
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autophagy, such as pexophagy (peroxisomes), mitophagy (mitochondria), ribophagy 
(ribosomes) and reticulophagy (endoplasmic reticulum, ER) (van der Vaart et al., 2008). This 
study focuses on macroautophagy, which is herein referred to as autophagy.  
 
2.4.2 Basic steps in autophagy 
Although autophagic vesicles were previously thought to be derived from the ER, Golgi or a 
less well-characterized pre-existing membranous structure called the phagophore, recent 
studies demonstrate that they are in fact formed de novo (Noda et al., 2002) (Figure G). The 
elongated double membranes form autophagosomes, sequestering cellular constituents and 
organelles in an ATP-dependent manner. The autophagosomes mature with acidification by 
the H
+
-ATPase and fuse with lysosomes or late endosomes to generate autolysosomes 
(Yamamoto et al., 1998). The autophagic cycle is finally completed as lysosomal hydrolases 
degrade the autophagic cargo together with its inner membrane (Gozuacik and Kimchi, 2004). 
The entire sequence of events, from the synthesis of autophagosomes, delivery of sequestered 
contents to the lysosome, to the eventual degradation of autophagic cargo within the 
autolysosomes, is denoted by the term “autophagic flux” (Mizushima et al., 2010). It is now 
appreciated that an increase in autophagic vacuolization does not necessarily indicate elevated 
autophagic flux because accumulation of autophagosomes can also be caused by defective 
autophagosomal maturation or impaired clearance of autophagosomes (Levine and Kroemer, 





Figure G: Autophagy: a dynamic process controlled by multiple molecular players. 
Different stages of the autophagic pathway include: vesicle nucleation (formation of the 
isolation membrane/phagophore), vesicle elongation and completion of autophagosome, 
fusion of the double-membrane autophagosome with the lysosome to form an autolysosome, 
and degradation of the autophagic cargo along with the lysis of the autophagosome inner 
membrane. These stages of autophagy are regulated by molecular pathways that involve 
mainly the Atg proteins, which form different complexes at each respective phase of 
autophagy.  In addition, the activation of autophagy is regulated by various signaling 
pathways, and the ones that have been targeted pharmacologically in experimental or clinical 






Figure H: Accumulation of autophagosomes and induction/suppression of autophagic 
flux in different physiological conditions.  
Shown in the diagram are the relative amounts of isolation membrane (IM), autophagosomes 
(AP), and autolysosomes (AL). (A) Basal autophagy takes place under baseline conditions. 
(B) Upon induction of autophagy by a particular stimulus, there is an accumulation of all 
types of autophagic structures with a general increase in autophagic flux. (C) If autophagy is 
suppressed at an upstream induction step, no autophagic structures are formed and there is no 
autophagic flux. (D) If a downstream step of autophagy (after the complete closure of 
autophagosome) is suppressed, there will be an accumulation of autophagosomes, but a 
decrease in autophagic flux. (Mizushima et al., 2010) 
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2.4.3 Molecular components in the autophagic machinery  
2.4.3.1 Class I PI3-K/Akt/mTOR signaling negatively regulates autophagy 
induction 
The mammalian target of rapamycin (mTOR) kinase is the molecular gatekeeper guarding 
against autophagy initiation. As a sensor for amino acids and ATP, active mTOR suppresses 
autophagy in the presence of abundant nutrients(Gozuacik and Kimchi, 2004). In addition, 
upstream class I PI3-K/Akt signaling molecules connect receptor tyrosine kinases to mTOR 
activation; for example, growth factors such as insulin/insulin-like growth factor receptor 
negatively regulate autophagy through activation of mTOR (Lum et al., 2005a). Hence, 
inactivation of mTOR by rapamycin treatment induces autophagy in both yeast and 
mammalian cells (Noda and Ohsumi, 1998).  
 
Downstream of the TOR kinase in yeast is a group of genes known as the autophagy-related 
genes (Atg genes) (Klionsky et al., 2003). Evolutionarily conserved in mammals, these genes 
encode proteins that are essential for the operation of autophagy. Under nutrient-rich 
conditions, active yeast TOR phosphorylates Atg13, resulting in low affinity of Atg13 for 
Atg1. Conversely, when TOR activity is inhibited, dephosphorylated Atg13 associates with 
Atg1, triggering Atg1 activation which induces nucleation of autophagic isolation membrane 
(Kamada et al., 2000). In mammals, ULK1 is identified as the homologue of yeast Atg1. 
Consistent with its critical role in autophagy induction, small interfering RNA (siRNA) 
against ULK1 inhibits autophagy in certain cell types (Chan et al., 2007). In addition to 
autophagy induction, ULK1 regulates the cycling of the integral membrane protein 
mammalian Atg9 (Young et al., 2006) 
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2.4.3.2 Class III PI 3-kinase complexes involved in autophagy nucleation 
During the vesicle nucleation step, one key event is the activation of mammalian Vps34, a 
class III PI3-K (Petiot et al., 2000). Unlike class I PI3-K, which as previously mentioned 
negatively regulates autophagy, class III PI-3K is positively involved in autophagy induction. 
Activation of Vps34 requires formation of a multiprotein complex in which Vps34, Beclin 1 
(mammalian orthologue of Atg6), a myristylated serine kinase (Vps15 in yeast, or p150 in 
humans) and possibly a mammalian specific Beclin 1-interacting WD40 domain protein, 
Ambra 1, constitute the core complex (He and Levine, 2010). Major advances have been 
made in expanding the repertoire of autophagy-specific class III PI3-K complexes and 
literature has reported that the autophagic-specific core complex (Beclin 1, Vps34, Vps15, 
and maybe Ambra1) may bind either mammalian Atg14 (Atg14 in yeast) or UVRAG (Vps 38 
in yeast) in a mutually exclusive manner to mediate vesicle nucleation (Itakura et al., 2008). 
 
Activation of Vps34 generates phosphatidylinositol-3-phosphate (PIP3). Although the role of 
this lipid product in autophagosomes formation is only beginning to be understood, one of its 
functions appear to be to recruit effectors WIPI-1 (Atg18 in yeast) on the preautophagosomal 
(PAS) membrane through interaction with their FYVE and PX motifs (Gillooly et al., 2001; 
Proikas-Cezanne et al., 2007; Wishart et al., 2001).  
 
2.4.3.3 Ubiquitin-like conjugation systems involved in membrane elongation  
Two ubiquitin-like conjugation systems are critical to the vesicle elongation process. The first 
system involves the covalent conjugation of Atg12 to Atg5, facilitated by the E1-like enzyme 
Atg7 and the E2-like enzyme Atg10. This conjugation is instrumental to the formation and 
stabilization of a larger protein complex, comprised of Atg12/Atg5 and Atg16. The 
Atg12/Atg5/Atg16 complex is recruited to the outer membrane of the forming 
autophagosome but falls out upon completion of autophagosome synthesis.  
46 
 
In the second conjugation system, proteolytic activity of Atg4 cleaves the carboxy-terminus 
of yeast Atg8, and Atg8 then undergoes activation by E1-like Atg7. Finally, another E2-like 
enzyme Atg3 mediates conjugation of Atg8 via an amide bond to an amino group of 
phosphatidylethanolamine (PE). In mammals, one of the Atg8 homologues is microtubule-
associated protein 1 light chain 3 (MAP1LC3, or LC3 for short). The lipid conjugation 
process converts the cytoplasmic soluble form of LC3 (named LC3-1) to the 
autophagosomes-associated conjugated form LC3-II. To date, LC3-II is the only Atg known 
to persist on autophagosomes, while others are observed on isolation membranes but not 
complete autophagosomes. Therefore, LC3-II represents a useful biochemical marker of 
autophagy because its lipidation causes an increased electrophoretic mobility on gels 
compared with LC3-1, while its specific recruitment to the autophagic membrane enables 
visualization from diffuse to punctate staining of the green fluorescent protein-tagged LC3 
(GFP-LC3).  
 
2.4.4 Dual role of autophagy in cell survival and cell death 
2.4.4.1 Physiologic pro-survival role of autophagy 
Autophagy is active at a low basal level in virtually all cells, and this points towards a 
homeostatic function of this process in regulating the turnover of long-lived proteins and 
whole organelles in general. Autophagy also eradicates damaged organelles such as 
mitochondria (Rodriguez-Enriquez et al., 2004), or functionally superfluous ones such as 
peroxisomes (Shintani and Klionsky, 2004). Due to its important role in the clearance of 
misfolded or aggregate-prone mutant proteins, defective autophagy underlines pathogenesis 
of several neurodegenerative diseases such as Alzheimer’s and Huntington’s disease. 
(Rubinsztein et al., 2007; Williams et al., 2006). Beyond this homeostatic function, autophagy 
is also rapidly upregulated during nutrient depletion or growth factor withdrawal. Autophagic 
catabolism of macromolecules provides constituents needed to meet bioenergetics demands, 
thus safeguarding survival of the cell (Lum et al., 2005b).  
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2.4.4.2 Autophagic cell death 
The overt paradox pertaining to autophagy in cell fate decisions is that, in several settings, 
autophagy serves as a cell-protective adaptation response to thwart cell death, whereas in 
other scenarios, it is considered as a mode of non-apoptotic PCD termed autophagic cell 
death. Historically, this form of PCD is defined by the morphological appearance of higher-
than-normal autophagic activity (Maiuri et al., 2010). However, due to a conflicting school of 
thought advocating a pro-survival role of autophagy in response to death stimulus, there is 
now a prevailing consensus that a mere concomitant occurrence of cell death and autophagy 
is not sufficient to qualify as autophagic cell death, but rather “cell death with autophagy”. 
Several investigators have proposed an operational definition for autophagic cell death, in 
which specific inhibition of autophagy should avert irreversible loss of cellular functions and 
confer cells with survival (Kroemer and Levine, 2008). 
 
Opponents of autophagic cell death quote that under most forms of cellular stress, autophagy 
exerts a pro-survival function, as evidenced by Atg gene knockdown which hastens rather 
than prevents apoptotic cell death (Boya et al., 2005). However, numerous studies do clearly 
demonstrate the existence of bona fide autophagic cell death. Hyperactivation of autophagy 
by Beclin 1 overexpression in mammalian cells (Pattingre et al., 2005), as well as Atg1 
overexpression in Drosophila both lead to cell death (Scott et al., 2007). Nevertheless, 
mechanistic insights are still lacking with regards to how autophagy constitutes a lethal event. 
Two main mechanisms have been put forward, the first being autophagic killing via excessive 
and irreversible cellular atrophy. Corroborating this concept, Xue et al. reported that in cells 
treated with a death stimulus in the presence of caspase inhibitors, a vast majority of 
mitochondria were demolished by autophagy and the cells became drastically reduced in size 
before succumbing to death. It is thus suggested that colossal autophagic activity may be 
capable of annihilating major portions of the cytosol and organelles, resulting in irreversible 
loss of vital functions. The second proposed mechanism references the idea that autophagy 
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mediates cell death by acting as an essential trigger of apoptosis, which is discussed in further 
detail as follows.  
 
2.4.5 Functional relationships between autophagy and apoptosis in cell fate 
decisions 
Intricately intertwined with autophagy is apoptosis, and the complex interplay between these 
two machineries are crucial for determining overall cell fate. Clearly, there are multiple ways 
in which these two processes may be interconnected (Figure I), contingent upon different 
cellular contexts and stimuli. In certain cases, autophagy may antagonize apoptosis by 
creating a pro-survival cellular milieu. For an instance, inhibition of autophagy rendered HT-
29 cells sensitive to sulindac sulfide-induced apoptosis (Bauvy et al., 2001), and caused HeLa 
or HCT116 cancer cells to undergo apoptotic cell death during nutrient deprivation (Boya et 
al., 2005). Under other conditions however, autophagy is restrained by the apoptotic pathway, 
but takes over to effect cell kill once the apoptotic pathway is functionally invalidated. To 
illustrate this idea, Shimizu et al. reported that etoposide, staurosporine or thapsigargin 
induced massive autophagy in apoptosis-incompetent Bax/Bak
-/-
 MEFs, which resulted in cell 
death (Shimizu et al., 2004). In such cases, autophagy and apoptosis act as mutually exclusive 
backup mechanisms to each other to ensure cell elimination. Also possible is the concurrent 
activation and requirement of autophagy and apoptosis for the execution of cell death. This 
phenomenon was observed in cell kill exerted by proteasome inhibitor MG132 in PC3 
prostate cancer cells(Yang et al., 2006), arsenic trioxide treatment in T-lymphocytic 
leukemias (Qian et al., 2007), and vitamin K2 treatment in HL-60 leukemia cells (Yokoyama 
et al., 2008).  
 
The two pathways appear to be coordinately regulated by common molecular components. 
The Bcl-2 protein family, initially characterized as modulators of apoptotic cell death, is now 
demonstrated to also regulate autophagy. Anti-apoptotic proteins such as Bcl-2 and Bcl-XL 
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bind Beclin 1 and interfere with Beclin1/Vps34 complex formation (Noble et al., 2008; 
Pattingre et al., 2005). On the other hand, competitive displacement of Beclin 1 from Bcl-
2/Bcl-XL can be achieved by pro-apoptotic BH3-only proteins, for example BNIP3 (Maiuri et 
al., 2007a; Zhang et al., 2008). Another molecular link between autophagy and apoptosis is 
represented by Atg5. In addition to the critical role of Atg5 in autophagosomes formation, 
proteolysis of this protein reveals a novel pro-apoptotic role. It was observed that calpain-
mediated cleavage of Atg5 gives rise to a 24-kDa fragment that has no autophagic function. 
Instead, this Atg5 fragment is able to induce MOMP by translocation to mitochondria, or 
trigger caspase-dependent cell death by association with FADD (Pyo et al., 2005; Yousefi et 
al., 2006). These examples represent only but a piecemeal in the vast canvass of molecular 




Figure I: Cross-talk between autophagy and apoptosis to jointly determine cell fate. 
(A) Autophagy and apoptosis are partners cooperating to induce cell death. (1) In certain 
scenarios, they may act in independent and parallel pathways. (2) Or, autophagy may be 
required for apoptosis, thus placing it hierarchically upstream of apoptosis, while 
simultaneously inducing an independent mechanism of death. (3) Under certain conditions, 
autophagy is suppressed by apoptosis, and the former takes over the execution of the cell only 
when apoptosis is inhibited. In that manner, autophagy serves as a back-up death mechanism 
to apoptosis. (B) Autophagy antagonizes apoptotic cell death by acting as an adaptive survival 
response to escape death. (Eisenberg-Lerner et al., 2009) 
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2.4.6 Autophagy in cancer 
Cancer is one of the first pathological conditions associated with defects in autophagy. Genes 
that constitute critical executioners of the autophagic machinery are frequently lost or 
inactivated in cancers, the most well-known example being Beclin 1. Beclin 1 is 
monoallelically deleted in 40-75% of human breast, ovarian and prostate carcinomas (Liang 
et al., 1999). Importantly, mice subjected to heterozygous disruption of Beclin 1 have reduced 
autophagic activity and increased susceptibility to spontaneous carcinogenesis (Qu et al., 
2003). Other components of the autophagic pathway, such as Atg5, Atg4c, UVRAG and 
Ambra 1, also play tumor suppressive roles (Fimia et al., 2007; Takahashi et al., 2007; 
Yousefi et al., 2006). Furthermore, numerous well-established oncogenes (class I PI-3K, 
PKB, TOR, Bcl-2) are now discovered to inhibit autophagy, while many tumor suppressor 
genes (p53, PTEN, DAPk, TSC1/TSC2) are positive regulators of autophagy (Mizushima et 
al., 2008).  
 
Even though accumulating experimental findings reinforce the concept that autophagy is a 
true tumor suppressor pathway, exact molecular mechanisms remain unclear. First, Atg genes 
may be guardian of the genome, deletions of which may compromise genomic stability in 
metabolically stressed cells, paving the way to oncogene activation and tumor initiation. In 
support of this hypothesis, immortalized mouse epithelial cells with mono-allelic or bi-allelic 
loss of Beclin 1 or Atg5 exhibited elevated DNA damage, gene amplification, and 
chromosomal aberrations (Mathew et al., 2007). Secondly, autophagy may negatively impact 
cell growth by degrading essential organelles or proteins required for proliferation. Indeed, 
enforced Beclin 1 expression dampens proliferation of tumor cell lines with concomitant 
decrease in the expression of cyclin E and phosphorylated Rb (Koneri et al., 2007; Liang et 
al., 1999). Thirdly, activation of autophagic pathway in response to metabolic stress can 
prevent death of apoptosis-incompetent cells by necrosis, hence avoiding local inflammatory 
responses that can promote tumor progression (Degenhardt et al., 2006).  
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Another issue that is a matter of heated debate is the role of autophagy in cancer treatment. 
Despite incriminating data demonstrating the tumor suppressive role of autophagy, there are 
arguments that activation of autophagy may be one of the mechanisms by which tumors 
acquire resistance against chemotherapeutic drugs. As such, clinical trials are currently 
ongoing to assess the therapeutic potential of combining an “autophagy inhibitor” 
hydroxychloroquine and standard regimen in cancer settings (Chen et al., 2010). It is 
important to note that even though chloroquine is an alkalinizing lysosomotropic drug that 
hampers autophagic degradation (Amaravadi et al., 2007), this drug is not a specific inhibitor 
of autophagy and exerts pleiotropic effects (Apetoh et al., 2007). Caution is thus warranted 
before jumping to the conclusion that chloroquine-mediated antitumor effects are mediated by 
autophagy inhibition. On the other hand, abundant in vitro data derived from experimental or 
clinically approved drugs suggest that activating autophagy could be a promising therapeutic 
approach. Tamoxifen, which antagonizes the estrogen receptor, induces autophagic cell death 
in breast carcinoma cells via downregulation of PKB/Akt (Bursch et al., 1996; Scarlatti et al., 
2004). In another example, temozolomide (TMZ), a DNA alkylating agent, causes cell death 
in malignant glioma cells by autophagy instead of apoptosis (Kanzawa et al., 2004). In 
particular, compounds inducing autophagic cell death could have therapeutic utility in cancers 
mutated in the signaling pathways leading to apoptosis. In illustration of this idea, the histone 
deacetylase inhibitors sodium butyrate and SAHA induce classical apoptosis in HeLa cells, 
but trigger autophagic cell death instead in the Bcl-XL-overexpressing counterpart (Shao et 
al., 2004). In recent years, preliminary clinical studies indicate antineoplastic efficacy of 
mTOR inhibitors such as rapamycin and its derivatives CC1-779, RAD001 and AP23573 in a 
wide range of cancers (Chan, 2004). Further studies aimed at determining a functional 
association between autophagy induction and rapamycin-mediated antiumour effect will 




3 Lanthanide-based compounds as anticancer agents 
Lanthanides (Ln), also commonly known as rare-earth elements, are a series of 15 elements 
with similar physiochemical properties, changing periodically with the atomic number 57-71. 
They are f-electronic, chemically active and silvery-white. The term “rare-earth element” is in 
fact beguiling, because these elements exist in the earth’s crust at levels comparable to some 
physiologically important elements such as iodine, cobalt and selenium (Palasz and Czekaj, 
2000). It is important to note that one of the lanthanides is praseodymium, which is present in 
the compound praseodymium (2-mercaptopyridine N-oxide)(dimethyl sulfoxide) (Pr-MPO) 
used in this study.  
 
Intensified research endeavors in metal-containing compounds were incited by the landmark 
discovery in the 1960s of platinum-based cisplatin as a chemotherapeutic agent. Since then, 
cisplatin has dominated the treatment of a wide variety of tumors including ovarian, cervical, 
head and neck cancers, and so forth (Kelland, 2007). Despite its therapeutic efficacy, cisplatin 
is notoriously toxic to the kidneys and gastrointestinal tract. In a drive to develop safer 
platinum-based compounds, thousands of platinum-based analogs have since been generated, 
with only carboplatin (2
nd
 generation) and oxaliplatin (3
rd
 generation) being approved for 
clinical use (Alama et al., 2009). Although more manageable, problems pertaining to toxicity 
and tumor resistance persisted, triggering continuous efforts to explore the use of other 
metals, Ln included. In particular, Ln are found to competitively suppress iron uptake, inhibit 
ROS production by binding to hydroperoxides, and mask free radicals via magnetic 
interaction (Kostova, 2005). Hence, given the proposed role of iron-mediated ROS in 
triggering oncogenesis, Ln compounds appear to be promising as therapeutic drugs for 




 compounds and complexes, 
with little or no information about the other lanthanides. LaCit and CeCl3 were reported to 
tumor-selectively inhibit DNA synthesis of PG cancer cells, while sparing human embryo 
diploid fibroblasts (Kostova, 2005). This tumor-targeted action was thought to be due to 
53 
 
differential uptake, accumulation and metabolism of the Ln compounds. In vivo, 
intraperitoneal administration of mixed Ln nitrates exerted antitumor effects on S180 sarcoma 
and Lewis lung cancer grafted in mice (Kostova, 2005). Furthermore, Tb
3+
 was demonstrated 
to augment the lethal effect of cisplatin in cancer cells, especially cisplatin-resistant breast 
carcinoma (Fuller and Canada, 1999). It was later found that cancer cells contain a specific 
Tb
3+
-binding receptor that mediates accumulation of cisplatin in tumors, indicating a role for 
Tb
3+
 or other Ln in combination chemotherapies (Mack et al., 1997). In sum, though 
mechanistic understanding of their tumor-targeted actions is far from complete, Ln-based 
compounds demonstrate significant potential as anticancer agents. Clearly, more studies are 
required to evaluate the less studied Ln counterparts of La and Ce, in order for new 
compounds with improved therapeutic profiles to be developed.  
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MATERIALS AND METHODS 
1 Cell lines and cell culture 
SHEP-1 neuroblastoma cells, a generous gift from Dr. Eva L Feldman (University of 
Michigan Health System, Ann Harbor, Michigan, USA), were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM, Hyclone, Logan, Utah, USA) supplemented with 10% 
fetal bovine serum (FBS, Hyclone, Irvine, CA) and 1% penicillin/streptomycin (Hyclone, 
ThermoScientific, Waltham, MA). MDA-MB-231, MCF-7, T47D breast cancer cell lines, , 
Jurkat lymphoma and Raji T-lymphocytic leukemia cells, DU145 prostate carcinoma cell line 
and SHSY5Y neuroblastoma cell line were all purchased from American Type Culture 
Collection (ATCC, Rockville, MD) and maintained in Roswell Park Memorial Institute 1640 
medium (RPMI, Hyclone, Logan, Utah, USA) supplemented with 1% L-glutamine, 1% 
penicillin/streptomycin and 10% FBS. MCF10a immortalized normal mammary epithelial 
cell line was purchased from ATCC and cultured in Mammary Epithelial Growth Medium 
(MEGM, Clonetics, La Jolla, CA) supplemented with 5% horse serum (Clonetics, La Jolla, 







 cells were generously given by Dr. Bert Vogelstein (The Johns Hopkins 
University School of Medicine, Baltimore, MD) and maintained
 
in McCoy 5A (Gibco 
Invitrogen Corporation, Carlsbad, CA) supplemented with 10% FBS, 1% L-glutamine and 
1% penicillin/streptomycin. All cell lines were maintained in a humidified incubator at 37
o
C 
with 5% CO2 and sub-cultured according to suppliers’ recommendations two to three times a 
week. Only cells from less than 20 passages were used for the experiments. 
 
2 Synthesis and analysis of the patented small-molecule compound Pr-MPO 
The starting material, praseodymium oxide (Pr6O11) was purchased from Sigma Aldrich (St 
Louis, MO). In a small flask, Pr6O11 (102.1 mg, 0.1 mmol) was dissolved in 10ml of HCl (6 
M). The solution was neutralized with a solution of 1 M sodium hydroxide to pH 5. A 
solution of MPONa (282.3 mg, 1.8 mmol, 95% active) in water was added. The solution was 
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stirred for 2 hours at 40
 0
C and then was cooled to room temperature to give green 
microcrystals, which were collected by filtration, washed successively with H2O, ethanol, and 
dried in vacuo. Pale green prism crystals suitable for X-ray analysis were obtained by 
recrystallization of the precipitate from dimethyl sulfoxide. The molecular formula of the 
compound is C19H24N3O5S5Pr, and the molecular weight is 675.62. Elemental analysis 
(calculated values were given in parentheses): C, 33.81 (33.78); H, 3.62 (3.58); N, 6.28 
(6.22%). Spectroscopic analysis: IR (cm-1): 1141(s, C S), 1090 (s, N O); UV-vis (DMSO): 
290, 346 nm. 
 
3 Reagents and chemicals 
15d-PGJ2 and pan-caspase inhibitor zVAD-fmk were purchased from Alexis Biochemicals 
(Lausane, Switzerland). Rosiglitazone, ciglitazone, GW9662, GW7647 and GW0742 were 
purchased from Cayman (USA). Praseodymium oxide (Pr6O11), Nec-1, 3-MA, Pepstatin A, 
E64-d, MTT, crystal violet, bromophenol blue, Tween 20, EDTA, DTT, glycine, BSA, 
DMSO and actinomycin D were purchased from Sigma Aldrich Co (St Louis, MO). 
Fluorogenic substrates of caspase-3, -6, -8 and -9 were purchased from Biomol (Plymouth 
Meeting, PA, USA). Coomassie Blue was purchased from Pierce Biotechnology (Rockford, 
IL, USA). 10x PBS, 10x SDS, Tris-HCl buffer (pH7.4) were purchased from NUMI Media 
Preparation Facility (NUS, Singapore). TNF-α was bought from Millipore (Billerica, MA). 
Hygromycin B was purchased from Invitrogen (Carlsbad, CA, USA).  
 
4 Drug treatments 
Fine green crystals of Pr-MPO were dissolved in sterile water to prepare 10µM or 100µM 
stock solutions which were stable for at least three months in -20
o
C. Stock solutions of 
rosiglitazone, ciglitazone, GW9662, GW7647, GW0742, necrostatin-1, E64-d and 
actinomycin D were prepared in DMSO. 15d-PGJ2 was dissolved in pure ethanol solvent and 
pepstatin A was dissolved in 70% ethanol. For all compounds, final working concentrations 
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were attained by freshly diluting stock solutions with complete medium before use. For 
treatment of 3-MA, weighed 3-MA powder was dissolved in sterile water by heating briefly at 
70
o
C and subsequently cooled at 37
o
C for 5 minutes before being added to cells. Durations of 
drug treatment and inclusions of ethanol or DMSO vehicle controls were indicated in the 
respective figure legends.  
 
5 Plasmids and siRNAs 
GAL4-mPPARα-LBD, GAL4-mPPARγ-LBD, GAL4-PPARδ-LBD chimeric constructs and 
GAL4-luc reporter plasmid were generously provided by Dr. Javier F. Piedrafita (Torrey 
Pines Institute for Molecular Studies, San Diego, CA, USA).  
 
3xPPRE-tk-luc reporter construct, pTA-luc empty vector and pCMX-mPPARγ encoding for 
mouse PPARγ were kindly given by Dr. Ronald M. Evans (The Salk Institute for Biological 
Studies, San Diego, CA, USA).  
 
Dominant negative mPPARγ mutant (pCMX-mPPARγC126A/E127A) containing two amino acid 
substitutions in the DNA binding domain that abolish binding to PPAR response elements, 
was kindly provided by Dr. Christopher K. Glass (University of California, San Diego, CA, 
USA).  
 
pCMV-HA-NHE-1 encoding N-terminal haemagglutinin (HA) epitope tagged-NHE-1 was 
contributed by Dr. Jeffrey R. Schelling (MetroHealth Medical Center, Cleveland, Ohio, 
USA).  
 
pGFP-rLC3 and pGFP empty vector were a generous gift from Professor T. Yoshimori 




pcDNA-MnSOD , pcDNA-Bcl-2 and pIRES-Hygromycin-resistance plasmid were gifts from 
Dr. Marie-Veronique Clement (Department of Biochemistry, National University of 
Singapore, Singapore).  
 
pcDNA 3.1 and pCMX empty vectors were purchased from Invitrogen (Carlsbad, CA) and 
renilla plasmid was purchased from Clonetech Laboratories Inc. (Palo Alto, CA).  
 
HuSH 29mer shRNA constructs against PPARγ in pGFP-V-RS vector and shRNA negative 
control were purchased from Origene (Rockville, MD). Four different constructs with 
different sequences were provided. The shRNA construct that was most efficient in transient 
knockdown of PPARγ in SHEP-1 cells had the following sequence: 
TGAGAAGACTCAGCTCTACAATAAGCCTC (ID G1379055), while that for MDA-MB-
231 cells was CCTTCACTACTGTGTTGACTTCTCCAGCATT (ID GI379053) .  
 
ON-TARGETplus SMARTpool siRNAs (a mixture of 4 siRNAs in a single reagent) targeting 
PPARγ, Atg7, ULK1, Beclin 1, BNIP3, RhoB, PTEN, HIF1-α as well as siRNA negative 
control (non-homologous to any known gene sequence) were purchased from Dharmacon 
Technologies (ThermoFisher Scientific, Lafeyette, CO). For BNIP3, ON-TARGETplus Set of 
4 siRNAs were also purchased from Dharmacon Technologies (ThermoFisher Scientific, 
Lafeyette, CO), which were four individual siRNAs targeting siBNIP3.  
 
6 Transfection of plasmids and siRNAs 
In all cells, the Calcium Phosphate Mammalian Transfection Kit (Clonetech Laboratories 
Inc., Palo Alto, CA) was used for transfection of plasmids or siRNAs. Cells to be transfected 
were grown to 40% confluency on 6-well plates (for western blot analyses and GFP-LC3 
fluorescence visualization, seeded at 0.22 x 10
6
 cells/well) or 12-well plates (for MTT and 
luciferase reporter assays, seeded at 0.07 x 10
6
 cells/well). Before transfection, the cell culture 
medium was changed to fresh DMEM supplemented with 10% FBS, 1% L-glutamine and 1% 
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penicillin/streptomycin. On 6-well plates, 8µg of plasmids were used per well for all 
expression plasmids except for pcDNA-Bcl-2, in which case 3µg was used. On 12-well 
plates, 5µg of plasmids were used per well except for pcDNA-Bcl-2 (1.5µg). For siRNAs, 
50nM was used per sample for all siRNAs except for siPPARγ, in which case 200nM was 
used. To prepare the transfection mixture, calculated amounts of DNA or siRNAs were 
diluted in sterile dH2O, followed by addition of 12.4µl of 2.5mM CaCl2 in a total amount of 
100µl per 6 well. For a 12-well, all calculations were halved. The DNA-CaCl2 or siRNA-
CaCl2 solution was then mixed drop-wise with an equal volume of the DNA precipitation 
buffer (2x HEPES-buffered saline) while gently vortexing. The resultant mixture was 
incubated for 20 minutes at room temperature before added drop-wise into the cells (200µl 
per 6-well, 100µl per 12-well). After 16h of incubation, cell were washed with 1x PBS and 
recovered in cell culture medium used normally for maintenance. Downstream procedures 
were carried out at least 48h from the time of adding transfection reagents.  
 
7 Luciferase Gene Reporter Assays 
In the luciferase reporter assay based on chimeric constructs, cells were grown to 30-40% 
confluency on 12-well plates before being co-transfected with 5µg of chimeric constructs 
(GAL4-mPPARα-LBD, GAL4-mPPARγ-LBD or GAL4-PPARδ-LBD), 5µg of GAL4-luc 
reporter and 0.1µg of renilla plasmid using the calcium phosphate precipitation method as 
described above. In the luciferase reporter assay utilizing 3 x PPRE-tk-luc plasmids, cells 
were co-transfected with 5µg of 3 x PPRE-tk-luc (DR1) plasmid and 0.1µg of renilla plasmid 
instead. To assay for the effect of PPARγ overexpression, mutation, or knockdown on DR1 
reporter activity, another 5µg of pCMX-mPPARγ, pCMX-mPPARγC126A/E127A, or shPPARγ 
was co-transfected correspondingly. Cells co-transfected with pCMX empty vector or shRNA 




In both chimeric construct-based and DR1-based assays, luciferase activity was assessed by a 
dual-luciferase assay kit (Promega, Madison, WI) according to manufacturer’s instructions. 
48h after transfection, cells were subjected to drug treatments for specified durations. Media 
were then aspirated from the wells and cells were washed once with 1X PBS. Cells were 
lysed with 100µl of reporter lysis buffer. To measure reporter activity, 10µl of cell lysate was 
added to 50µl of luciferase substrate solution, and the bioluminescence generated (first 
bioluminescence reading) was measured by a Sirius luminometer (Berthold). Following this, 
50µl of stop & glow buffer was added to generate a second reading of bioluminescence, 
corresponding to the renilla activity. To calculate total reporter activity, the first 
bioluminescence reading is normalized to the second bioluminescence reading to account for 
transfection efficiency, after which the luminescence reading is normalized to the protein 
content of the corresponding cell lysate (assessed by Coomassie Blue reagent).  
 
8 Amplification and purification of plasmids 
In the transformation step, 100µl of Escherichia coli (E.coli) competent cells were incubated 
with 100ng of a plasmid at 4
o
C for 3 minutes before being subjected to heat-shock treatment 
for 1 minute at 42
o
C, and then incubated on ice for 5 minutes. The competent cells were then 
incubated with 900µl of sterile lysogeny broth (LB) for 30 minutes on a rotator set at 200rpm 
in a 37
o
C bacterial incubator with 5% CO2. Subsequently, 100µl of the mixture was plated on 
LB plates containing kanamycin (for shRNAs, pGFP-LC3 and pGFP empty vector) or 
ampicillin (for all other plasmids used in this study) antibiotics and incubated at 37
o
C. After 
16 hours of incubation, a single cell colony was picked from the LB plate and mixed with 5ml 
of sterile LB medium containing the appropriate antibiotic to prepare a mini culture. The mini 
culture was incubated for 16 hours at 37
o
C in 5% CO2, after which 1ml of mini culture was 
added to 250ml of LB medium containing the appropriate antibiotic to prepare a maxi culture. 
The maxi culture was again incubated for 16 hours at 37
o
C in 5% CO2, following which the 
maxi culture was centrifuged at 2,500rpm for 30 minutes at 4
o
C. Downstream steps were 
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carried out by using Nucleobond
TM
 DNA purification kit (Macherey-Nagel, Germany) 
according to the manufacturer’s instructions. The pellet was resuspended in 10ml of S1 buffer 
and then lysed with 10ml of S2 buffer for 10 minutes on ice. The suspension was then 
incubated with 10ml of S3 buffer for neutralization and then subjected to centrifugation at 
12,000rpm for 30 minutes at 4
o
C. The supernatant was then filtered through the 
Nucleobond
TM
 ion-exchange column, which was pre-equilibrated with 5ml of N2 buffer. 
After the supernatant had been filtered, 12ml of N3 buffer was run through twice to wash the 
column. The plasmid was then eluted with 12ml of N5 buffer, which was followed by 
precipitation with 8.4ml of isopropanol and centrifugation at 12,000rpm for 30 minutes at 
4
o
C. For further purification, the plasmid was resuspended in 1/10 volume of 5M NaCl and 2x 
volume of 95% v/v ethanol before being incubated in -80
o
C for 30 minutes. After incubation, 
the mixture was centrifuged at 14,000rpm for 30 minutes at 4
o
C, following which the pellet 
was washed with 70% v/v ethanol twice. The pellet was air-dried briefly before resuspension 
in 100µl of sterile water. Plasmid concentration was determined using NanoDrop 1000 
Spectrophotometer (Thermo Fischer Scientific, Wilmington, DE). 
 
9 Computational identification of PPREs in the promoter regions of target 
genes 
The promoter regions of BNIP3 and HIF1-α were searched for the presence of PPREs using 
the PPREsearch database as described previously (Venkatachalam et al., 2009). This is the 
only online transcription factor binding program that is capable of searching for both DR-1 
and DR-2 binding sites. The promoter sequences 5 kb upstream of the transcription start site 
from transcripts of human BNIP3 and HIF1-α were retrieved from the Transcriptional 
Regulatory Element Database (TRED). The PPREsearch program searched the extracted 
promoter sequences against the established database of previously in vitro and in vivo 
validated consensus PPREs. In this program, both the homology of identified motifs in the 
target genes’ promoter regions matched against consensus sequences, as well as the 
61 
 
nucleotide sequences in the 5’flanking region of the identified PPREs were taken in account 
to yield an estimated reading of binding affinity.  
 
10 Determination of cell viability by MTT assay 
The effects of various treatments on cell viability was determined by the 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) assay as described previously (Mosmann, 
1983), with minor modifications. 0.07 x 10
6
 cells per well were seeded in duplicates on a 12-
well plate and cultured for two days before drug treatment. At the end of drug treatment, 
floating cells were collected and cells still attached to the culture dish were trypsinized. Cells 
from the same well were pooled and re-plated onto a 96-well plate (100µl of medium per 
well) and incubated with 100µl of MTT per well at 37
o
C for 4 hours. After this, formazan 
crystals formed were spun down with centrifugation at 3,000rpm for 15 minutes, following 
which the supernatant was aspirated and the formazan crystals were dissolved with DMSO. 
Absorbance was measured with a TECAN sprectrophotometer (Tecan Trading AG, 
Switzerland) at 570nm. The optical density (OD) measured is proportional to the number of 
viable cells. Percentage of cell survival is calculated relative to the untreated control cells as 
(mean triplicate OD of treated cells/mean triplicate OD of vehicle control cells) x 100%.  
 
11 DNA fragmentation assay by propidium iodide staining 
DNA content of cells was analysed using propidium iodide (PI) staining. Cells were scraped 
on ice, collected and pelleted down by centrifugation at 2,500 rpm. After washing twice with 
ice-cold 1% (v/v) FBS in PBS, cells were fixed with 70% (v/v) ethanol for at least 30 minutes 
at 4
o
C. The cells were vortexed while adding ethanol to prevent clumping. The fixed cells 
were then pelleted by centrifugation at 10,000rpm for 5 minutes at 4
o
C, washed twice with 
ice-cold 1% FBS/PBS before being stained with 500µl of PI/RNase solution for 30 minutes at 
37
o
C. The staining solution contains 10µg/ml PI and 250µg/ml RNaseA dissolved in PBS. 
Stained cells were filtered through a 61µm pore size filter. At least 10,000 events were 
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analysed for DNA content with flow cytometry (CyAn ADP, Beckman Coulter, USA) with 
the excitation set at 488nm and emission at 610nm. Data collected were analysed with the 
WinMDI software (Windows multiple document interface for flow cytometry, Beckman 
Coulter Inc., Sunnyvale, CA). In a typical DNA analysis, the apoptotic population of cells are 
represented in the histograms as having hypodiploid DNA content, marked as the sub-G1 
population. 
 
12 Colony forming assay 
At the end of drug treatment, cells were washed with 1 x PBS, trypisinized, and counted. For 
every treatment, 8000 cells were re-plated onto a 100mm dish in complete tissue culture 
medium. Re-plated cells were left to form colonies over a period of 10 to 14 days in a 
humidified incubator at 37
o
C with 5% CO2. , supplemented with complete medium every 3-5 
days. Colonies formed were assessed by staining cells with crystal violet. The number of 
colonies formed was manually scored using a 1cm x 1cm grid system, with at least three 
randomly selected 1mm
3
 areas scored for every plate and then averaged to give a 
representative reading.  
 
13 Caspase activity assay 
Activation of caspases was determined using fluorogenic substrates, which are synthetic 
oligopeptides of the caspase cleavage site where the C-terminal aspartic acid has been 
modified with 7-amino-4-trifluoromethyl coumarin (AFC). Cells were harvested on ice at the 
end of different time points and lysed with chilled 1 x Cell Lysis Buffer (BD Pharmingen, San 
Diego, CA). Cell lysates were added to equal volumes of 2 x Reaction Buffer (10mM 
HEPES, pH 7.4, 2mM EDTA, 6mM DTT, 10mM and 1.5mM MgCl2) and respective caspase 
substrates on a 96-well plate. Caspase-3 substrate is Ac-DEVD-AFC, caspase-6 substrate is 
Ac-VEID-AFC, caspase-8 substrate is Ac-IETD-AFC and caspase-9 substrate is Ac-LEHD-
AFC. Samples were incubated at 37
o
C for 1 hour, after which enzyme-catalyzed release of 
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AFC fluorescence was measured with TECAN spectrophotometer (Tecan Trading AG, 
Switzerland) (excitation: 400nm, emission: 505nm). Protein concentration of each sample 
was determined using the Coomassie Blue reagent. Caspase activity was normalized with 
protein amount and expressed as relative fluorescence unit (RFU)/µg protein.  
 
14 Western blot analysis 
Whole cell protein extracts were prepared after drug treatments using 1x RIPA lysis buffer. 
Mitochondrial, nuclear and cytosolic fractions were obtained as described in other sections 
(see Mitochondrial-cytoplasmic fractionation and Nuclear-cytoplasmic fractionation). Protein 
concentration was quantified using Coomassie Blue reagent. Briefly, 1µl of the lysate 
supernatant was added to 200µl of Coomassie Blue reagent on a 96-well plate. Absorbance 
was read at 595nm using a TECAN spectrophotometer (Tecan Trading AG, Switzerland). 
Equal amounts of proteins (50 to 80µg) from the lysates were mixed with 5x Laemmli 
loading dye and incubated at 37
o
C (for detection of NHE-1 protein) or 100
o
C (for detection of 
all other proteins) for 5 minutes. The samples were then subjected to sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) with 8, 10, 12 or 15% (v/v) 
acrylamide resolving gel depending on the molecular weight of the target proteins. 
Kaleidoscope pre-stained standards (Bio-Rad, CA, USA) were included to estimate the 
molecular sizes of the protein bands detected. The resolved proteins were then transferred 
onto PVDF membranes (BioRad, CA, USA) using the wet transfer method at 300mA for 1 
hour in an ice-bath. Membranes were then blocked with 5% (w/v) fat-free milk in Tris-
buffered saline/Tween 20 (TBST) for 30 minutes and washed thrice with TBST to remove 
excess milk. Membranes were probed for the target proteins with the corresponding primary 
antibodies (refer to list of antibodies below) in 5% BSA in TBST overnight at 4
o
C. The 
primary antibodies were then removed, and the membranes were washed thrice to remove 
unbound primary antibody and exposed again to HRP-conjugated secondary antibody in 5% 
(w/v) fat-free milk in TBST for 1 hour at room temperature. After three washes with TBST to 
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remove any excess unbound secondary antibody, the proteins of interest were detected with 
Kodak Biomax MR X-ray film (Eastman Kodak Co., Rochestor NY) by enhanced 
chemiluminescence using the SuperSignal West Pico Chemiluminescent Substrate (Pierce, 
Rockford, IL, USA). Protein bands obtained were scanned in CanoScan LiDE 200 and 
analysed by FujiFilm Multigauge V3.0 for densitometry analysis. Band densities of target 
proteins were normalized against band densities of house-keeping β-actin or GAPDH. 
 
For re-probing of the same membrane for different proteins, membranes were stripped with 
Restore Western Blot Stripping Buffer (Pierce, Rockford, IL, USA) before being re-probed 
with primary and secondary antibodies for another target protein.  
 
14.1 Buffers used in western blot analysis 
RIPA lysis buffer: 50mM Tris-HCl (pH 7.5), 150mM NaCl, 1% v/v Nonidet P40, 1% v/v 
deoxycholic acid, 0.1% (v/v) SDS and 1mM EDTA. Before use, the buffer was supplemented 
with protease inhibitors (5µg/ml leupeptin, 1mM PMSF, 10μg/ml aprotinine, 20μg/ml 
pepstatin A) and a phosphatase inhibitor (1mM Na3VO4). 
 
Running Buffer for SDS-Page gel: 10X (2L): Tris-base 60g, glycine 288g, SDS 20g, 
topped up to 2L with dH2O 
 
Transfer Buffer for western blot: 1X (1L): Tris-base 2.42g, glycine 11.57g, methanol 
200ml, topped up to 1L with dH2O 
 
Laemmli Loading Buffer: 5X (10 ml): Tris-HCL (pH 6.8) 3.1ml (stock: 1M, final 
concentration: 100mM), SDS 1g (10%), glycerol 2ml (20%), β-Mercaptoethanol 2.5ml 




TBS: 500ml of 1M Tris-HCl (pH 7.4) with 87.6 g of NaCl in 10L of dH2O and stored at 
room temperature 
 
TBST: 2L TBS with 2ml of Tween-20 and stored at room temperature 
 
15 Primary antibodies for western blot analysis 
Primary antibodies specific for PPARγ, PPARδ, PPARα, NHE-1, BNIP3, Bax, cytochrome c, 
VDAC, AIF, SQSTM1/p62, p53, β-actin and GAPDH were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). Primary antibodies probing for PTEN, RhoB, HIF1-
α, Atg7, ULK1, Beclin 1, LC3B, CuZnSOD, PARP, Bcl-2, caspase-3, caspase-7, caspase-8 
and caspase-9 were purchased from Cell Signaling Technology (Danvers, MA). Primary 
antibodies for MnSOD, and phosphorylated-PPARγ were purchased from Upstate/Millipore 
Corporation (Billerica, MA).  
 
16 Mitocondrial-cytoplasmic fractionation 
1.0 x 10
6
 cells were seeded on 100mm dish for two days before drug treatment. At least three 
dishes were required per treatment. Cells were harvested and washed once with ice-cold 1 x 
PBS before incubation on ice for 15 minutes with extraction buffer A (50mM PIPES-KOH 
pH 7.4, 200mM mannitol, 68mM sucrose, 50mM KCl, 5mM EGTA, 2mM MgCl2, 1mM 
DTT, pH7.4) containing the usual protease inhibitors described under Western blot analysis. 
After incubation, cells were homogenized using a dounce homogenizer and passaged for 23 
strokes before being centrifuged at 300g for 10 minutes at 4
o
C. The supernatant was 
transferred out and centrifuged again at 12,000g for 15 minutes at 4
o
C. The pellet containing 
intact mitochondrial fraction was lysed with standard 1 x RIPA lysis buffer supplemented 




17 Nuclear-cytoplasmic fractionation 
Isolation of nuclear and cytoplasmic fractions was conducted using the NE-PER Nuclear and 
Cytoplasmic Extraction Reagents (PIERCE, Thermo Fisher Scientific Inc, Rockford, USA). 
1.0 x 10
6
 cells were seeded on 100mm dish for two days before drug treatment. At least three 
dishes were required per treatment. At the end of drug treatment, cells were harvested on ice 
and pelleted by centrifugation at 2,200 rpm for 5 minutes at 4
oC. According to manufacturer’s 
instructions, 100µl of CERI was added to the sample, after which the tube was vortexed 
vigorously for 15 seconds and the sample was then incubated on ice for 10 minutes. 5.5µl of 
ice-cold CER II was then added, after which the sample was vortexed for 5 seconds and 
incubated on ice for 1 minute. The sample was then centrifuged for 5 minutes at maximum 
speed. The supernatant was transferred out and used as cytoplasmic extract, while the pellet 
was resuspended in 50µl of NER. The resuspended pellet was vortexed for 15 seconds every 
10 minutes, for a total of 40 minutes. The suspension was then centrifuged at maximum speed 
for 10 minutes and the supernatant obtained was used as the nuclear extract.  
 
18 mRNA isolation and measurement of mRNA levels by real-time PCR 
At the end of drug treatment, cells plated on 6-well plates were lysed with 1ml of TRIzol 
(Invitrogen, Carlsbad, CA) per well. Homogenized samples were incubated for 10 minutes at 
room temperature. The homogenates were then added with 0.2ml of chlorofoam per sample, 
mixed by vigorous inversions and incubated for 10 minutes at room temperature. The samples 
were then centrifuged at 12,000g for 15 minutes at 4
o
C. The top aqueous phase containing 
RNA was transferred out into a fresh eppendorf tube and mixed with 0.5ml of isopropyl 
alcohol for precipitation of RNA. After 15 minutes incubation at room temperature, the 
samples were centrifuged at 12,000g for 15 minutes. After discarding the supernatant, the 
RNA precipitate was washed once with 1ml of 70% ethanol. The RNA pellet was air-dried 
for 30 minutes before resuspension in RNAse-free water and determination of RNA 
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concentration with NanoDrop 1000 Spectrophotometer (Thermo Fischer Scientific, 
Wilmington, DE). 
 
Reverse transcription (RT) was then carried out. RT reaction contained 200ng of total RNA, 
1x RT buffer, 5mM MgCl2, 425µM each of dNTPs, 2µM random hexamers, 0.35U/µl RNase 
inhibitor and 1.1U/µl MultiScribe
TM
 reverse transcriptase made up to 10µl with sterile water. 
RT reaction was carried out in PCR thermal cycler (Mastercycler gradient, Eppendorf, USA) 
at 25
o
C for 10 minutes, followed by 37
o
C for 60 minutes and a terminating step at 95
o
C for 5 
minutes. A negative control was included in which RNA was replaced by sterile water; in 
another negative control, only RNA and sterile water were added.  
 
For real-time PCR, 5µl of RT product was mixed with 1x TaqMan® Universal PCR Master 
mix, 2.5µl of 20x specific TaqMan probe, 2.5µl of 18sRibosomal RNA TaqMan probe, 
topped up to 50µl with sterile water. Real-time PCR was carried out using 7500 Fast Real-
Time PCR System (Applied Biosystems, USA) with a protocol consisting of 50
o
C for 2 
minutes, 95
o
C for 10 minutes followed by 40 cycles of denaturing at 95
o
C for 15 seconds and 
extension at 60
o
C for 1 minute. Real-time PCR was performed in multiplex, whereby both 
target and endogenous control were co-amplified in the same reaction. Results were analysed 
using Sequence Detection Software version 1.3 (Applied Biosystems, USA). Relative gene 
expression was analysed by the software after normalization with endogenous 18sRibosome 
and determination of the difference in threshold cycle (Ct) between treated and untreated cells 
using the 2
-ΔΔCt
 method. Pre-designed primer/probe sets used for detection of huBNIP3, 
huHIF1-α, huMnSOD, huNHE-1, huPTEN and huRhoB were purchased from Applied 




19 Fluorescence microscopy for GFP-LC3 
48 hours after transfection with pGFP empty vector or pGFP-LC3, cells were treated with 
drugs as indicated. GFP fluorescence was visualized by a fluorescent microscope (Eclipse 
TE2000-S, Nikon) using excitation wavelength of 488nm and emission wavelength of 525nm. 
The number of GFP-positive cells per well was scored under magnification of x 40,000. At 
least 100 transfected cells were counted and only cells with at least five punctate dots were 
scored as positive. Duplicate samples were used for each treatment.  
 
20 Transmission electron microscopy 
Cells were fixed overnight in 2.5% glutaraldehyde in 0.1M phosphate buffer (pH 7.2) at 4°C, 
before being post-fixed in 1% osmium tetraoxide for 1h on a rotator. The cells were washed 
three times with 1 x PBS and then resuspended in 6% gelatin for 10 minutes. After spinning 
the sample at 3,000rpm, excessive gelatin was removed while the pellet was fixed with 2.5% 
glutaraldehyde for another 10 minutes. After three washes with dH2O, the sample was cut into 
1 mm
3
 cubes, which were subsequently dehydrated with increasing concentrations of ethanol 
(25% alcohol to 100% alcohol and finally to 100% acetone). The samples were gradually 
infiltrated with Epon-Araldite (starting with a 1:6 ratio of Epon-Araldite:acetone to 100% 
Epon-Alraldite). On the next day, three changes of fresh Epon-Araldite were made at 40°C to 
50°C before the samples were polymerized at 60°C for 24 hours. Ultrathin sections of 90-
100nm were cut with a Leica EM UC6 microtome and collected on copper slot grids. These 
sections were counterstained with uranyl acetate and lead citrate and observed under a JEOL 
JEM-1230 transmission electron microscopy operating at beam energy of 100keV. Images 
were acquired by a Gatan ES500W Erlangshen camera with 1350 x 1040 pixels.  
 
21 Measurement of mitochondrial superoxide by MitoSoxTM Red 
Detection of intra-mitochondrial superoxide (O2
·-





 Indicator (Molecular Probes, Invitrogen Corporation, CA). This is a live-
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cell permeable dye with hydroethidine (HE) covalently linked to a triphosphonium (TPP
+
) 
cation through a hexyl carbon chain. The positive charge on the phosphonium group enables 
this dye to be selectively targeted to the negatively charged mitochondrial membrane. Upon 
oxidation of the HE moiety by O2
·-
, the dye exhibits red fluorescence. Treated cells were 
incubated with MitoSox
TM
 RED at 37
0
C for 30 minutes before washing twice with 1 x PBS. 
Stained cells were immediately analysed by flow cytometry (CyAn ADP, Beckman Coulter, 
USA) set at an excitation wavelength of 590nm and emission wavelength of 619nm. At least 
10,000 events were analyzed. Data collected were analysed using the WinMDI software 
(Beckman Coulter Inc., Sunnyvale, CA).  
 
22 Determination of intracellular ROS/RNS by CM-H2-DCFDA 
At the end of drug treatment, cells were trypsinized, washed with 1 x PBS, and loaded with 5-
(and-6)-chloromethyl-2,7-dichlorofluorescin diacetate (CM-H2-DCFDA, Molecular Probes, 
Invitrogen Corporation, CA) at 37
0
C for 15 minutes. Stained cells were washed again with 1 x 
PBS and analysed by flow cytometry (CyAn ADP, Beckman Coulter, USA) using an 
excitation wavelength of 488nm and emission wavelength of 525nm. At least 10,000 events 
were analysed. Data collected were analysed with the WinMDI software (Beckman Coulter 
Inc., Sunnyvale, CA).  
 
23 Extraction and purification of PBMCs 
Human peripheral blood mononuclear cells (PBMCs) were kindly provided by Dr. Herbert 
Schwarz (National University of Singapore, Singapore). To extract the PBMCs, buffy coat 
was diluted with 2x volume of PBS and added with 2mM EDTA to stop coagulation. The 
blood was then gently loaded on 12ml of Histopaque-1077 and centrifuged at 400g for 30 
minutes at 25
o
C. Most of the top layer, which contained plasma and PBS, was carefully 
removed. The interface layer, containing PBMCs, was gently transferred out, and diluted with 





The supernatant, which was PBS, was aspirated. 1x volume of red blood cells (RBC) lysis 
buffer was then added and the mixture was incubated at room temperature for 10 minutes. To 
remove the lysed red blood cells, the mixture was centrifuged at 300g for 10 minutes at 25
o
C. 
1x volume of PBS and 2mM EDTA were again added and centrifuged at 300g for 10 minutes. 
Finally, the supernatant comprised of PBMCs was transferred out and resuspended in RPMI 
supplemented with 10% FBS, 1% L-glutamine and 1% penicillin/streptomycin. 
 
24 Extraction and purification of clinical tumors 
The lymphoma samples were excised by surgeons from the National University Hospital 
(NUH) after receiving patients’ consent under a protocol approved by the National University 
of Singapore’s Institutional Review Board. After the clinical samples were received, the 
lymphoma tissues were grinded between two glass slides and strained through MACS 
separation filter to achieve single cell suspension. The suspension was then topped up with 
RPMI supplemented with 10% FBS, 1% L-glutamine and 1% penicillin/streptomycin before 
further treatment. The histopathological identities of the samples were listed as follows: 
 
Sample Diagnosis Malignant/Benign 
Patient sample 93 Follicular lymphoma Malignant 
Patient sample 94 Diffused B-cell lymphoma Malignant 
Patient sample 95 Metastasized ovarian carcinoma Malignant 
Patient sample 96 Follicular lymphoma Malignant 
 
 
25 Statistical analysis 
All experiments were carried out 3 times or more, unless otherwise stated. Results were 
expressed as mean + s.e.m. Statistical differences for experiments involving more than two 
groups were evaluated using the one-way analysis of variance (ANOVA) followed by the 
Post-hoc Dunnett test, while the paired Student’s t-test was used when comparisons between 




1 Pr-MPO is a potent activator of PPARγ 
1.1 Pr-MPO elicits robust activation of exogenous PPARγ and PPARα 
Despite PPARγ activation being a promising anticancer strategy, high attrition rate of PPARγ 
agonists in the clinical setting underscore a critical need for novel synthetic activators of 
PPARγ that are efficacious yet safer. To identify potential PPARγ agonists, we screened 
numerous novel compounds previously synthesized in our laboratory for their abilities to 
activate PPARγ receptor in a physiologically relevant cell-based model.  
 
In this cell-based assay of ligand identification, SHEP-1 neuroblastoma cell line was chosen 
as the main model of study due to reported overexpression of functional PPARγ in 
neuroblastoma cells, rendering this cancer type responsive to conventional PPARγ ligands 
(Han et al., 2001b; Sato et al., 2003). We co-transfected SHEP-1 cells with a chimeric 
receptor composed of PPARγ Ligand Binding Domain (LBD) fused to the GAL4 DNA 
Binding Domain (GAL4-mPPARγ LBD), along with a GAL4-responsive luciferase reporter 
construct, and renilla plasmid as internal control (Figure 2A). In parallel experiments, cells 
were transfected with either GAL4-mPPARα LBD or GAL4-mPPARδ LBD. Transcriptional 
activation of the respective PPAR isoforms by the test compounds was then respectively 
assessed by luciferase assay as described in Materials and Methods. This reporter assay based 
on exogenous PPAR LBD is elucidated in Figure 2B. GW7647, Ciglitazone and GW0742 
were included as positive controls as they are specific agonists for PPAR, , and δ, 
respectively.  
 
Our initial screen resulted in the selection of Pr-MPO (Figure 1), a small-molecule compound 
synthesized from rare earth element Praseodynium (Pr), which efficiently stimulated 
transcriptional activity of PPARγ in a dose-dependent manner (Figure 2C). Moreover, Pr-
MPO was significantly more potent than pre-existing ligand Ciglitazone at equimolar 
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concentrations (2.90 + 0.39 fold by Pr-MPO 10µM vs. 1.64 + 0.16 fold by Ciglitazone 10µM, 
p < 0.05). Concurrently, we also observed a modest activation of exogenous PPARα by Pr-
MPO in cells co-transfected with GAL4-PPAR-LBD, albeit less substantially than the 
positive control GW7647 (2.20 + 0.10 by Pr-MPO 10µM vs. 10.82 + 1.23 fold by GW7647 
10µM, p < 0.05) (Figure 2D). Conversely, no effect was exerted on the  isoform (Figure 2E).  
 
These data shed the first light on the role of Pr-MPO as a novel PPARγ/α dual agonist. 
However, as reviewed in our introduction, PPARγ is the isoform that is most commonly 
overexpressed in cancer cells and hence implicated in tumorigenesis and cancer therapeutics. 
Thus, in this pilot study of Pr-MPO, we focused on addressing the role of the γ-isoform in 
mediating antineoplastic effects. At this juncture, it is important to note that SHEP-1 cell line, 
as with other neuroblastoma cell lines, is reported to express PPARγ and , but not PPARα 
(Han et al., 2001b; Isaac et al., 2006). Hence, the use of this cell line as our main 
experimental model allows us to gain mechanistic insights on PPARγ without confounding 
effects from putative Pr-MPO-induced α activation.  
 
Figure 1: Chemical structure of Pr-MPO. 
Chemical structure and molecular weight of the small molecule compound, praseodymium (2-










                      
 
Figure 2: Pr-MPO induces transcriptional activation of exogenously transfected PPARγ 
and α, but not PPARδ. 
Chimeric receptors employed to decipher Pr-MPO’s transactivation effect on different PPAR 
subtypes. (A) (I,II) Schematic representations of plasmids used, as previously described (Kim 
et al., 2005).Cells were co-transfected with a luciferase reporter construct containing a Gal4 
binding site (I) and chimeric receptors (II) (Gal4-mPPARγ-LBD for PPARγ transactivation, 
Gal4-mPPARα-LBD for PPARα transactivation, and Gal4-mPPARδ-LBD for PPARδ 
transactivation, respectively). (B) Transactivation system by a ligand/agonist using Gal4 DBD 
and PPAR-subtype-LBD chimeric receptor. Upon ligand binding to the LBD of a specific 
PPAR-subtype in the chimeric receptor, conformational changes of the LBD would be 
induced, followed by subsequent binding of the GAL4-DBD to the co-transfected Gal4 
binding site of the luciferase reporter construct, triggering transcription of the luciferase gene. 
(C-E) SHEP-1 cells were transfected with the plasmids shown in A, along with renilla 
plasmid for internal control. 48h after transfection, cells were exposed to Pr-MPO or positive 
controls at various concentrations as indicated for 16h before being harvested for luciferase 
activity as described in Materials and Methods. In all panels, reporter activity was normalized 
for transfection efficiency using renilla values and for cell viability using µg total protein. 
Thus, data were calculated as luciferase RLU/renilla/µg total protein and expressed as fold 
increase relative to untreated control. The bars represent means + s.e.m from three 
independent experiments with duplicates. In all panels, *, p < 0.05 as compared with 




1.2 Pr-MPO induces potent transcriptional activation of endogenous PPARγ 
in SHEP-1 cells 
Given that data from the initial test screen reflect merely LBD transactivation of exogenous 
transfectants, we employed an additional luciferase system to study Pr-MPO’s effect on 
endogenous PPARγ transcriptional activation. To this end, SHEP-1 cells were transiently 
transfected with a luciferase-linked PPARγ reporter construct containing 3 X PPARγ response 
element (PPRE), or pTA-luciferase (pTA-luc) empty vector before exposure to various doses 
of Pr-MPO (Figure 3A). Corroborating data from Figure 2C, Pr-MPO elicited robust dose-
dependent transcriptional activation of SHEP-1’s endogenous PPARγ receptor as 
demonstrated by 3xPPRE-tk-luc transfected cells (Figure 3B) (1.95 + 0.04 and 3.87 + 0.49 
fold increases for Pr-MPO 5µM and 10µM, respectively), with negligible luciferase activity 
elicited in pTA-luc empty vector transfected control cells (Figure 3B, inset). Further kinetic 
studies revealed that Pr-MPO-induced activation of PPARγ was evident at the shortest time-
point tested (2 hours after treatment), and increased stably in a time- and dose-dependent 
manner, reaching a peak at 8h after treatment (4.00 + 0.35 and 5.14 + 0.45 fold increases for 
Pr-MPO 5 and 10µM, respectively) (Figure 3C). This activation of PPARγ receptor was 
sustained for the entire duration of our 16h-study, and was still observable and pronounced at 
the 16h endpoint (1.95 + 0.036 and 3.87 + 0.50 fold increases for 5 and 10µM Pr-MPO, 
respectively). These data demonstrate the efficacy of Pr-MPO in triggering robust and 






Figure 3: Transcriptional activation of endogenous PPAR-γ by Pr-MPO as determined 
by luciferase activity. 
SHEP-1 cells were transiently co-transfected with either 3 X PPRE luciferase reporter or 
pTA-luc empty vector as represented in the schematic diagrams (A), along with renilla 
plasmids. The luciferase reporter constructs used contained the minimal TA promoter (PTA) 
from the herpes simplex virus thymidine kinase promoter (tk), upstream of the luciferase 
reporter gene (luc). Three copies of PPRE elements were inserted upstream of the TK 
promoter. (B) 48h after transfection, cells were exposed to various doses of Pr-MPO for 16h. 
(C) 3xPPRE-tk-luc transfected cells were treated with 0, 5 or 10µM Pr-MPO for indicated 
durations. Data were calculated as luciferase RLU/renilla/µg total protein and expressed as 
fold increase relative to untreated 3xPPRE-tk-luc transfected cells. The bars represent means 
+ s.e.m from four independent experiments with duplicates. In all panels, *, p < 0.05 as 
compared with untreated control; **, p < 0.005 as compared with untreated control. 
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1.3 PPAR silencing, pharmacological antagonism and DNA Binding Domain 
(DBD) mutation attenuate Pr-MPO-induced receptor activation 
1.3.1 Effect of PPARγ silencing on Pr-MPO-mediated receptor activation 
Since Pr-MPO does not activate PPARδ receptor (Figure 2E), and neuroblastoma cell lines do 
not express PPARα (Han et al., 2001b; Isaac et al., 2006), it is highly probable that PPARγ is 
the only isoform that is physiologically relevant for Pr-MPO’s effect in SHEP-1 cancer cells. 
To confirm the involvement of PPARγ receptor in the induction of 3xPPRE-tk-luciferase 
reporter activity, we conducted a series of experiments in which PPARγ was silenced, 
antagonized or mutated. A knockdown experiment was carried out by transiently transfecting 
SHEP-1 cells with either short-hairpin RNA plasmid (shRNA) targeting PPAR protein or 
shRNA negative control. ShRNA plasmids with different targeting sequences were tested and 
the most efficient plasmid for PPAR knockdown was utilized for subsequent assays (Figure 
4A).It is important to note that transfection with this knockdown plasmid (PPARγ shRNA-3) 
did not affect protein expression of PPARδ in SHEP-1 cells (Figure 4A). In addition, 
corroborating previous reports (Han et al., 2001b; Isaac et al., 2006), our western blot showed 
that PPARα is not expressed in SHEP-1 cells, in contrast to MCF-7 cells (Suchanek et al., 
2002), which was included as a positive control for detection of PPARα (Figure4A). Our 
luciferase data demonstrated that knockdown of PPAR protein alone completely abolished 
Pr-MPO-induced transactivation (0.80 + 0.18 fold increase in PPARγ-knockdown cells vs. 
2.43 + 0.37 fold increase in shRNA negative control cells, both receiving Pr-MPO 5µM, p < 
0.05) (Figure 4B). Our knockdown results imply that PPARγ is likely to be the only 




Figure 4: Transient knockdown of PPARγ with short-hairpin RNA (shRNA) plasmid 
transfection abrogates PPARγ transcriptional activation by Pr-MPO. 
(A) Western blot shows silencing of PPARγ after 48h transfection of SHEP-1 cells with 
short-hairpin RNA (shRNA) plasmids of varying sequences targeting PPARγ. PPARγ 
shRNA-3 was used for subsequent silencing experiments as it was the most effective plasmid 
for PPARγ knockdown. PPAR protein expression was unaffected by shRNA-3, while 
PPARα was not expressed in SHEP-1 cells. Basal cell lysate of MCF-7 was included as a 
positive control for PPARα protein detection. (B) SHEP-1 cells were co-transfected with 
either PPARγ shRNA-3 or shRNA negative control, 3 X PPRE luciferase reporter and renilla 
plasmid. 48 hours after transfection, cells were exposed to varying doses of Pr-MPO for 16h. 
Data were calculated as luciferase RLU/renilla/µg total protein and expressed as fold increase 
relative to untreated shRNA negative control-transfected cells. The bars represent means + 
s.e.m from three independent experiments with duplicates. *, p < 0.05 and **, p < 0.005 as 





1.3.2 Effect of pharmacological antagonism of PPARγ on Pr-MPO-responsive 
receptor activation 
We next determined if Pr-MPO-promoted PPARγ transcriptional activation requires ligand-
binding to the receptor. To achieve this, we pre-incubated SHEP-1 cells with GW9662, a 
specific and irreversible antagonist of PPARγ, which acts by covalently modifying a cysteine 
residue in PPARγ ligand binding domain. Notably, it is known that this specific antagonist of 
PPARγ has negligible effect on the activity of PPARα and δ (Leesnitzer et al., 2002). As 
illustrated in Figure 5, we observed that both doses of GW9662 tested (1 and 10µM) 
markedly attenuated Pr-MPO-induced ligand-dependent PPARγ-activation (1.17 + 0.13 fold 
with GW1µM pre-incubation, 2.00 + 0.50 fold with GW10µM pre-incubation vs 3.69 + 0.54 
with Pr-MPO 5µM alone) (Figure 5). GW9662-mediated inhibition of transcriptional activity 
is possibly due to molecular displacement of Pr-MPO from the ligand-binding domain of 
PPAR. 
 
Figure 5: PPARγ antagonism with GW9662 led to near complete loss of Pr-MPO-
induced PPARγ transcriptional activation. 
SHEP-1 cells were transfected with 3 x PPRE luciferase reporter plasmid as described in 
Figure 3. Transfected cells were preincubated with 1 or 10µM GW9662 for two hours before 
exposure to 5µM Pr-MPO for 8h. Data were calculated as luciferase RLU/renilla/µg total 
protein and expressed as fold increase relative to untreated control. The bars represent means 
+ s.e.m from three independent experiments with duplicates. *, p < 0.05 and **, p < 0.005 as 
compared with cells receiving Pr-MPO 5µM alone.  
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1.3.3 Effect of DBD mutation on PPARγ’s response to Pr-MPO-mediation 
transactivation  
Consequently, to investigate whether DNA-binding function of PPARγ was required for Pr-
MPO’s effect, we transfected SHEP-1 cells with empty vector, wild-type or a DNA-binding-
defective form of PPAR (Figure 6A). This dominant negative form of PPAR 
(PPARC126A/E127A) contains a double amino acid substitution in the DNA-binding domain 
(DBD), which annuls its ability to bind PPRE without affecting its potential for ligand 
binding (Li et al., 2000; Pascual et al., 2005) (Figure 6B). Western blot analysis showed 
comparable enforced expression levels of wild type and dominant negative PPARγ. As 
predicted, mutation in the DBD of PPAR completely abolished Pr-MPO-induced 
transcriptional activation (1.04 + 0.19 fold increase vs 2.60 + 0.27 fold increase in empty 
vector transfected cells, both receiving Pr-MPO 10µM)(Figure 6C, inset). This finding is 
consistent with previous studies which demonstrated that point mutations of these two critical 
amino acids in the first zinc finger of the DBD renders the receptor completely dysfunctional 
for transactivation (Li et al., 2000; Pascual et al., 2005). In fact, dominant negative PPARγ 
also reduced basal activation by approximately 40% to 0.62 + 0.05 fold of untreated empty 
vector control cells. Our data indicate the requirement of PPARγ as a functional DNA-
binding transcription factor for Pr-MPO-stimulated activation, presumably by acting as a 
ligand. In contrast, overexpression of wildtype PPARγ potently augmented basal and Pr-
MPO-triggered transcriptional activity (4.56 + 0.44 fold increase in basal activity with no Pr-
MPO treatment; 3.50 + 0.49 fold for empty vector control vs. 32.2 + 6.18 for wildtype 
PPARγ-transfected cells, both receiving Pr-MPO 5µM, p < 0.005).  
 
Overall, transient knockdown, pharmacological inhibition and DBD mutation of PPARγ serve 
as important negative control experiments to confirm PPARγ as the critical isoform 




Figure 6: Mutation in PPARγ DNA binding domain (DBD) abolishes Pr-MPO-promoted 
receptor transactivation. 
(A) SHEP-1 cells were transfected with either pCMX empty vector, wildtype mPPARγ, or 
dominant negative mPPARγ. 48h after transfection, cell lysates were collected and levels of 
total PPARγ protein were analyzed by Western blot. (B) Schematic representation of the 
functional domains of wildtype murine PPARγ1 protein. In the dominant negative form of 
PPARγ, point mutations of two critical amino acids (C126A/E127A)were made in the DBD 
as previously described (Li et al., 2000). (C) SHEP-1 cells were co-transfected with pCMX 
empty vector, wildtype mPPARγ or dominant negative mPPARγ, along with 3 x PPRE-tk-luc 
reporter construct and renilla. 48h post-transfection, cells were treated with indicated doses of 
Pr-MPO for 4h before being harvested for luciferase activity. Data were calculated as 
luciferase RLU/renilla/µg total protein and expressed as fold increase relative to untreated 
empty vector control. The bars represent means + s.e.m from three independent experiments 
with duplicates. *, p < 0.05 and **, p < 0.005 as compared with empty vector cells receiving 




1.4 Assessment of Pr-MPO’s transactivation effects in other cell lines 
1.4.1 Breast carcinoma cell lines: Endogenous PPARγ expression levels are 
determinant for Pr-MPO’s transactivation effects 
To provide evidence that Pr-MPO-mediated transactivation of endogenous PPARγ is not a 
SHEP-1 cell line-exclusive effect, we repeated the preceding luciferase reporter assay in other 
PPARγ-overexpressing cancer cells. For this purpose, we utilized a panel of different breast 
cancer cell lines, chosen on the basis of their varying PPARγ protein expressions. Analogous 
to earlier studies (Allred and Kilgore, 2005), our western blot data analyzing basal PPAR 
protein levels confirmed overexpression of this transcriptional factor in breast carcinoma cell 
line (MDA-MB-231) compared to their normal mammary epithelial counterpart (MCF10a) 
(Figure 7A). Also, even though breast carcinoma cells generally overexpress PPARγ(Allred 
and Kilgore, 2005; Elstner et al., 2002; Kumar et al., 2009), we observed that different cancer 
cell lines overexpress this receptor protein to different degrees; namely, MDA-MB-231 
expressed PPARγ most abundantly, followed by MCF7 showing intermediate expression, 
while T47D harbored the lowest level of endogenous PPARγ (Figure 7A). We predict that a 
disparity in response to Pr-MPO would exist among these different cancer cell lines. Indeed, 
differential intrinsic expression levels of PPAR were predictive of the degree of luciferase 
reporter transactivation in response to Pr-MPO (Figure 7B). MDA-MB-231 and MCF-7, 
which had the most abundant levels of PPAR protein, elicited the highest levels of reporter 
transactivation (5.10 + 0.44 fold and 2.63 + 0.17 fold with Pr-MPO 10µM, respectively). 
Similar to what we observed with SHEP-1 cells (Figure 5), pre-incubation of MDA-MB-231 
cells with various doses of PPARγ antagonist GW9662 successfully abrogated any increase in 
luciferase activity (1.09 + 0.12 with GW9662 1µM pre-incubation vs 2.33 + 0.24 with Pr-
MPO 5µM alone, p < 0.05) (Figure 8).  
 
On the contrary, T47D cell line showed only slight induction of receptor activity (1.29 + 0.08 
fold with Pr-MPO 10µM) (Figure 7B), which is seemingly associated with its lower 
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endogenous PPAR expression. Notably, Pr-MPO had no influence on the reporter activity of 
MCF10a, a normal mammary cell line, thus indicating its cancer-specificity (Figure 7B). 
 
 
Figure 7: Relative endogenous PPARγ expression levels in breast cell lines correlate with 
Pr-MPO-mediated receptor transcriptional activity. 
(A) Whole cell extracts were prepared and total PPAR expression was examined by Western 
Blot analysis. β-actin was used as a control for loading. Immunoblots are representative of 
three independent experiments. (B) Various cells lines were transiently co-transfected with 3 
X PPRE luciferase reporter and renilla plasmids. Cells were exposed to varying doses of Pr-
MPO for 16h. Data were calculated as luciferase RLU/renilla/µg total protein and expressed 
as fold increase relative to untreated control. Data represent means  + s.e.m of at least two 
experiments, with duplicates in each experiment. *, p < 0.05 as compared with untreated 
control; **, p < 0.005 as compared with untreated control. Statistical comparisons were only 






Figure 8: PPARγ antagonism with GW9662 abrogated Pr-MPO-induced PPARγ 
transcriptional activation in breast carcinoma cells. 
MDA-MB-231 cells were transfected with 3 x PPRE luciferase reporter plasmids as described 
in Figure 3. Transfected cells were preincubated with 1 or 10µM GW9662 for two hours 
before exposure to 0 or 5µM Pr-MPO for 16h. Data were calculated as luciferase 
RLU/renilla/µg total protein and expressed as fold increase relative to untreated control. The 
bars represent means + s.e.m from three independent experiments with duplicates. *, p < 0.05 
as compared with cells receiving Pr-MPO 5µM alone. 
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1.4.2 T47D breast carcinoma cell line: transient overexpression of PPARγ 
restores sensitivity to Pr-MPO-mediated receptor activation 
To test the hypothesis that T47D cancer cell line was unresponsive towards Pr-MPO-induced 
luciferase activation due to insufficient expression of endogenous PPAR protein level 
(Figure 7), we overexpressed wildtype murine PPAR (mPPAR) in this cell line. Despite the 
difference in species origin, overexpression of mPPAR successfully stimulated T47D’s 
response to Pr-MPO-induced reporter transactivation, producing a strong 5.86 + 0.21 fold 
activation with Pr-MPO 5µM (Figure 9). This observation underlines the importance of 
PPARγ expression for Pr-MPO’s transactivation effects.  
 
 
Figure 9: Overexpression of PPARγ in T47D induces response to Pr-MPO-mediated 
receptor transactivation. 
(A) T47D cells were transfected with either pCMX empty vector or wildtype mPPARγ. 48h 
after transfection, cell lysates were collected and levels of total PPARγ protein were analyzed 
by Western blot. (B) T47D cells were co-transfected with pCMX empty vector or wildtype 
mPPARγ, along with 3xPPRE-tk-luc reporter construct and renilla. 48h post-transfection, 
cells were treated with indicated doses of Pr-MPO for 16h before being harvested for 
luciferase activity. Data were calculated as luciferase RLU/renilla/µg total protein and 
expressed as fold increase relative to untreated empty vector control. The bars represent 
means + s.e.m from three independent experiments with duplicates. 
86 
 
1.4.3 SHSY5Y neuroblastoma cell line: intrinsic phosphorylation of PPARγ 
attenuates transactivation potential  
In addition to SHEP-1 which was the primary model of study, SHSY5Y was another 
neuroblastoma cell line selected to test the effect of Pr-MPO. Intriguingly, while SHEP-1 
cells showed dose-dependent increase in reporter activity over the range of Pr-MPO 
concentrations tested (Figure 3B), the induction of SHSY5Y’s reporter activity leveled off at  
Pr-MPO 5µM (Figure 10B), despite these two cell lines expressing comparable basal levels of 
PPAR protein (Figure 10A). Since even positive control 15d-PGJ2 failed to elicit any 
appreciable response in this cell line, we hypothesized that Pr-MPO’s lesser effectiveness in 
SHSY5Y does not rule out the compound’s general role as a PPARγ activator, but rather 
point to inherent PPAR modifications specific to neuroblastoma cell lines that might affect 
their responses to PPAR agonists. As earlier studies have demonstrated the reduction of 
PPAR’s transactivation potential by phosphorylation (Adams et al., 1997; Camp and Tafuri, 
1997; Chang et al., 2006), we assessed the levels of phosphorylated PPAR protein in the two 
neuroblastoma cell lines. Corroborating earlier reports (Cellai et al., 2006), SHSY5Y 
harbored a markedly elevated level of phosphorylated PPAR compared to SHEP-1 cells 
(Figure 10A), which might have restrained its response to Pr-MPO. Nonetheless, it is 
noteworthy that despite phosphorylated PPAR in SHSY5Y being inherently low in 
transactivation potential, Pr-MPO was still able to induce a better response than equimolar 
concentrations of positive control 15d-PGJ2 (1.70 + 0.18 fold with Pr-MPO 5µM vs. 1.18 + 







Figure 10: Basal phosphorylation status of PPARγ in SHSY5Y possibly limits maximal 
response to Pr-MPO. 
(A) Basal expression levels of phosphorylated- PPAR (p-PPARγ) were determined by 
Western Blot in neuroblastoma cell lines, using phosphospecific PPAR- antibody (pSer84). 
The membrane was then stripped and reprobed for total PPARγ protein. β-Actin was 
measured as a loading control. Immunoblots are representative of three independent 
experiments. (B) SHSY5Y cells were transiently co-transfected with 3 X PPRE luciferase 
reporter and renilla plasmids and subsequently exposed to various doses of Pr-MPO or 15d-
PGJ2 for 16h. Data were calculated as luciferase RLU/renilla/ug total protein and expressed as 
fold increase relative to vehicle control for each treatment group. The bars represent means + 
s.e.m from two independent experiments with duplicates. *, p < 0.05 as compared with 
untreated control; **, p < 0.005 as compared with untreated control.  
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1.5 Transactivation of PPARγ by Pr-MPO is associated with increased 
degradation of the receptor protein 
Several members of the nuclear hormone receptor family are shown to be degraded by the 
ubiquitin-proteasome pathway in a ligand-dependent manner, including but not restricted to 
estrogen, progesterone, thyroid hormone and PPARγ. Hence, in good agreement with 
previous reports demonstrating TZD- and IFNγ-mediated PPARγ downregulation (Floyd and 
Stephens, 2002; Hauser et al., 2000), our western blot analyses of SHEP-1 whole cell lysates 
demonstrated dose-dependent reductions in PPARγ protein at various time-points following 
Pr-MPO treatment (Figure 11A). Contrary to conventional cases where the decrease of a 
protein in response to any stimulus signifies downregulation of its function, nuclear hormone 
receptor turnover usually occurs simultaneously with activation of its transcriptional function 
(Dennis et al., 2001). As such, degradation of PPARγ protein after Pr-MPO treatment is an 
expected phenomenon inherently associated with receptor transactivation. In addition, 
literature has reported that not only are the majority of PPARγ proteins residing in the nucleus 
regardless of whether cognate ligands are present (Akiyama et al., 2002; Burton et al., 2008; 
Floyd and Stephens, 2002), ligand-dependent activation and subsequent degradation of the 
receptor proteins also occur in the nucleus without the need for nuclear export (Floyd and 
Stephens, 2002; Waite et al., 2001). We hypothesized that the same response may be acquired 
with transactivation of PPARγ by Pr-MPO. Indeed, after subcellular fractionation of Pr-MPO-
treated SHEP-1 cells to obtain nuclear and cytosolic fractions, we found that PPARγ was 
mostly localized in the nucleus, where dose-responsive reduction in the receptor protein was 
evident as early as 30min after Pr-MPO treatment (Figure 11B). These data suggest that 
PPARγ activation is rapidly and efficiently induced by Pr-MPO within half an hour of 
treatment. Moreover, pre-incubation of cells with PPARγ-specific inhibitor GW9662 at both 1 
and 10µM prevented Pr-MPO-induced PPARγ protein degradation (Figure 11C), which 
correlated well with GW9662-mediated inhibition of PPARγ activity as reported in literature 
(Leesnitzer et al., 2002). Thus, by corroborating the notion of transactivation-regulated 
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turnover of nuclear receptors, our observations of Pr-MPO-mediated decrease in total and 
nuclear PPARγ protein levels provide additional correlative evidence to substantiate the claim 




Figure 11: Pr-MPO treatment is associated with transactivation-dependent degradation 
of PPARγ protein. 
(A) SHEP-1 cells were treated with Pr-MPO at 0, 5, and 10µM for various durations as 
indicated. Cells were then harvested and whole cell lysates were subjected to Western blot 
analysis of PPARγ levels. (B) SHEP-1 cells were treated with Pr-MPO at 0,5, and 10µM for 
30min or 1h. Subcellular fractionation was performed as described in Materials and Methods 
to obtain nuclear and cytosolic fractions. CuZnSOD and PARP were included as markers for 
cytosolic and nuclear fractions, respectively. (C) SHEP-1 cells were pre-incubated with 
GW9662 at 0, 1, or 10µM for 2h before treatment with Pr-MPO at 0 or 10µM for 8h. In all 





1.6 Functional activation of PPARγ by Pr-MPO results in regulation of bona 
fide transcriptional targets 
1.6.1 Pr-MPO transcriptionally activates or downregulates PPARγ target genes  
Even though we have established that Pr-MPO activates PPRE-containing luciferase reporter, 
the question remains if this transactivation of PPARγ leads to functional transcription of its 
bona fide target genes. In this study, we are particularly interested in the transcriptional 
regulation of PPARγ effector genes responsible for mediating anticancer effects. The set of 
criteria we used for selection of reported target genes was as follows: (1) PPARγ-dependent 
transcriptional regulation of the selected gene has been demonstrated in a cancer model; (2) 
reported gene has at least one PPRE in its promoter region; (3) selected gene has been 
experimentally validated as a bona fide PPARγ target; (4) selected gene has been reported to 
mediate PPARγ-dependent antitumor effects. Based on these criteria, we shortlisted a panel of 
cancer-relevant targets of PPARγ, namely, PTEN, RhoB, BNIP3, HIF1-α, NHE-1 and 
MnSOD (referenced in Table 2). Published works have experimentally validated all six genes 
to be PPARγ transcriptional targets, but only PTEN, RhoB, MnSOD and NHE-1 were 
previously revealed to contain PPRE in their promoter regions (Table 2). Because the first 
paper which identified BNIP3 and HIF1-α as PPARγ-responsive genes neglected to report the 
presence of PPREs in the promoter regions, we henceforth examined the 5’-proximal region 
of BNIP3 and HIF1-α using the online PPREsearch program (Venkatachalam et al., 2009). 
Our analysis showed that the promoter regions of BNIP3 and HIF1-α both contained a 
putative DR-2 PPRE motif, with a strong predicted binding efficiency of 0.81 and 0.89, 
respectively (Table 3). Taken together with experimental validation work done by the 
previous group showing activation of BNIP-3 and HIF1-α promoter reporter constructs by 
TZDs (Zhou et al., 2009), our PPREsearch results confirmed that BNIP3 and HIF1-α are 




Having ascertained through literature and PPREsearch that these genes are PPARγ targets, we 
proceeded to assess the mRNA transcript levels of these target genes in response to Pr-MPO 
by quantitative real-time PCR. In concordance with published results obtained with 
conventional ligands, Pr-MPO was observed to dose- and time-dependently upregulate 
mRNA transcript levels of PTEN (Figure 12A), RhoB (Figure 12B), BNIP3 (Figure 12C) and 
HIF1-α (Figure 12D), and conversely downregulated mRNA transcripts of MnSOD (Figure 
12E) and NHE-1 (Figure 12F). Unsurprisingly, slight variations in kinetic profiles were 
exhibited for these target genes in response to Pr-MPO. For the four PPARγ transactivation 
targets tested, mRNA levels steadily increased in a dose-dependent manner over the range of 
time-points tested (4-24h) (Figure 12A-D), with the exception of PTEN, of which mRNA 
upregulation lasted from 4 to 18h and waned off at 24h (Figure 12A). Maximal induction of 
PTEN mRNA was observed to be 2.83 + 0.37 fold at 4h time-point; RhoB, 2.56 + 0.18 fold at 
18h time-point; BNIP3, 2.77 + 0.17 fold at 24h time-point; and HIF1-α, 2.32 + 0.20 fold at 
24h time-point. In terms of PPARγ-mediated transcriptional downregulation of target genes, 
MnSOD mRNA levels were stably decreased from 4h onwards to 18h post Pr-MPO treatment 
(0.64 + 0.08 fold of control for Pr-MPO 10µM at 18h time-point), after which downregulation 
of this target was no longer evident (12E). In contrast, NHE-1 mRNA levels showed a 
different kinetic profile. Firstly, Pr-MPO 10µM was much more consistent and effective than 
5µM in producing downregulating NHE-1 gene (Figure 12F). Secondly, suppression of NHE-
1 mRNA levels was generally more pronounced at later time points (0.73 + 0.05 and 0.62 + 
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Table 2: PPARγ target genes in cancer cells 
1
 Troglitazone induced transactivation of cells transfected with BNIP3 promoter reporter 
plasmid.  
2
 Rosiglitazone and Troglitazone induced transactivation of cells transfected with HIF1-α 





































Table 3: Sequence analyses of BNIP3 and HIF1-α promoters 
The promoter sequences 5 kb upstream of the transcription start site from transcripts of 
human BNIP3 and HIF1-α were retrieved from the Transcriptional Regulatory Element 
Database (TRED). For both target genes, DR-2 motifs were identified, with no detected 
presence of DR-1 motifs. “Identified PPRE” represents the putative DR-2 motif found in the 
promoter region of the searched gene, and the mismatched nucleotide bases from the 
consensus were displayed in bold letters; “Validated PPRE from Database” shows the PPRE 
pattern that was used from the PPRE database (composed of published PPREs which have 
been experimentally validated) to search the input sequence; “Binding efficiency” is a 















Figure 12: Pr-MPO transcriptionally increases or decreases PPARγ bona fide target 
genes in a time- and dose-dependent manner. 
SHEP-1 cells were treated with 0, 5, or 10µM Pr-MPO for various durations as indicated. 
Total mRNA was collected as described in Materials and Methods. (A) PTEN, (B) RhoB, (C) 
BNIP3, (D) HIF1-α, (E) MnSOD, and (F) NHE-1 mRNA transcript levels were quantified by 
real-time PCR. Data are normalized using human 18sRibosome and expressed relative to 
untreated control of each time-point. The bars represent means + s.e.m from three 
independent experiments. In all panels, *, p < 0.05 as compared with untreated control; **, p 
< 0.005 as compared with untreated control.  
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1.6.2 Pr-MPO exerts a direct effect on transcription of PPARγ target genes  
Next, to verify that Pr-MPO directly affects transcription of these PPARγ genes, we pre-
incubated SHEP-1 cells with a non-toxic dose of Actinomycin D (2µg/ml) before treatment 
with Pr-MPO. Pre-incubation of cells with Actinomycin D, which is a widely-used inhibitor 
of transcription, effectively abolished Pr-MPO-promoted increases in PTEN and BNIP3 
mRNA (1.03 + 0.06 vs. 1.33 + 0.03 fold induction of PTEN with Pr-MPO 5µM alone, p < 
0.05; 0.78 + 0.05 vs. 1.80 + 0.05 fold induction of BNIP3 with Pr-MPO 5µM alone, p < 
0.005) (Figure 13). These results provide evidence to show that Pr-MPO-induced increases in 




Figure 13: Inhibition of transcription blocks Pr-MPO-induced upregulation of PPARγ 
target genes. 
SHEP-1 cells were preincubated with Actinomycin D 2µg/ml for 2h before exposure to Pr-
MPO 5µM for 4 (for BNIP3 mRNA upregulation) or 8h (for PTEN mRNA upregulation). 
BNIP3 and PTEN mRNA levels were measured by real-time PCR and normalized to human 
18sRibosome. Data are expressed relative to non-Pr-MPO-treated control. The bars represent 
means + s.e.m from three independent experiments. *, p < 0.05 as compared with Pr-MPO 






1.6.3 Transcriptional regulation of PPARγ target genes by Pr-MPO leads to 
changes in protein expression 
Earlier reports have also shown that these target genes act as molecular effectors of PPARγ-
mediated antineoplastic effects (Kumar et al., 2009; Marlow et al., 2009; Patel et al., 2001; 
Teresi et al., 2006; Zhou et al., 2009). Hence, PPARγ-mediated transcriptional modulations of 
these genes are expected to be translated into actual changes in protein expressions in order 
for antitumor functions to be exerted. Corroborating the mRNA data, our western blot 
analyses revealed dose-dependent upregulations of PTEN, RhoB, BNIP3 and HIF1-α proteins 
and downregulation of MnSOD and NHE-1 protein levels in SHEP-1 cells after Pr-MPO 
treatment (Figure 14A). These effects were validated to be dependent upon PPARγ activation, 
as pre-incubation of cells with GW9662, the pharmacological inhibitor of PPARγ, markedly 
attenuated modulations of these target genes (Figure 14A). These observations were 
reproducible in another Pr-MPO-responsive cell line, namely, MDA-MB-231 (Figure 14B). 
We went further to transiently knockdown PPARγ protein with shRNA plasmids in both 
SHEP-1 (Figure 14C) and MDA-MB-231 cells (Figure 14D), which as predicted reversed the 
up- or downregulation of the corresponding target genes (Figure 14C, D). On the contrary, 
overexpression of PPAR in T47D cell line sensitized the cells to Pr-MPO-induced target 
genes regulation. Unlike control cells transfected with pCMX empty vector, which hence 
expressed low basal levels of PPAR, T47D cells that transiently overexpressed PPAR 
demonstrated significant inductions or repressions of the respective PPAR- transcriptional 
targets (Figure 14E). This response is consistent with our overexpression data from the 
luciferase reporter assay (Figure 9). 
  
Overall, regulation of these six bona fide target genes at both the mRNA and protein levels 
serves as an indicative readout of the functional status of PPARγ as a transcription factor. 
Thus, strong evidence is presented herein to demonstrate Pr-MPO-induced transactivation of 
















Figure 14: Pr-MPO modulates protein expression of  bona fide PPARγ target genes. 
(A) SHEP-1 and (B) MDA-MB-231 cells were treated with indicated doses of Pr-MPO with 
or without 2h pre-incubation of  GW9662 10µM. (C- D) Transient knockdown of PPARγ 
with shRNA plasmids in SHEP-1 cells (C) and MDA-MB-231 cells (D) was carried out 
before treatment with indicated doses of Pr-MPO. In all panels from (A-D), PTEN, RhoB, 
BNIP3 and HIF1-α protein levels were assayed by Western blotting after cells were treated 
with Pr-MPO for 8h; NHE-1 and MnSOD protein levels were analyzed after 24h treatment. 
Longer treatment duration was required for the latter in order for downregulation of protein 
levels to be observed. (E) T47D cells were transfected with either pCMX empty vector or 
wildtype mPPARγ before treatment with Pr-MPO for 24h (I) or 48h (II). For each target gene, 
the time point at which maximum effect by Pr-MPO was induced is shown. All data shown 
represent one of three independent experiments with similar results, and the relative 
differences in expression were obtained by densitometry and expressed as fold increase with 1 





2 Pr-MPO induces potent PPARγ-dependent cell viability loss in human 
cancer cells 
2.1 Pr-MPO effectively reduces cell viability of SHEP-1 in a time- and dose-
dependent fashion 
Thus far, evidence accrues in literature to demonstrate tumor inhibitory effects mediated by 
PPARγ agonists. In light of Pr-MPO-mediated PPARγ activation and transcriptional 
regulation of PPRE-containing tumor suppressor genes, we investigated if this novel 
compound possesses anticancer properties as well. SHEP-1 neuroblastoma cell line, our main 
model of study, was treated with increasing doses of Pr-MPO (0-20µM) for 24, 48, and 72 
hours, respectively. Resultant loss of cell viability was assessed by MTT (3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyltetrazolium bromide) assay, where the reduction of MTT dye by active 
mitochondrial enzymes to formazan crystals is proportional to the amount of viable cells. 
Clearly demonstrated by Figure 15A, 24h treatment of Pr-MPO elicited effective loss in 
SHEP-1 cell viability, which was further enhanced with 48h treatment; and incubation up to 
72h led to near complete loss in cell viability at higher concentrations tested (15.84 + 7.43% 
viability with Pr-MPO 10µM relative to untreated control after 72h treatment, p < 0.05). This 
profound inhibitory effect was steadily dose-responsive, with 50% reduction achieved by 1-
10µM concentrations according to different time points (IC50 ~ 10, 5, and 1µM at 24, 48 and 
72h time-points, respectively). For subsequent experiments conducted, we selected Pr-MPO 5 
and 10µM as effective working concentrations. A detailed kinetic analysis using these two 
concentrations revealed that Pr-MPO’s effect was initiated as rapid as 8h, with a slight but 
reproducible inhibition of cell growth induced (86.11 + 0.15% viability with Pr-MPO 5µM, 
85.12 + 4.29% viability with  Pr-MPO 10µM, p < 0.05 for both data points) (Figure 15B). 
This growth inhibitory effect remained relatively static between 8 to 15h, but the following 
hours (between 18-24h post-treatment) marked the end point of cell death for at least 50% of 
cells treated with Pr-MPO. These observations frame critical considerations on which 





Figure 15: Pr-MPO effectively reduces cell viability of SHEP-1 cells. 
(A) SHEP-1 cells were treated with various concentrations of Pr-MPO for 24, 48 and 72h. (B) 
SHEP-1 cells were treated with Pr-MPO at 0, 5 or 10µM for 8 to 24h as indicated. In all 
panels, cell viability was determined by MTT assay and expressed as % of untreated control. 




2.2 Pr-MPO-induced potent cell viability loss in PPARγ-overexpressing 
cancer cells is a general phenomenon 
Not restricting ourselves to only one cancer model, we selected an extensive panel of cancer 
cell lines from five disparate PPARγ-overexpressing-cancer types to be tested with varying 
doses of Pr-MPO. In addition to SHEP-1, these cell lines are, namely, neuroblastoma cell line 
SHSY5Y (Figure 16A), colorectal cancer cell line HCT116 and prostate cancer cell line 
DU145 (Figure 16B), three breast cancer cell lines MDA-MB-231, MCF7, T47D and their 
non-cancerous counterpart, MCF10a breast epithelial cell line (Figure 16C), and lastly, two 
lymphoma cell lines Raji, Jurkat and their non-transformed counterpart, Peripheral blood 
mononuclear cells (PBMCs) (Figure 16D).  
 
In general, our MTT data revealed that Pr-MPO-induced pronounced loss of cell viability 
could be extended to all PPARγ-overexpressing cancer cells tested. As displayed in Figure 
16A and B, despite their differing cancer origins, SHEP-1, DU145 and HCT116 cell lines all 
responded well in a dose-dependent manner to Pr-MPO’s growth-inhibitory effect. Of note, in 
line with our luciferase reporter data which showed a ceiling effect despite increasing doses 
of Pr-MPO, SHSY5Y’s viability data reflected the same trend where the decrease in cell 
viability seemed to level off after Pr-MPO 5µM onwards (72.92 + 5.85, 72.93 + 8.76 and 
80.06 + 5.78% cell viability for Pr-MPO 5, 10, and 20µM, respectively) (Figure 16A). This 
correlation between the two experimental data strongly implies a regulatory link between 
PPARγ activation and cancer cell death. 
 
2.3 Anticancer efficacy of Pr-MPO correlates with endogenous PPARγ 
expression of cancer cells 
Advancing on this concept that Pr-MPO’s tumoricidal property is a functional consequence of 
PPARγ activation, we employed two different cancer models to compare the effect of Pr-
MPO in cells with overt expression of PPARγ versus those with intrinsically low expression 
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of the nuclear receptor. Analogous to our luciferase reporter results for human breast 
carcinoma cell lines (Figure 7B), Pr-MPO exerted potent growth inhibitory effects on MDA-
MB-231 and MCF7 cell lines, with MDA-MB-231 being the most responsive at all 
concentrations of the compound evaluated (Figure 16C). In agreement with our postulation 
that PPARγ is essential for Pr-MPO-triggered cancer viability loss, T47D cell line was 
observed to be unresponsive to Pr-MPO, which could be attributed to its low PPARγ 
expression and concomitantly weak PPARγ activation response (Figure 9, Figure 14E). 
Worthy to note, unlike its cancerous counterparts (MDA-MB-231 and MCF7) which showed 
drastic decreases in cell viability, non-cancerous breast epithelial cell line MCF10a, being 
inherently low in PPARγ expression, was also conferred significant survival advantage (86.73 
+ 3.85% viability with Pr-MPO 5µM vs. 47.34 + 2.13% viability of MDA-MB-231 cells 
receiving the same treatment, p < 0.005).  
 
For further confirmation of PPARγ-mediated tumor suppressor functions, we examined Pr-
MPO’s effects on a lymphoma model. Of the cell lines tested, Raji and Jurkat cells were both 
high expressers of PPARγ, as reflected by our western analyses which detected comparable 
PPARγ levels of the two cell lines from their basal cell lysates (Figure 16D). On the other 
hand, PBMCs harbored such low endogenous PPARγ protein level that it was non-detectable 
in most of our western blots (Figure 16D). As expected, this PPARγ expression pattern is 
predictive of the cell lines’ responsiveness to Pr-MPO; a profound loss in cell viability 
induced in the two lymphoma cell lines, while PBMCs were sparingly affected in comparison 
(90.12 + 0.20% viability vs. 23.32 + 0.39% viability of Raji cells and 32.32 + 9.09 % viability 
of Jurkat cells, all receiving Pr-MPO 5µM) (Figure 16D). Taken together with our data from 
the breast carcinoma model, the observed survival advantage of PBMCs and MCF10a 
underscores the clinical potential of Pr-MPO as a potent and effective cancer-specific 







Figure 16: Pr-MPO induces potent loss of cell viability in PPARγ-overexpressing cancer 
cells. 
SHEP-1 and SHSY5Y neuroblastoma cell lines (A), HCT116 colorectal and DU145 prostate 
cancer cell lines (B), MDA-MB-231, T47D, MCF7 breast cancer cell lines and MCF10a 
normal breast epithelial cell line (C), Jurkat and Raji lymphoma cell lines and PBMCs (D) 
were treated with indicated concentrations of Pr-MPO for 24h. Cell viability was determined 
by MTT assay and expressed as % of untreated control. Data are shown as means + s.e.m of 
four independent experiments. Endogenous expression levels of PPARγ protein in various 
cell lines were examined by Western blot analyses. β-Actin was measured as a control for 





2.4 Pr-MPO drastically inhibits long-term colony formation of PPARγ-
overexpressing cancer cells 
Stimulated by the positive MTT data obtained, we went further to evaluate if short-term 
treatment of Pr-MPO translates into long-term suppression of cancer cells’ clonogenic 
abilities. To this end, SHEP-1 and MDA-MB-231 cells were treated with increasing doses of 
Pr-MPO for 18h, followed by a colony forming assay as described in Materials and Methods. 
For both cell lines, a marked reduction in colonies formed was observed after Pr-MPO 
treatment, which was dose-dependent (Figure 17). As the colony forming assay detects cells 
that retained progeny-producing ability after chemotherapeutic treatment (Franken et al., 
2006), our results are indicative of long-term reproductive death triggered by Pr-MPO.  
 
Figure 17: Pr-MPO reduces clonogenic abilities of SHEP-1 and MDA-MB-231 cells. 
SHEP-1 (A, B) and MDA-MB-231 (A, C) cells were treated with various concentrations of 
Pr-MPO for 18h before being re-plated onto 100mm dishes (5000 cells/plate) and allowed to 
form colonies over 14 days. Colonies formed were then assessed by staining cells with crystal 
violet. (A) Diagrams of colonies formed are representative of at least three independent 
experiments. (B-C) Colonies formed were scored and expressed as % number of colonies 




2.5 Pr-MPO’s antineoplastic property is a function of PPARγ  
2.5.1 PPARγ protein silencing confers protection against Pr-MPO’s anti-
viability effect 
Next, to provide direct evidence that PPARγ is essential for Pr-MPO’s anticancer effect, we 
performed a transient knockdown of PPARγ protein in SHEP-1 cells with shRNA plasmids 
before exposure to 18h treatment of Pr-MPO (Figure 18A). When observed under the 
microscope, it was apparent that shRNA negative control-transfected cells rounded up and 
detached from the culture dish after Pr-MPO treatment, which was reversed by PPARγ 
protein silencing. Aside from appearing healthier and more attached to the culture dish, 
PPARγ-knockdown cells also presented in visibly higher numbers than their shRNA negative 
control counterparts after exposure to the compound (Figure 18B). Quantitative analysis of 
cell viability changes with MTT assay confirmed that PPARγ protein knockdown markedly 
restored cell viability in exposure to Pr-MPO (88.70 + 1.55% viability vs. 55.51 + 0.82% 






Figure 18: Silencing of PPARγ protein confers significant protection against Pr-MPO-
induced anti-viability effect. 
(A) Knockdown of PPARγ protein was performed by transfecting SHEP-1 cells with shRNA 
plasmids as described in Figure 4. (B) 48h post transfection, cells were treated with indicated 
doses of Pr-MPO for 18h. Cellular morphology was examined under phase contrast 
microscope (Magnification: x20,000). (C) Cell viability of transfected cells after 18h Pr-MPO 
treatment was measured by MTT assay. The bars represent means + s.e.m from three 
independent experiments. *, p < 0.05 and **, p < 0.005 compared with shRNA negative 
control cells receiving the same treatment.  
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2.5.2 PPARγ overexpression restores sensitivity of T47D to Pr-MPO-induced 
loss in cell viability and reduction of clonogenic ability 
To further verify PPARγ protein’s critical involvement in Pr-MPO’s anticancer activity, we 
employed an exogenous PPARγ overexpression system in T47D cell line as described in 
Results Part 1.4.2. Plausibly due to its intrinsically low PPARγ expression, T47D was 
relatively unresponsive to Pr-MPO’s cell viability reductive effects (Figure 16C), which was 
also associated with its lack of reporter transactivation (Figure 7C) and absence of target 
genes modulation in response to Pr-MPO (Figure 13E). Measurement of cell viability with 
MTT assay demonstrated that wildtype mPPARγ-transfected T47D cells displayed notably 
enhanced sensitivity to Pr-MPO treatment compared to their non-overexpressing counterparts 
(52.73 + 7.93% cell viability vs. 90.52 + 0.01% cell viability of empty vector-transfected 
cells, both receiving Pr-MPO 10µM, p < 0.05) (Figure 19C). Interestingly, even though Pr-
MPO did not exert any pronounced effect on the short-term viability of T47D (Figure 16C), a 
reductive effect was observed in terms of long-term clonogenic ability, which was further 
augmented by enforced PPARγ expression (19.58 + 2.95% vs 80.49 + 10.71% colony 
formation in empty vector control cells, both receiving Pr-MPO 5µM, p < 0.005)  (Figure 20). 
Considering the cell viability, colony formation, and receptor transactivation data, we provide 
evidence that T47D’s response to Pr-MPO is restored in the event of enforced PPARγ 
overexpression by way of mimicking physiological effects of the nuclear receptor in naturally 






Figure 19: PPARγ overexpression sensitizes T47D to Pr-MPO-promoted loss in cell 
viability. 
(A) T47D cells were transfected with either empty vector or wildtype mPPARγ before 
exposure to Pr-MPO. (B) Cell viability of transfected T47D cells was assessed after 48h 
treatment of Pr-MPO by MTT assay. The bars represent means + s.e.m from three 
independent experiments. *, p < 0.05 compared with empty vector-transfected cells receiving 












Figure 20: PPARγ overexpression enhances Pr-MPO-mediated reduction in clonogenic 
ability of T47D cells. 
(A) Diagrams of colonies formed by empty vector- or wildtype mPPARγ-transfected cells 
after 48h Pr-MPO treatment. T47D cells were co-transfected with either pCMX empty vector 
or PCMX-mPPAR along with pIRES-Hygromycin resistance plasmid at a 10:1 ratio. 48 
hours after transfection, cells were treated with Pr-MPO at 0 or 5µM for 48h. Re-plating of 
cells was carried out as described in Materials and Methods. Hygromycin antibiotic was 
added onto colony plates with fresh medium every 3 days with increasing doses up to 
100μg/ml as a selection pressure to select for transfected cells. Figure 19A shows successful 
overexpression of PPAR- protein in T47D as determined by Western Blot.(B) Colonies 
formed were scored and expressed as % number of colonies formed by untreated control. The 
bars represent means + s.e.m from two independent experiments. **, p < 0.005 compared 
with empty vector-transfected cells receiving the same treatment.  
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2.6 PPARγ receptor activation is required to mediate its anticancer effects 
2.6.1 Pre-incubation of cells with GW9662 significantly reversed Pr-MPO-
induced loss of cancer cell viability 
Our previous figures have illustrated the effectiveness of GW9662 as a PPARγ-specific 
inhibitor in blunting receptor transactivation after Pr-MPO stimulation (Figure 5, Figure 14A- 
B). Capitalising on this PPARγ-inhibitory property of GW9662, we pre-incubated SHEP-1 
cells with the same effective working concentrations (1 and 10µM) of the antagonist before 
exposure to Pr-MPO. Antagonism of PPARγ transcriptional activities resulted in the recovery 
of a significant portion of viable cells, as reflected by short-term MTT data (69.46 + 12.32% 
viability of GW9662 1µM pre-incubated cells vs. 42.63 + 2.69% viability of cells receiving 
Pr-MPO 5µM alone, p < 0.05) (Figure 21A), and corroborated by long-term colony forming 
assay (Figure 21B-C). GW9662-conferred protection was also reproducible in the other Pr-
MPO-responsive cell line MDA-MB-231, in which microscopic examination revealed a 
restoration of normal cellular morphology by pre-incubation with GW9662 (Figure 22A). 
Untreated MDA-MB-231 cells displayed a standard epithelial cell phenotype with spindle-
shaped extensions, which fully rounded up and reduced visibly in numbers upon treatment 
with Pr-MPO; such alterations in cellular morphology were abrogated by inhibition of PPARγ 
activation (Figure 22A). Furthermore, colony forming assays confirmed that GW9662 
endowed MDA-MB-231 cells with pronounced long-term survival advantage against Pr-
MPO-triggered cell death (Figure 22B). 
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Figure 21: Pharmacological inhibition of PPARγ with GW9662 significantly rescues  
SHEP-1 cells from Pr-MPO-mediated antineoplastic effects. 
(A) SHEP-1 cells were pre-incubated with GW9662 1µM for 2 hours before exposure to 24h 
treatment of Pr-MPO 10µM. Cell viability was measure by MTT assay. (B) Diagrams of 
colonies formed by SHEP-1 cells exposed to 18h treatment of Pr-MPO at 0 or 5µM with or 
without 2h pre-incubation of GW9662. (C) Colonies formed were scored and expressed as % 
number of colonies formed by untreated control. In all panels, the bars represent means + 
s.e.m from two independent experiments. *, p <  0.05, and **, p <  0.005 compared with Pr-







Figure 22: Pre-incubation of MDA-MB-231 cells with PPARγ antagonist GW9662 
resists Pr-MPO-prompted antineoplastic effects. 
(A) Morphology of MDA-MB-231 cells was photographed under phase contrast microscope 
18h after Pr-MPO 5µM treatment with or without 2h pre-incubation of GW9662 1µM. (B) 
Colony forming assay was performed on MDA-MB-231 cells after 18h treatment of Pr-MPO 




2.6.2 PPARγ inactivation by DBD mutation markedly inhibits viability loss 
mediated by Pr-MPO 
In addition to pharmacological antagonism with GW9662, we investigated whether 
inactivation of PPARγ by mutation in the DBD could influence Pr-MPO-promoted loss in cell 
viability. Overexpression of SHEP-1 cells with dominant negative PPARγ containing DBD 
mutation (Figure 23A) significantly blunted PPARγ’s transcriptional activity (Figure 6C), 
which led to an expected protection of cells from Pr-MPO-mediated cellular insult (97.21 + 
2.70% viability of dominant negative PPARγ-transfected cells vs. 58.37 + 6.77% viability of 
empty vector-transfected cells, both receiving Pr-MPO 10µM, p < 0.05) (Figure 23B).  
 
 
Figure 23: Inactivation of PPARγ by DBD mutation confers SHEP-1 cells with survival 
advantage against Pr-MPO treatment. 
(A) SHEP-1 cells were transfected with either pCMX empty vector or dominant negative 
mPPARγ containing two point-mutations in the DBD as previously illustrated in Figure 6B. 
(B) 48h after transfection, cells were treated with indicated doses of Pr-MPO for 18h before 
cell viability was assessed by MTT assay. The bars represent means + s.e.m from three 
independent experiments. *, p < 0.05 compared with empty vector-transfected cells receiving 
the same treatment.  
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Hence, three independent paradigms that negate PPARγ activation either by protein 
knockdown, pharmacological antagonism or DBD mutation congruously inhibited Pr-MPO-
induced cell death in a panel of different cancer cell lines. On the contrary, enforced PPARγ 
overexpression markedly enhanced Pr-MPO’s antineoplastic effects. Taken together with 
correlative observations from cell lines with varying intrinsic levels of PPARγ, these data 






3 Unraveling the mechanism of Pr-MPO-induced cell death in cancer cells 
3.1 Pr-MPO triggers cell death bearing apoptotic hallmarks 
3.1.1 Cell death is accompanied by DNA fragmentation 
PPARγ research in the past few decades has endeavored to delineate its biological effects in 
cancer cells, with particular interest in understanding the underlying mechanisms involved in 
its growth inhibitory and cytotoxic effects. It is clear that activation of PPARγ yields 
pleiotropic effects influencing cell viability, but experimental data from earlier literature have 
congruously expounded on its ability to arrest cell cycle or trigger apoptotic machinery. Thus, 
having ascertained that Pr-MPO exerts profound anti-viability effects on PPARγ-
overexpressing cancer cells, our next logical step entails distinguishing whether the observed 
reduction in viability is a consequence of cell death or a mere growth statutory effect. We 
analyzed the DNA content of Pr-MPO-treated cells from two responsive cell lines, SHEP-1 
and MDA-MB-231 by flow cytometry after propidium iodide (PI) staining. In both cell lines 
tested, sub-G1 populations, which are representative of cells with fragmented DNA, were 
dose-dependently increased by Pr-MPO treatment (2.51 + 0.43% sub-G1 population in SHEP-
1 control cells vs. 19.71 + 4.12% with Pr-MPO 10µM treatment, p < 0.05; 7.08 + 0.20% sub-
G1 population in MDA-MB-231 control cells vs. 15.65 + 1.46% with Pr-MPO 10µM 
treatment, p < 0.05)(Figure 24). Little effect on other cell cycle phases was otherwise 
observed, even though SHEP-1 cells showed a minor increase in S phase population, which 
was however not observed with MDA-MB-231 (Figure 24C). Given that DNA fragmentation 
is a hallmark of apoptosis, our data seemingly suggest the occurrence of apoptotic cell death, 
which was partially inhibited by pre-incubation of cells with GW9662, the specific antagonist 
of PPARγ (~3.09 fold increase in sub-G1 population of cells with GW9662 pre-incubation vs. 




























Control Pr-MPO 3µM Pr-MPO 5µM Pr-MPO 10µM 
Sub G
1
 2.51 + 0.43 7.18 + 0.07** 13.1 + 1.20** 19.71 + 4.12* 
G
1
 44.37 + 3.35 38.87 + 0.18 35.97 + 0.83 38.52 + 2.37 
S 12.32 + 1.74 16.51 + 1.86 17.62 + 0.064* 16.80  + 0.78 
G
2
/M 19.63 + 2.74 24.59 + 2.36 22.98 + 0.81 18.82 + 1.12 
 
  MDA-MB-231   
Cell 
Cycle 
Control Pr-MPO 3µM Pr-MPO 5µM Pr-MPO 10µM 
Sub G
1
 7.08 + 0.20 16.16 + 1.57* 17.64 + 0.51** 15.65 + 1.46* 
G
1
 40.41 + 1.80 38.92 + 2.05 41.26 + 1.32 41.01 + 0.65 
S 8.53 + 0.34 8.94 + 0.45 10.14 + 0.02 9.46 + 0.66 
G
2
/M 21.44 + 2.51 23.92 + 3.49*  28.09 + 4.81 20.89 + 4.22 
 
Figure 24: Pr-MPO induces DNA fragmentation in PPARγ-overexpressing cells. 
SHEP-1 (A) and MDA-MB-231 (B) cells were treated with increasing doses of Pr-MPO for 
24h. DNA content was analyzed by flow cytometry after staining with propidium iodide (PI) 
as described in Materials and Methods. Cell cycle profiles obtained from one set of 
experiment are shown here; they are representative of three independent experiments. (C) The 
percentages of cells in different cell-cycle phases are summarized in this table. Data are 
presented as means + s.e.m from three independent experiments. *, p < 0.05 and **, p < 0.005 






Figure 25: GW9662 partially protects cells from Pr-MPO-mediated DNA 
fragmentatation. 
SHEP-1 cells were pre-incubated with GW9662 10µM for 2h before treatment with Pr-MPO 
5µM for 24h. DNA content was analyzed by flow cytometry after staining with PI. Cell cycle 
profiles shown here are representative of three independent experiments.  
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3.1.2 Cell death is associated with PARP cleavage 
In addition to the above observations, 24h treatment of Pr-MPO also resulted in the cleavage 
of poly (ADP-ribose) polymerase (PARP) (Figure 26A). Of note, PARP, besides being 
recognized as a primary substrate of the major executioner caspase, caspase 3, (Nicholson et 
al., 1995), its cleavage to the 89 kDa fragment is also a classical apoptotic feature which 
severely invalidates its DNA repair function (Berger and Petzold, 1985). In our model, PARP 
cleavage in response to Pr-MPO was significantly attenuated by knockdown of PPARγ 
protein (Figure 26B), reiterating PPARγ’s defining role in mediation of Pr-MPO-triggered 
cell death. Incidentally, in the same immunoblot which demonstrated substantive knockdown 
of PPARγ by shRNA plasmid, we also detected dose-dependent reductions of PPARγ protein 
by Pr-MPO, which is reflective of PPARγ transactivation (Floyd and Stephens, 2002).  
 
           
 
Figure 26: Pr-MPO induces PARP cleavage, which is inhibited by PPARγ silencing. 
(A) SHEP-1 cells were treated with indicated doses of Pr-MPO for 24h. The cells were then 
harvested and whole cell lysates were analyzed by Western blotting. (B) SHEP-1 cells were 
transfected with either shRNA negative control or PPARγ shRNA plasmids before 18h 




3.2 Classical apoptotic machinery is not the primary executioner of Pr-MPO-
triggered cell death 
3.2.1 Pr-MPO-induced cell death is merely partially caspase-dependent 
3.2.1.1 Western blots show weak proteolytic processing of caspases 
The aforementioned observations of apoptotic hallmarks such as DNA fragmentation and 
PARP cleavage prompted us to investigate the involvement of caspases in Pr-MPO triggered 
cell death. Caspases act as the main ‘executioners’ of apoptosis by cleaving specific cellular 
substrates involved in controlled cellular demise. The central role of caspases in the dogma of 
apoptosis has been well established until recent experimental evidence surfaces to challenge 
its importance in alternative caspase-independent cell death paradigms. 
 
Here we investigated the activities of 5 key caspases, namely caspase-9, -8, -6, -7 and -3, 
which covered both broad categories of initiator (-9, -8) and effector (-3, -6, -7) caspases. In 
terms of the initiator caspases, caspase-8 is proteolytically processed and activated by the 
extrinsic or death receptor pathway, while caspase-9 is activated by the intrinsic or 
mitochondrial signaling pathway (reviewed in Introduction). Surprisingly, our western blot 
analyses revealed weak proteolytic conversion of pro-caspase-3, -8, and -9 into catalytically 
active subunits as late as 18h post-treatment, with no detectable time-dependent processing of 
caspases prior to the occurrence of massive cell death (Figure 27A). Activation of caspase-7, 
the other effector caspase, was absent throughout the course of kinetic study (Figure 27A). 
Even for those caspases which exhibited perceivable activation, their cleaved active 




3.2.1.2 Cleavage of caspase-3 substrate, PARP, occurs as a late event in cell death 
Of note, in parallel to the observed proteolytic conversion of caspase-3 into 17- and 19-kDa 
fragments at 18h, its intracellular substrate PARP was correspondingly cleaved at 18h but not 
earlier (Figure 27B). Moreover, in stark comparison to Staurosporine-induced pronounced 








          
 
Figure 27: Pr-MPO triggered only minimal proteolytic cleavage of caspases. 
SHEP-1 cells were treated with either Pr-MPO at 0, 5, 10µM  or Staurosporine 1µM for the 
indicated durations before whole cell lysates were harvested for Western blot analysis. (A) 
Caspase-3, -7, -8 and -9 were immunoblotted using antibodies that recognize both the pro- 
and cleaved forms of the respective caspases. (B) PARP cleavage was detected by Western 
blot analysis. In all panels, β-actin or GAPDH was included as a loading control.   
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3.2.1.3 Fluorogenic substrate-based assay detects minimal activation of caspases 
at late time-points 
To verify our western blot results, we repeated the assessment of various caspases’ activity 
(caspase-3, -6, -8, -9) using their respective fluorescence-conjugated caspase substrates 
(DEVD-AFC, VEID-AFC, IETD-AFC and LEHD-AFC). An extensive number of time-
points with close intervals were investigated in this kinetic analysis of caspase activity 
between 6 to 24h post-Pr-MPO-treatment. Even this sensitive method of caspase activity 
measurement detected only weak but reproducible activation of caspase-3, -8, and -9 at late 
time-points (15-24h), with no noticeable effect displayed by caspase-6 throughout the course 
of study in spite of two different Pr-MPO concentrations tested (Figure 28). In fact, late time-
point activity levels of caspase-8 and -9 were still consistently below 2 fold of untreated 
control, even though SHEP-1 cells were evidently endowed with efficient apoptotic cascade 
machinery in view of its robust response to positive control Staurosporine (3.49 + 0.11 and 
4.13 + 0.69 fold increases in caspase-8 and -9 activity, respectively, with Staurosporine 1µM) 
(Figure 28). Caspase-3 activation by Pr-MPO was slightly stronger compared to other 
caspases, being detectable from 15h onwards and reaching peak activation of 4.08 + 0.35 fold 
over untreated control at 24h (Figure 28A). This level of activation was, nonetheless, still a 
far cry from Staurosporine’s 18.13 + 2.13 fold maximum activation (at the 12h time-point), 





Figure 28: Pr-MPO induces only weak activation of caspases. 
SHEP-1 cells were exposed to Pr-MPO 5µM (A) or 10µM (B) for varying durations as 
indicated. Total cell lysates were used to assess caspase-3, -6, -8, and -9 activation levels 
using fluorescence-conjugated substrates. Cells treated with Staurosporine 1µM were 
included as positive control. Caspase activity was normalized to total protein and expressed as 
fold increase over untreated cells from each time-point. The bars represent means + s.e.m of 
three independent experiments. *, p < 0.05 compared with untreated control cells.  
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3.2.1.4 Pan-caspase inhibitor zVAD-fmk recovers only 20% of cells  
Consistent with the minimal activation of caspases observed, pre-incubation of cells with the 
pan-caspase inhibitor zVAD-fmk for 2h only recovered 20% of treated-cells (72.78 + 6.96% 
viability vs. 54.15 + 7.68% viability with  Pr-MPO 10µM alone, p < 0.05) when assayed by 
MTT dye (Figure 29B). This result is further supported by data from PI cell cycle analysis, 
where zVAD-fmk pre-treatment only partially rescued the apoptotic fraction (Figure 29C). 
This was despite the ability of zVAD-fmk to completely inhibit caspase activity as evidenced 









Figure 29: zVAD-fmk confers only partial resistance to Pr-MPO-mediated cell death. 
In all panels, SHEP-1 cells were pre-incubated with zVAD-fmk 100µM for 2h before 
treatment with Pr-MPO. (A) PARP cleavage was assessed by Western blot analysis. (B) Cell 
viability of treated cells was measured by MTT assay. The bars represent means + s.e.m of 
three independent experiments. *, p < 0.05 and **, p < 0.005 compared with Pr-MPO or 
Staurosporine treatment alone. (C) After zVAD-fmk pre-incubation, SHEP-1 cells were 
exposed to Pr-MPO 5µM for 24h. DNA content was analyzed by flow cytometry after 
staining with PI.  
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3.2.2 MMP modulator proteins Bax and Bcl-2 are not essential for induction of 
cell death 
3.2.2.1 Features of MOMP are late events in cell death 
The dogmatic view of cell death stipulates mitochondrial membrane permeabilization (MMP) 
as a universal feature of cellular demise, and this phenomenon is viewed by many as 
symptomatic of the “point of no return” being trespassed (Kroemer and Reed, 2000). In 
accordance to this stigma, the release of apoptogenic factors such as cytochrome c, which 
normally reside in the intermembrane space (IMS), is regarded as an indication of 
mitochondrial outer membrane permeabilization (MOMP). On the other hand, mitochondrial 
translocation of cytosolic pro-apoptotic Bax (or Bak) is implicated as a common mechanism 
for the induction of MMP, where the full insertion of Bax or Bak’s multimeric homo-
oligomers form gigantic pores in the outer membrane of mitochondria, thus compromising its 
membrane integrity, leading to subsequent release of the aforementioned IMS-occupant 
proteins.  
 
To unravel the exact mechanism of Pr-MPO-induced cell death with apoptotic features, we 
studied the subcellular distribution of cytochrome c and bax after exposure to Pr-MPO by 
preparing cytosolic- and mitochondrial-enriched fractions of SHEP-1 cells. After 24h Pr-
MPO treatment in SHEP-1 cells, we observed a loss of mitochondrial cytochrome c, which 
was accompanied by a corresponding release into the cytosolic fraction (Figure 30A). 
Concomitantly, Bax protein was observed to be dose-responsively recruited to the 
mitochondrial fraction, with a simultaneous loss from the cytosolic fraction (Figure 30A). 
However, these events were observed at a late time-point by when substantial cell death had 
already ensued (Figure 15B). As such, despite being accompanying features of cell death, the 





3.2.2.2 Stable knockout of Bax does not confer protection 
Thus, we sought to validate the true functional relevance of Bax in our cell death model. For 
this purpose, we compared the effect of Pr-MPO on HCT116, a cell line formerly established 
to be Pr-MPO responsive (Figure 16B), and its Bax stable-knockout counterpart (HCT116 
Bax
-/-
) (Figure 30B). It was revealed that genetic invalidation of Bax did not affect cell fate in 
any appreciable manner, with Pr-MPO reducing both HCT116 and HCT116 Bax
-/-’s viability 
equally and substantively (Figure 30B). This observation is consistent with the concept that 
Bax recruitment to mitochondria observed as a late event in cell death is an artifact of the 
apoptotic machinery set in motion by an alternative mechanism, rather than a direct 




Figure 30: Pr-MPO-induced cell death does not require Bax, even though cell death is 
accompanied by features of MOMP. 
(A) SHEP-1 cells were treated with indicated doses of Pr-MPO for 24h, after which cells 
were harvested and fractionated to obtain mitochondrial and cytosolic fractions. Levels of 
cytochrome c and Bax were assayed by Western blot analysis. VDAC and CuZnSOD were 
used as mitochondrial and cytosolic marker, respectively, to control for cross-contamination 
of fractions. (B) Absence or presence of Bax expression was confirmed in HCT116 and 
HCT116 Bax
-/- 
cell lines by Western blot analysis of basal cell lysates. Both cell lines were 
treated with various doses of Pr-MPO for 24h and cell viability was measured by MTT assay. 
Data are shown as means + s.e.m of four independent experiments.  
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3.2.2.3 Transient overexpression of Bcl-2 does not confer any survival advantage 
To further confirm that the mitochondria are not essential for the execution of Pr-MPO-
induced cell death, we also examined the involvement of another critical MMP regulator, 
namely, the anti-apoptotic Bcl-2 protein. As expected, enforced overexpression of Bcl-2, the 
MMP modulator that protects cells from mitochondria-mediated apoptosis (Kroemer and 
Reed, 2000) (Figure 31A), failed to bestow SHEP-1 cells with any survival advantage in the 
face of Pr-MPO-triggered cellular insult (Figure 31B). On the contrary, the protective effect 
of Bcl-2 overexpression was evident in the context of Cisplatin treatment (Figure 31B), which 




Figure 31: Pr-MPO-induced cell death is insensitive to Bcl-2 overexpression. 
(A) Western blot analysis showed successful overexpression of Bcl-2 in SHEP-1 cells 48h 
post-transfection. (B) Transfected cells were treated with either Pr-MPO or Cisplatin for 18h 
and cell viability was assessed by MTT assay. The bars represent means + s.e.m of three 
independent experiments. *, p < 0.05 compared with Cisplatin treatment alone.  
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3.3 Pr-MPO-induced cell death is independent of AIF and p53 statuses, and is 
not inhibited by necrostatin 1(Nec-1) 
3.3.1 AIF is not required for cell death induction 
In view of several lines of evidence strongly implying the involvement of an alternative 
paradigm of cell death induced by Pr-MPO that is independent of mitochondria and partially 
independent of caspases, we investigated the role of other well-known caspase-independent 
death effectors. Apoptosis Inducing Factor (AIF) came into consideration as a candidate death 
executioner, which, like cytochrome c, is identified as an IMS protein (Zamzami et al., 1996). 
There is now a growing body of experimental data to demonstrate its ability in mediating 
apoptosis-like PCD in the absence, or independent of, caspase activation. (Joza et al., 2001; 
Susin et al., 2000). In particular, it was reported that AIF nuclear translocation is crucial for 
its lethal effects, where it triggers chromatin condensation and high molecular weight DNA 
fragmentation (Loeffler et al., 2001; Susin et al., 1999; Yu et al., 2002). In addition, PPARγ 
agonist Ciglitazone was shown to induce caspase-independent apoptosis via AIF nuclear 
translocation (Kwon et al., 2008). Thus, we performed a nuclear-cytosolic fractionation to 
investigate if Pr-MPO induces AIF translocation to the nucleus. Western blot analysis of the 
subcellular localization of AIF showed no visible increase of AIF protein in the nuclear 
fractions of both cell lines SHEP-1 and MDA-MB-231 despite 24h treatment of Pr-MPO 
(Figure 32A). Moreover, silencing of AIF in SHEP-1 cells by siRNA transfection did not 
exert any noticeable change in Pr-MPO-triggered cell death (Figure 32C). Therefore, AIF is 




    
Figure 32: AIF is not responsible for Pr-MPO-induced caspase- and mitochondria-
independent cell death. 
(A) MDA-MB-231 and SHEP-1 cells were treated with indicated doses of Pr-MPO for 24h 
before being subjected to fractionation to obtain nuclear and cytosolic fractions. AIF levels 
were measured by Western blot analysis. PARP and CuZnSOD were included as nuclear and 
cytosolic markers, respectively. (B) SHEP-1 cells were transfected with either siRNA 
negative control or specific siRNA targeting AIF. Western blot analysis confirmed successful 
knockdown of AIF protein by siRNA transfection in SHEP-1 cells after 48h. (C) 48h post-
transfection, cells were treated with Pr-MPO for 18h. Cell viability was assessed by MTT 
assay. The bars represent means + s.e.m of three independent experiments. 
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3.3.2 p53 status is inconsequential to cancer cells’ response 
Our next molecular target of investigation is p53, not only because of its cult status as a tumor 
suppressor gene, but rather due to recent reports which surfaced to demonstrate an alternative 
death paradigm that is p53-dependent but caspase- and Bcl-2-independent (Godefroy et al., 
2004). In order to determine possible dependence of Pr-MPO’s cytotoxic effect on p53, we 
compared the response of a p53 null cell line (HCT116 p53
-/-
) to its p53 wildtype counterpart 
(HCT116 p53
+/-
) after confirming the expression status of p53 in both cell lines by Western 
blotting (Figure 33A). As illustrated by our MTT results, stable knockdown of p53 had no 
impact on the response of HCT116 to Pr-MPO, which exhibited dose-dependent decrease in 
cell viability (Figure 33B). Even though we have to rule out the importance of yet another key 
regulatory molecule of caspase-independent cell death, the observed sensitivity of HCT116 
p53
-/-
 cell line nonetheless highlights therapeutic potential of Pr-MPO in cancer types that are 
either mutated or deficient in the p53 gene.  
 
 
Figure 33: Pr-MPO-mediated cell death is independent of p53 status. 
(A) Western blot analysis confirmed p53 null status of HCT116 p53
-/- 
cell line, in comparison 
with its p53 
+/-
 counterpart. (B) Cell viability of both cell lines was measured by MTT assay 
after 24h treatment with various doses of Pr-MPO. Data shown  represent means + s.e.m of 
four independent experiments.  
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3.3.3 Pr-MPO-mediated cell death is not necroptosis 
Of late, the classic dogmatic view of necrosis being a non-regulated, chaotic way of dying is 
disputed by emerging experimental evidence to demonstrate the existence of a necrotic cell 
death pathway that is distinctively regulated, termed “necroptosis” (Degterev et al., 2005). 
The same research group that coined this term also identified necrostatin-1 (Nec-1) as a small 
molecule inhibitor that specifically targets necroptosis.  If necroptosis is indeed induced by 
Pr-MPO, pre-incubation of cells with Nec-1 should theoretically block Pr-MPO’s lethal 
effects. As a positive control, we treated SHEP-1 cells with a cocktail of TNFα and zVAD-
fmk, which was previously established to induce necroptotic cell death mediated by death 
receptor in the absence of caspase activation (Degterev et al., 2005; Holler et al., 2000). 
Unlike positive control treatment which was successfully reversed by Nec-1 as formerly 
described (Figure 34B), Pr-MPO’s cytotoxic effect remained unaffected by this inhibitor 
(Figure 34A), thus affirming the absence of this alternative PCD.  
 
Figure 34: Pr-MPO does not trigger necroptosis. 
(A) After 2h pre-incubation with necrostatin 1 (Nec-1), SHEP-1 cells were treated with Pr-
MPO 5µM for 24h. (B) SHEP-1 cells were treated with TNFα 100ng/ml and zVAD-fmk 
100µM with or without Nec-1 pre-incubation. In all panels, cell viability was assessed by 
MTT assay and the bars represent means + s.e.m of four independent experiments. *, p < 0.05 
compared with TNFα and zVAD-fmk treatment.  
135 
 
3.4 Pr-MPO increases autophagic activity in cancer cells 
Recent years heralded a new dawn for research interest surrounding “autophagic cell death” 
or type II cell death, posited as a distinctive means of genetically programmed self-
elimination mechanism, which has been shown by increasing experimental evidence to be 
intricately linked to apoptosis in a multifaceted interplay that is still poorly defined.  Of 
particular interest to us are previous reports which have demonstrated autophagy-mediated 
cell death exhibiting apoptotic features (Bhoopathi et al., 2010; Hoyer-Hansen et al., 2005; 
Scarlatti et al., 2008; Xue et al., 1999). As such, we endeavoured to determine if this 
alternative mechanism of cell death is relevant to our Pr-MPO-based model. Two main 
considerations frame our subsequent experiments; firstly, the examination of Pr-MPO’s effect 
on the dynamic process of autophagy requires a combination of experimental techniques for 
reliable measurement, and secondly, the true functional relevance of Pr-MPO-modulated 
autophagic activity in its induction of cell death has to be established to rule out the 
possibility of a mere “by-stander effect”. 
 
3.4.1 Transmission electron microscopy (TEM) displays an increase in 
autophagic vacuoles 
The first method we employed to detect presence of Pr-MPO-induced autophagy was by 
transmission electron microscopy, which allows for direct visualisation of any 
autophagosomes (double-membrane bound vacuoles enclosing undigested cytoplasmic 
contents) or autolysosomes (formed from the fusion between autophagosomes with 
lysosomes). TEM examination of SHEP-1 cells revealed that Pr-MPO treatment drastically 
increased the number of autophagosome-like membranous cytoplasmic vacuoles containing 
cellular contents, which were absent in untreated control cells (Figure 35, black arrows). 
Cargo contained in these membrane-bound structures assumed different shapes and sizes, 
suggesting the presence of “bulk autophagy” due to the variety in organelles engulfed. 
Moreover, in certain TEM pictures of Pr-MPO-treated cells, fusions between autophagosome-
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like and lysosome-like structures appeared to be underway (Figure 35, black double arrows; 
dark electron-dense vesicles resemble lysosomes, while the adjacent membrane-bound 
vacuoles are autophagosome-like).  In addition, we observed a number of vacuoles in 18h Pr-
MPO-treated cells which were suggestive of autolysosomes carrying partially degraded 
cytoplasmic materials (Figure 35, red arrows).  
 
 
Figure 35: Pr-MPO induces dramatic autophagosome formation. 
Transmission EM images of SHEP-1 cells left untreated (control) or treated with Pr-MPO 
10µM for 6 or18h as indicated. Insets represent close-up images of the respective larger 
pictures placed directly above. Black single arrows indicate autophagosomes with content; 
red arrows indicate autolysosome-like vacuoles; double black arrows indicate probable 
ongoing fusions between autophagosome-like and lysosome-like structures.  
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3.4.2 Pr-MPO induces time- and dose-dependent LC3-II formation 
To verify our findings from TEM examination, a biochemical assay to detect autophagosomes 
was undertaken, using the generation of LC3-II as a marker of autophagosomes. An essential 
step in the formation of autophagosomes entails the conjugation of cytosolic LC3-I to 
phosphatidylethanolamine (PE) to form LC3-phosphatidylethanolamine conjugate (LC3-II), 
which is stably recruited to the autophagosomal membrane. Due to its specific association 
with the autophagosomes and not pre-autophagosomal structures (PAS) (Kirisako et al., 
1999), levels of LC3-II formed are correlative with the number of autophagosomes per cell 
(Kabeya et al., 2000). Corroborating our TEM analysis, Pr-MPO treatment resulted in 
significant formation of LC3-II in SHEP-1 cells in a time- and dose-dependent manner 
(Figure 36). In fact, Pr-MPO’s induction of autophagosomes formation was not exclusive to 
this cell line alone, but also observed for MDA-MB-231, Raji and HCT116 (Figure 36), 
namely cell lines established to be susceptible to Pr-MPO’s cytotoxic effects (Figure 16).  
 
Figure 36: Pr-MPO increases LC3-II formation in cancer cells. 
SHEP-1, MDA-MB-231, Raji, and HCT116 cells were treated with indicated doses of Pr-
MPO for 4, 8, 18 or 24h before cells were harvested to obtain whole cell lysates. LC3-II 




3.4.3 Pr-MPO-treated cells exhibit increased GFP-LC3 punctae 
In addition, visualization of GFP-LC3 by fluorescence microscopy was performed as a third 
ancillary measure to quantify autophagosomes formation. During autophagy, lipidation and 
subsequent targeted recruitment of GFP-LC3-II to autophagosomes results in a perceivable 
change from diffuse cytoplasmic staining to punctate staining, which denotes presence of 
autophagosomes. Hence, SHEP-1 cells were transfected with GFP-LC3 or GFP-empty vector 
plasmids prior to treatment with Pr-MPO to allow for visualization of LC3-II distribution. 
Western blot analysis confirmed successful transfection of GFP-LC3 which corresponded to a 
band that appeared at approximately 40kDa (Figure 37B). As illustrated by Figure 37A, Pr-
MPO treatment markedly increased the number of fluorescent puncta in GFP-LC3-transfected 
cells, while untreated control cells displayed uniformly diffuse LC3-associated green 
fluorescence. Besides, punctate pattern was generally undetectable in GFP-empty vector-
transfected cells, which were included in parallel as negative controls. To measure changes in 
autophagosome number quantitatively, we scored only GFP-LC3-transfected cells with at 
least five punctate dots as punctae-positive, in consideration of the small numbers (< 5) of 
punctae observed occasionally even at basal conditions(Mizushima et al., 2010; Scarlatti et 
al., 2008). A prominent increase in punctae-positive cells in response to Pr-MPO treatment 
(165.10 + 7.16% punctae-positive cells of untreated control with Pr-MPO 5µM, p < 0.05) 
(Figure 37C), accompanied by data from TEM and Western blot analyses, provides 
compelling evidence to establish Pr-MPO-induced increase in autophagosomes. 
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Figure 37: Pr-MPO increases punctate staining of GFP-LC3. 
(A) 48h after transfection with GFP-empty vector- or GFP-LC3, SHEP-1 cells were treated 
with Pr-MPO at 0 or 5µM for 6h before viewing with a fluorescence microscope. Red arrows 
point towards GFP-LC3 punctae, which are indicative of LC3-II aggregation in 
autophagosomes. The larger images were taken with a x40,000 objective and the smaller 
images represent close-up images of GFP-LC3 punctae. (B) Successful GFP-LC3 transfection 
in SHEP-1 cells was validated by Western blot analysis. SHEP-1 cells were transfected with 
mock (transfection reagents only without plasmids), GFP-empty vector or GFP-LC3 for 48h 
before being harvested. (C) Quantitative analysis of punctae-positive cells are described in 
Materials and Methods. After 6h treatment with Pr-MPO at 0 or 5µM, the fraction of punctae-
positive cells (5 or more punctae per cell) out of at least 100 transfected cells was scored and 
expressed as percentage increase relative to untreated GFP-LC3-transfected cells. The bars 




3.4.4 Pr-MPO triggers functional autophagic flux 
Nonetheless, a mere increase in autophagosome numbers should not be directly construed as 
amplified autophagic activity, given the dynamic nature of the “autophagic flux” which 
features constant synthesis of autophagosomes, their subsequent conversion into 
autolysosomes  and eventual degradation of autophagic cargo. Even though autophagic 
activation (with an increase in autophagosomes formation and functional autophagic 
degradation) will generally elevate the number of autophagosomes, the same increase in 
autophagosomes numbers observed however, can also be attributed to a downstream blockade 
of autophagic catabolism (due to, for an instance, a defect in autophagosomes maturation) 
(Figure H). Hence, it is important to include additional methods for monitoring autophagic 
flux per se. 
 
One such method is based on the principle of LC3 turnover, due to the known fact that LC3-II 
is ultimately degraded in autolysosomes. If there is no defect in autophagosomes clearance in 
the tested model, the use of lysosome protease inhibitors should theoretically cause enhanced 
accumulation of LC3-II (Tanida et al., 2005). Thus, we pre-treated SHEP-1 cells with E64d 
and pepstatin A for 2h before treatment with Pr-MPO. In good agreement with our postulation 
that Pr-MPO activates functional autophagic activity, Western blot analyses showed a further 
increase of Pr-MPO-induced LC3-II levels with lysosomal inhibitors treatment (Figure 38A), 
with the extent of increase indicative of the amount of LC3 degraded in the autolysosomes  at 
the time-points of investigation (18, 24h) (Klionsky et al., 2008). It is noteworthy that even 
though there was a slight increase in LC3-II levels with lysosomal inhibitors even in basal 
conditions, the difference is markedly augmented with Pr-MPO treatment, strongly implying 
an intensification of autophagic flux (Figure 38A). 
 
Independent of the LC3 turnover assay, we also studied degradation of a well-established 
autophagy-specific substrate, p62 (also known as SQSTM1/sequestrome 1). Recent studies 
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have shown that p62 mediates aggregation and subsequent targeting of autophagic cargo to 
autophagosomes by direct binding to LC3 on the autophagosomal membranes, thus 
facilitating autophagic clearance of these proteins (Bjorkoy et al., 2005). Since p62 itself is 
degraded along with the autophagic cargo, a decrease in its cellular expression indicates 
activation of autophagic flux. As further support to our LC3 accumulation data, Western blot 
analyses of p62 levels showed appreciable Pr-MPO-induced reductions in both SHEP-1 and 
MDA-MB-231 cell lines throughout the kinetic studies (Figure 38B).  
 
Therefore, with the aforementioned combination of varied experimental techniques, we 
hereby provide a convincing case arguing in favour of Pr-MPO-dependent induction of 
autophagic activity.  In view of how elevated LC3-II levels and GFP-LC3 punctae numbers 
are validated to correlate with increased autophagy in our model as reflected by autophagic 
flux monitoring assays, we would henceforth capitalize on these two biochemical assays as 
operational indicators for our following assessment of modulations in autophagic activities.  
 
 
Figure 38: Pr-MPO induces functional autophagic flux in cancer cells. 
(A) SHEP-1 cells were pre-incubated with lysosomal protease inhibitors, E64d + Pepstatin A 
(Peps A) (each 10µg/ml) for 2h before treatment with Pr-MPO 5µM for 18 or 24h. Expression 
levels of LC3-II were assessed by Western blotting. (B) SHEP-1 and MDA-MB-231 cells 
were treated with indicated doses of Pr-MPO for varying durations before assessment of 
SQSTM1/p62 protein levels by Western blotting. In all panels, immunoblots are 
representative of at least two independent experiments. 
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3.5 Inhibition of autophagy with either pharmacological inhibitor 3-MA or 
Atg genes silencing completely abrogates Pr-MPO-induced cell death 
3.5.1 Pre-incubation of cells with 3-MA effectively blocks induction of 
autophagy 
Despite the observation of increased autophagy prior to the occurrence of cell death triggered 
by Pr-MPO, the conundrum remains as to whether autophagy induction is truly responsible 
for Pr-MPO-mediated cell death, or rather it merely accompanies cellular demise. To 
delineate the functional relevance of autophagy induction in our model, we performed 
experiments to effectively inhibit autophagy with the use of 3-Methyladenine (3-MA), one of 
the most commonly used pharmacological inhibitors of autophagy achieved by inhibition of 
class III PI3 kinase activity. Successful inhibition of autophagy was achieved with 2h pre-
incubation of 3-MA before Pr-MPO treatment, as evidenced by profound reduction of LC3-II 
levels in Pr-MPO-exposed SHEP-1 cells, and near complete abrogation of LC3-II formation 
in Pr-MPO-treated MDA-MB-231 cells (Figure 39A). This was confirmed by a diminished 
number of punctae-positive cells with 3-MA pre-treatment as viewed and scored by 
fluorescence microscopy (Figure 39B, C) (103.75 + 17.7% punctae-positive cells vs. 165.10 + 








Figure 39: Pr-MPO-dependent autophagic activity is inhibited by 3-MA pre-treatment. 
(A) SHEP-1 cells were pre-incubated with 3-MA 10mM for 2h before treatment with Pr-MPO 
at 0, 5, or 10µM for 8h; MDA-MB-231 cells were subjected to the same treatment for 4 or 8h. 
LC3-II expression levels were assessed by Western blot analyses. (B) GFP-LC3-transfected 
SHEP-1 cells were pre-treated with 3-MA 10mM for 2h before treatment with Pr-MPO at 0 or 
5µM for 6h, followed by viewing with a fluorescence microscope. The larger images were 
taken with a x40,000 objective and the smaller images represent close-up images of GFP-LC3 
punctae. Red arrows point towards GFP-LC3 punctae. (C) Quantitative analysis of punctae-
positive cells as described in Figure 37. The bars represent means + s.e.m from three 
independent experiments. *, p < 0.05 as compared with Pr-MPO 5µM treatment alone. 
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3.5.2 3-MA pre-incubation confers complete profection  
After validating the ability of 3-MA to effectively inhibit Pr-MPO-induced autophagy (Figure 
39), we investigated the effect of impairing autophagy in the context of Pr-MPO-mediated 
cell death. Remarkably, pre-treatment with 3-MA completely reversed cell death phenotype 
induced by Pr-MPO in SHEP-1 cells; morphological examination revealed that autophagy 
inhibition thoroughly obliterated manifestations of viability loss otherwise depicted by cells 
treated with Pr-MPO alone, and restored normal morphology to cells akin to untreated control 
(Figure 40A). These observations are corroborated by two additional assays, namely MTT 
viability assay (87.54 + 4.71% cell viability with 3-MA 5mM pre-incubation, 98.85 + 6.10% 
with 3-MA 10mM pre-incubation vs. 57.09 + 3.81% with Pr-MPO 10µM alone) (Figure 40B) 
and long-term clonogenic assay (Figure 40C). Not restricted to only SHEP-1 cells, 3-MA also 
exerted cytoprotective effect in MDA-MB-231 cells, as illustrated in Figure 40D where 3-MA 






Figure 40: Inhibition of autophagy by 3-MA completely rescues cells from Pr-MPO-
mediated cell death. 
SHEP-1 cells were pre-incubated with 3-MA 5 or 10mM for 2h before treatment with Pr-
MPO at 0, 5, or 10µM for 18h. 3-MA-mediated rescue of cell death was assessed by (A) 
morphological examination with phase-contrast microscopy (Magnification: x20,000), (B) 
MTT assay, and (C) colony-forming assay. In all panels, data shown are representative of at 
least three independent experiments. For (A), the bars represent means + s.e.m from three 
independent experiments. *, p < 0.05 and **, p < 0.05 as compared with Pr-MPO treatment 
alone.(D) Morphological examination of MDA-MB-231 cells treated with 0 or 10µM Pr-
MPO with or without 2h pre-incubation of 3-MA 10mM. Images were taken with phase-




3.5.3 Inhibition of autophagy by knockdown of specific ATG genes attenuates 
Pr-MPO-mediated cell death 
As with most pharmacological inhibitors, the use of 3-MA has raised concerns that its effects 
potentially spawn beyond autophagy inhibition (Caro et al., 1988; Punnonen et al., 1994; Wu 
et al., 2010; Xue et al., 2002). Hence, to verify our findings with 3-MA, we also used genetic 
manipulations to achieve higher specificity in autophagy inhibition (Mizushima et al., 2010). 
For this purpose, ULK1, Beclin 1, and ATG 7, each representing a critical ATG gene required 
at different steps of autophagosomes formation, were knocked down in insolation in SHEP-1 
cells with siRNAs. Not only did we confirmed complete suppression of these autophagy 
proteins with Western blot analyses of their expression levels (Figure 41A), we also verified 
significant inhibition of autophagy induction by silencing of ULK1 and ATG7 as evidenced 
by marked attenuation of Pr-MPO-dependent LC3-II accumulation (Figure 41B). Intriguingly, 
silencing of Beclin 1 inhibited neither Pr-MPO- nor positive control C2-ceramide-induced 
autophagy (Figure 41B), which might suggest non-canonical Beclin 1-independent autophagy 
in this cell line (Scarlatti et al., 2008). Consistently, autophagy inhibition with Atg7 and 
ULK1 silencing conferred SHEP-1 cells with considerable resistance against Pr-MPO-
induced cellular insult, as exhibited by pronounced recovery of viable cells assayed by MTT 
dye (94.74 + 6.25% cell viability with siAtg7, 95.36 + 5.95% with siULK1, vs. 75.24 + 
1.33% with siControl, all receiving Pr-MPO 5µM) (Figure 42A) and long-term clonogenic 
assay (Figure 42B). On the other hand, knockdown of Beclin 1, which was unable to inhibit 
autophagy (Figure 41B), was correspondingly incompetent in protecting cells against Pr-
MPO-mediated cell death (MTT data, 73.50 + 3.90% cell viability with siBeclin 1 vs. 75.24 + 






Figure 41: Silencing of ULK1 or Atg7 inhibits Pr-MPO-induced autophagy, but not 
silencing of Beclin 1. 
(A) Western blot analyses demonstrate complete suppression of ULK1, Atg7 and Beclin 1 
expression levels in SHEP-1 cells after 48h transfection with respective siRNAs. (B) ULK1, 
Atg7, or Beclin 1 knockdown SHEP-1 cells were treated with Pr-MPO at 0, 5, or 10µM for 
18h before assessment of LC3-II generation by Western blotting. Cells treated with C2-





             
 
Figure 42: Inhibition of autophagy by ULK1 or Atg7 silencing rescues cells from Pr-
MPO-triggered cell death. 
ULK1, Atg7 or Beclin 1 was knocked down in SHEP-1 as described in Figure 41 before 
treatment with Pr-MPO at 0, 5, or 10µM for 18h. Attenuation of cell death was assessed by 
(A) MTT assay, (B) colony-forming assay. For (A), the bars represent means + s.e.m from 




3.5.4 3-MA treatment after full-fledged induction of autophagy fails to prevent 
cell death 
Clearly, we have established that impairment of autophagy renders cancer cells insusceptible 
to Pr-MPO-induced cell death. It is, however, less patent as to whether the initial autophagic 
response to Pr-MPO was, right from the start, intended as the executioner machinery, or was 
it initially triggered as a pro-survival rescue mechanism that somehow went awry with 
debauched self-cannibalism. In an effort to address this conceptual lacuna, we conducted a 
kinetic study to determine the rescue effects of 3-MA added at different time-points after 
cellular exposure to Pr-MPO, as illustrated in Figure 43A. Interestingly, our MTT viability 
data collected after 18h Pr-MPO treatment showed that besides concurrent treatment of 3-MA 
with Pr-MPO which expectedly conferred SHEP-1 cells resistance, 3-MA treatment 30-, 60-, 
and 90-min after exposure to Pr-MPO was also able to rescue the cells, compared to Pr-MPO 
treatment alone (for example, 84.83 + 1.21% cell viability with 3-MA 5mM added 90 min 
after Pr-MPO 10µM treatment vs. 50.22 + 1.90% cell viability with Pr-MPO 10µM alone, p< 
0.05) (Figure 43B).  However, blocking autophagy 2h (and onwards) after exposure to Pr-
MPO no longer restored cell survival to cancer cells (for example, 59.12 + 2.03% cell 
viability with 3-MA 5mM added 2h after Pr-MPO 10µM treatment vs. 50.22 + 1.90% cell 
viability with Pr-MPO 10µM alone, p > 0.05) (Figure 43B). When viewed under the 
microscope at the end of the kinetic study, it was apparent that concurrent treatment of 3-MA 
with Pr-MPO was the most effective in reversing Pr-MPO-induced cell death morphology, 
followed by 3-MA-treatment -30 and -60min after adding Pr-MPO (Figure 43C). 3-MA 
treatment at the 90min time-point after Pr-MPO exposure conferred partial normalcy to the 
cells, with large fractions of cells still attached to the culture dish, but there was already 
visible reduction in cell number and increased portion of cells rounding up, in comparison to 
untreated control (Figure 43C). 3-MA addition at time-points later than that had no effect on 
Pr-MPO-treated cells, which displayed cell death morphology similar to cells dying from Pr-
MPO treatment alone (Figure 43C). On the other hand, our Western blot results clearly 
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showed that Pr-MPO-mediated LC3-II accumulation was first measurable at 90min, with no 
noticeable drug-induced changes at the earlier time-points (30 and 60min). But it was not 
until 2h post-treatment that substantial LC3-II induction was observed (Figure 43D). Thus, 
these data suggest that halting autophagy at any point prior to its full-blown activation 
prevents cell death, but once set in motion, autophagic activity determinately signals to 























             
 
Figure 43: Once autophagic activity is set in motion (2h post-Pr-MPO treatment and 
onwards), addition of 3-MA no longer protects cells from Pr-MPO-mediated cell death. 
(A) Illustration of experimental design. SHEP-1 cells were treated with Pr-MPO at 0, 5, or 
10µM, and 3-MA 5mM was either added concurrently with Pr-MPO, or at indicated time-
points after Pr-MPO treatment. At the end of 18h treatment of Pr-MPO, cell viability was 
assessed by (B) MTT assay and (C) morphological examination with phase-contrast 
microscopy (Magnification: x20,000). For (B), the bars represent means + s.e.m from three 
independent experiments. *, p < 0.05 and **, p < 0.05 as compared with Pr-MPO treatment 
alone. (D) SHEP-1 cells were treated with Pr-MPO at 0, 5, or 10µM for 30-, 60-, 90- or 120-




3.6 Autophagy is required for, but independent from, caspase activation 
Although the exact mechanisms continue to baffle researchers, it is now appreciated that there 
are multiple cross-talks between apoptosis and autophagy to jointly seal the fate of a cell. As 
Pr-MPO-mediated cell death manifests both autophagic and apoptotic phenotypes, we sought 
to understand if these two processes occur in a hierarchical or independent manner. In view of 
the kinetic sequence of events, whereby autophagy is induced as early as 2 hours post-
treatment (Figure 43D), as opposed to the late activation of caspases at the 15 and 18h time-
point (Figure 27-28), we propose that Pr-MPO-triggered autophagy is upstream of the mild 
activation of caspases. In support of this hypothesis, we observed that inhibition of autophagy 
invariably abrogated caspase 3 activity, as evidenced by abrogation of Pr-MPO-induced late 
PARP cleavage by both pharmacological agent 3-MA and ATG genes silencing (Figure 44A- 
B). On the other hand, we aimed to determine if autophagy induction requires caspase 
activation. This was achieved by examining if the pan-caspase inhibitor zVAD-fmk exerts 
any effect on Pr-MPO-induced autophagy. Western blot analyses of LC3-II levels revealed 
that pre-incubation of cells with zVAD-fmk did not engender changes in autophagy triggered 
after Pr-MPO treatment (Figure 44C), despite its effectiveness in inhibition of PARP cleavage 
(Figure 29A). Taken together, these results suggest that in the context of Pr-MPO-mediated 
cancer cell death, autophagy is triggered upstream of and independently from apoptotic 
events. Moreover, autophagy induction is required to trigger caspase activation, a key event in 
the apoptotic cascade that is at least in part responsible for eventual cell death execution 





Figure 44: Autophagy induction is an independent event upstream of caspase activation. 
(A) ULK1 or Atg7 were knocked down in SHEP-1 as described and confirmed in Figure 41A 
before treatment with Pr-MPO at 0 or 10µM for 18h. (B) SHEP-1 cells were pre-incubated 
with 3-MA at 0, 5 or 10mM for 2h before treated with Pr-MPO at 0, 5 or 10µM for 18h. (C) 
SHEP-1 cells were pre-incubated with zVAD-fmk 100µM for 2h before treatment with Pr-
MPO at 0, 5, or 10µM for 8h. In all panels, protein levels were assessed by Western blotting. 
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4 Pr-MPO-induced autophagic cell death is PPARγ-dependent 
4.1 PPARγ expression is determinant for autophagic response 
4.1.1 Autophagic response correlates with PPARγ expression level in cancer 
cells 
To date, the only handful of reports proposing the ability of PPARγ ligands to trigger 
autophagy-associated features fell short of rigorously demonstrating an up-regulation of 
autophagic activity per se(Butler et al., 2000; Wei et al., 2010; Yan et al., 2010). Moreover, 
only one report has presented preliminary evidence to suggest PPARγ-dependent autophagy 
induction, which however was based on acridine orange (AO) staining and not autophagy-
specific assays (Zhou et al., 2009). Hence, we sought to provide unprecedented evidence 
elucidating the role of PPARγ activation in autophagy induction, which in our model is causal 
to cell death.  
 
Having established two cancer models (lymphoma and breast carcinoma) comprising of cell 
lines with contrasting levels of inherent PPARγ protein which were predictive of their 
responses to Pr-MPO, we evaluated the autophagy-inducing effect of Pr-MPO on selected cell 
lines representative of high and low PPARγ expression. PPARγ-overexpressing Raji cell line 
(Figure 16D, Figure 45B) elicited strong autophagic response to Pr-MPO as evidenced by 
marked generation of LC3-II levels, which was dramatically muted in low-PPARγ-expressing 
normal PBMCs throughout the time-points tested (2, 4, 8h) (Figure 45A-B). In stark 
comparison to normal PBMCs of which endogenous PPARγ was hardly detectable, western 
blot analysis of Raji’s PPARγ protein demonstrated dose- and time-dependent depletion after 
Pr-MPO treatment, which is indicative of PPARγ activation (Floyd and Stephens, 2002) and 
corresponds to the trend of autophagic induction (Figure 45B). The same correlative pattern 
was observed in our breast cancer model, whereby Western blot analysis of LC3-II 
accumulation demonstrated pronounced induction of autophagy  in MDA-MB-231 cells as 
early as 2h post-treatment, which by comparison was minimal in T47D and MCF10a, cell 
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lines harboring low levels of PPARγ (Figure 7A, Figure 45C). Hence, observations from both 
cancer models lucidly imply the likelihood of a functional association between PPARγ 
expression and initiation of autophagic response, which in turn provides the discriminatory 
basis on which Pr-MPO’s cancer-specific effects are based.  
 
    
 
Figure 45: Autophagic response of cancer cells correlates with inherent PPARγ 
expression. 
(A, B) PBMCs and Raji cells were treated with indicated doses of Pr-MPO for 2, 4, or 8h 
before being subjected to Western blot analysis of LC3-II and PPARγ levels. (C) MCF10a, 
MDA-MB-231 and T47D were treated with Pr-MPO at 0 or 10µM for 2h, after which cells 
were harvested for measurement of LC3-II levels by Western blotting. 
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4.1.2 Pr-MPO-induced autophagy is abrogated by transient PPARγ 
knockdown and enhanced by transient PPARγ overexpression 
Should the lack of autophagic response in T47D breast carcinoma cell line be attributable to 
its status of PPARγ expression, enforced expression of functional PPARγ ought to logically 
restore its sensitivity to Pr-MPO-induced autophagy. Indeed, overexpression of wild-type 
PPARγ profoundly enhanced LC3-II formation in the event of Pr-MPO trigger (Figure 46A), 
buttressing the argument that sufficient expression level of PPARγ is required for Pr-MPO-
activated autophagy. 
 
To investigate if genetic invalidation of PPARγ results in the reversal of these observations, 
we transiently knocked down PPARγ in SHEP-1 cells before exposure to Pr-MPO treatment. 
Two different methods of PPARγ silencing utilising either siRNA or shRNA yielded 
consonant results, whereby suppression of PPARγ expression prominently blunted autophagy 
induction despite Pr-MPO exposure (Figure 46B). Clearly, these overexpression and 
knockdown studies allude to PPAR-γ as a pivotal determinant in the outcome of Pr-MPO-





Figure 46: PPARγ is critically required for Pr-MPO-induced autophagy. 
(A) T47D cells were transfected with either pCMX empty vector or wildtype pCMX-
mPPARγ. 48h after transfection, cells were treated with Pr-MPO at 0 or 10µM for 2h. (B) 
PPARγ was transiently knocked down in SHEP-1 cells by transfection with either siRNA or 
shRNA targeting PPARγ. Non-targeting siRNA and shRNA were included as respective 
controls. 48h post-transfection, cells were treated with indicated doses of Pr-MPO for 8h. In 
all panels, LC3-II and PPARγ levels were measured by Western blot analyses.  
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4.2 PPARγ activation is required for autophagic activity 
To delineate the mechanistic involvement of PPARγ in autophagy, we endeavoured to address 
if its bona fide function as a transcription factor is relevant for the activation of the autophagic 
machinery. This was achieved by the use of GW9662, an irreversible antagonist effective in 
abrogating Pr-MPO-based PPARγ activation (Figure 5). Pre-incubation of SHEP-1 cells with 
GW9662 resulted in substantial inhibition of Pr-MPO-mediated increase in LC3-II levels, 
correlative with blockade of autophagy initiation (Figure 47A). Strikingly, detailed 
examination of treated cells with transmission EM exhibited near complete absence of 
autophagic structures in cells preincubated with GW9662 prior to Pr-MPO treatment, which 
in glaring contrast were pervasively manifested in samples exposed to Pr-MPO alone (Figure 
47B). In order to quantify the cytoprotective effect exerted by GW9662 against autophagy 
induction, fluorescence microscopy was performed to compute the fraction of GFP-LC3-
transfected cells scored as punctae-positive. Both live images of significantly diminished 
GFP-punctate staining in cells pre-incubated with GW9662 (Figure 47C), as well as 
quantitative scoring of punctae-positive cells (119.49 + 20.25% punctae-positive cells with 
GW9662 pre-incubation followed by Pr-MPO treatment vs. 180.95 + 5.41% with Pr-MPO 
5µM alone, p < 0.05) (Figure 47D) reflected inhibition of autophagosomes formation as a 
consequence of PPARγ inactivation. As refutation to speculative claims that GW9662-
mediated decline in autophagosome numbers assessed by all these methods might well be due 
to expedited completion of the autophagic cycle, we demonstrate here that GW9662 
prevented autophagic degradation of SQSTM1/p62 by Pr-MPO, thus suggestive of a true 
inhibition of autophagic flux by the PPAR-γ antagonist (Figure 47E). 
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Figure 47: Pr-MPO-induced autophagy is dependent upon PPARγ activation. 
(A) SHEP-1 cells were pre-incubated with GW9662 at 0, 1, or 10µM for 2h before 8h 
treatment of Pr-MPO at 0, 5, 10µM as indicated. Cells were harvested for Western blot 
analysis of LC3-II levels. (B) Transmission EM images of SHEP-1 cells left untreated 
(control) or exposed to 6h treatment of Pr-MPO 10µM  with or without 2h pre-incubation of 
GW9662 10µM. The larger images were taken with a x6000 objective (5µm scale bar) and 
the close-up images with a x12 000 objective (2µm scale bar). (C) GFP-LC3 transfected 
SHEP-1 cells were pre-incubated with GW9662 10µM for 2h before being subjected to Pr-
MPO 5µM treatment for 6h. Transfected cells were viewed with a fluorescence microscope. 
Red arrows point towards GFP-LC3 punctae. The larger diagrams were taken with a x40 000 
objective and the smaller diagrams below represent their close-up images. (D) Quantitative 
analysis of punctae-positive cell as described in Figure 37C. The bars represent means + s.e.m 
from three independent experiments. *, p < 0.05 as compared with Pr-MPO 5µM treatment 
alone. (E) SHEP-1 cells were pre-incubated with GW9662 at 1 or 10µM for 2h before 
treatment with Pr-MPO 10µM for 8h. Cells were harvested for measurement of SQSTM1/p62 
levels by Western blotting. 
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4.3 Involvement of PPARγ transcriptional targets in Pr-MPO-induced 
autophagy 
4.3.1 Silencing of PTEN or RhoB does not inhibit autophagic cell death 
The implied importance of PPAR-γ transcriptional activity for mediating autophagic cell 
death warrants studies to gain mechanistic understanding pertaining to the involvement of its 
bona fide target genes as possible intermediary molecules linking PPAR-γ activation and 
autophagy induction. As previously detailed in Table 2, we have identified six direct targets 
of PPAR-γ potentially responsible for its cytotoxic properties. To ascertain if PPAR-γ-
mediated autophagy is a function of PTEN, RhoB, BNIP3 or HIF1-α upregulation, we 
suppressed the expression of these target genes with targeted RNA interference (RNAi) 
knockdown. It is important to note that not only did we confirm successful knockdown of 
these respective target genes prior to Pr-MPO treatment by Western blot analyses (Figure 
48A.I, 48B.I, 49A.I), we also monitored their modulations in response to Pr-MPO to ensure 
effective suppression of Pr-MPO-dependent upregulation by siRNAs (Figure 48A.II, 48B.II, 
49A.II). Western blot results revealed that abrogation of neither PTEN nor RhoB induction 
exerted noticeable effect on Pr-MPO-dependent formation of LC3-II levels (Figure 48A.III, 
48B.III). Therefore, their ineffectual influence on cell death as illustrated by MTT data (74.75 
+ 7.05% viability with siPTEN, 70.56 + 1.06% viability with siRhoB, vs. 72.28 + 2.14% 
viability with siControl, all receiving Pr-MPO 5µM) and their inability to inhibit late-time-
point PARP cleavage appeared as obvious consequences of their failure to manipulate 
autophagic activity (Figure 48C-D). Parenthetically, positive control 15d-PGJ2, an 
endogenous PPARγ ligand, induced mild PARP cleavage after 18h treatment which was 
inhibitable by silencing of PTEN or RhoB alone, suggesting that Pr-MPO-induced cell death 













Figure 48: PTEN and RhoB are not involved in PPARγ-dependent autophagic cell 
death. 
In all panels, SHEP-1 cells were transfected with 50nM of either control siRNA, PTEN 
siRNA or RhoB siRNA for 48h before performing subsequent experiments. (A.I, B.I) 48h 
post-transfection, cells were harvested to determine effectiveness of PTEN and RhoB 
knockdown by Western blotting. (A.II-III, B.II-III) siRNA-transfected cells were exposed to 
Pr-MPO at 0, 5, or 10µM for 4 or 18h. PTEN, RhoB, and LC3-II levels were measured by 
Western blot analysis. (C) siRNA-transfected cells were treated with Pr-MPO 5µM for 18h 
before assessment of cell viability by MTT assay. The bars represent means + s.e.m from 
three independent experiments. (D) siRNA-transfected cells were treated with indicated doses 
of Pr-MPO or 15d-PGJ2 for 18h, after which PARP cleavage was detected by Western 




4.3.2 Silencing of HIF1-α does not inhibit autophagic cell death 
On the other hand, despite previous reports implicating HIF1-α in hypoxia-induced as well as 
PPAR-γ-dependent autophagy, siRNA-mediated knockdown of HIF1-α did not reproducibly 
repress Pr-MPO-dependent LC3-II generation (Figure 49A). Consistent with its failure to 
block autophagy, silencing of HIF1-α did not endow cells with any survival advantage 
regardless of whether cell death was assessed by MTT assay (70.70 + 3.50% cell viability 
with siHIF1-α vs. 72.68 + 2.57% with siControl, both receiving Pr-MPO 5µM), colony 







Figure 49: HIF1-α is not the mediator of PPARγ-dependent autophagic cell death. 
In all panels, SHEP-1 cells were transfected with 50nM of either control siRNA or HIF1-α 
siRNA for 48h before performing subsequent experiments. (A.I) Western blot analysis 
confirmed effective knockdown of HIF1-α 48h post-transfection. (A.II, A.III) siRNA-
transfected cells were exposed to indicated doses of Pr-MPO for 4 or 18h. Subsequently, cells 
were harvested for Western blot analyses of LC3-II and HIF1-α levels. (B-D) siRNA-
transfected cells were treated with Pr-MPO at 0, 5 or 10µM for 18h before assessment of 
clonogenic abilities by 14-day colony forming assay (B), evaluation of cell viability by MTT 
assay (C), and detection of PARP cleavage by Western blotting (D). For (C), the bars 
represent means + s.e.m from three independent experiments. 
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4.3.3 Overexpression of MnSOD or NHE-1 confers cells resistance to 
autophagic cell death 
To negate the effect of MnSOD and NHE-1 downregulation in response to PPAR-γ 
activation, these respective targets were overexpressed with transfection of exogenous 
plasmids. Similar to previous setups, overexpression statuses of these target genes were 
verified both prior to (Figure50A.I, 51A.I) and after Pr-MPO treatment (Figure50A.II, 51A.II) 
in order to confirm nullification of Pr-MPO-mediated downregulation by enforced expression. 
We found that overexpression of either MnSOD or NHE-1 alone was effective in attenuating 
LC3-II formation after Pr-MPO exposure, which indicates their unprecedented roles in 
negative regulation of autophagy (Figure 50A.III, 51A.III). Hence, it is plausible that PPAR-γ 
transcriptional downregulation of these two target genes serve to release an otherwise 
imposed negative autophagic blockade, providing a favourable milieu for autophagic 
activation and its ensuing cell death effect. As a result, MnSOD overexpression conferred 
partial protection to cells in the face of Pr-MPO-mediated reduction in clonogenic ability and 
late cleavage of PARP (Figure 50B-C). An even more pronounced pro-survival effect was 
observed with NHE-1 overexpression, as evidenced by significant recovery of both short-term 








Figure 50: PPARγ-dependent downregulation of MnSOD is required for Pr-MPO-
induced autophagy. 
In all panels, SHEP-1 cells were transfected with either pcDNA 3.1 empty vector or pcDNA-
MnSOD for 48h before performing subsequent experiments. Western blot analysis confirmed 
successful overexpression of MnSOD 48h post-transfection (A.I), and effective abrogation of 
Pr-MPO-dependent MnSOD downregulation by enforced expression (A.II). (A.III) 
Transfected cells were treated with indicated doses of Pr-MPO for 8 or 18h. LC3-II levels 
were measured by Western blotting. (B) Empty vector or pcDNA-MnSOD-transfected cells 
were treated with Pr-MPO 0 or 5µM before being subjected to 14-day colony-forming assay. 
(C) Transfected cells were treated with indicated doses of Pr-MPO for 18h and PARP 






Figure 51: PPARγ-dependent downregulation of NHE-1 is required for Pr-MPO-
induced autophagy. 
In all panels, SHEP-1 cells were transfected with either pCMX empty vector or pCMV-HA-
NHE-1 plasmids for 48h before performing subsequent experiments. Western blot analysis 
confirmed successful overexpression of NHE-1 48h post-transfection (A.I), and effective 
abrogation of Pr-MPO-dependent NHE-1 downregulation by enforced expression (A.II). 
(A.III) Transfected cells were treated with indicated doses of Pr-MPO for 8 or 18h. LC3-II 
levels were measured by Western blotting. (B) Transfected cells were treated with indicated 
doses of Pr-MPO for 18h before assessment of cell viability by MTT assay. The bars 
represent means + s.e.m from three independent experiments. *, p < 0.05 as compared with 
empty vector control cells receiving Pr-MPO 5µM. (C) Transfected cells were treated with 
Pr-MPO 0 or 10µM for 18h before colony-forming abilities were assessed  
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4.3.4 Silencing of BNIP3 abrogates Pr-MPO-induced autophagic cell death 
Among the candidate target genes investigated, the most striking cytoprotective effect was 
observed with RNAi silencing of BNIP3, where ablation of this PPAR-γ target alone by 
SMARTpool siRNA (mixture of four individual siRNAs for enhanced potency and 
specificity) robustly mitigated LC3-II induction after Pr-MPO treatment (Figure 52A). In 
addition, we also performed knockdown studies using four individual siRNA sequences 
targeting BNIP3.  Western blot analysis showed that even when employed in isolation, all 
four different siRNAs achieved substantial knockdown of BNIP3 protein and led to 
abrogation of Pr-MPO-induced autophagy (Figure 52B), reaffirming that the observed 
phenomenon is not a mere off-target effect of SMARTpool siRNA. To cross-validate our 
Western blot results, we conducted the GFP-LC3 assay, which appeared to be even more 
sensitive in detecting complete nullification of Pr-MPO-dependent autophagy by BNIP3 
ablation, as evidenced by the drastic reduction in punctae-positive cells (55.60 + 3.34% 
punctae-positive cells with siBNIP3 vs. 170.65 + 4.90% with siControl, both receiving Pr-
MPO 5µM, p < 0.005) (Figure 52C-D). Finally, knockdown of BNIP3 completely prevented 
autophagic degradation of SQSTM1/p62 in the wake of Pr-MPO exposure (Figure 52E); in 
fact, it even resulted in slight accumulation of this autophagic cargo marker (Figure 52E), 
suggesting inhibition of basal autophagy which was also reflected by the diminished number 
of punctae-positive cells below control levels (55.60 + 3.34% punctae-positive cells as a 










Figure 52: BNIP3 upregulation is essential to Pr-MPO-mediated PPARγ-dependent 
autophagy. 
In all panels, SHEP-1 cells were transfected with 50nM of either control siRNA or BNIP3 
siRNA for 48h before performing subsequent experiments. (A) Cells were transfected with 
control siRNA or SMARTpool BNIP3 siRNA. Silencing of BNIP3 was confirmed 48h post 
transfection at the point of Pr-MPO treatment (A.I), as well as after Pr-MPO treatment (A.II) 
by Western blot analyses. (A.III) SMARTpool BNIP3-siRNA-transfected cells were treated 
with indicated doses of Pr-MPO for 8 or 18h. Cells were harvested for measurement of LC3-
II levels by western blotting. (B) SHEP-1 cells were transfected with control siRNA, 
SMARTpool BNIP3 siRNA, or four individual siRNAs targeting BNIP3 (Seq1, Seq2, Seq3, 
Seq4, respectively). LC3-II levels were measured after 8h treatment of Pr-MPO. (C-D) 
SHEP-1 cells were co-transfected with either control siRNA or SMARTpool BNIP3 siRNA, 
along with GFP-LC3 plasmids. Transfected cells were treated with Pr-MPO 0 or 5µM for 6h 
before viewing with fluorescence microscopy using a x40 000 objective. (C) Red arrows 
indicate GFP-punctae. (D) Fractions of punctae-positive cells were scored as previously 
described in Figure 37C. The bars represent means + s.e.m from three independent 
experiments. **, p < 0.005 as compared with siControl-transfected cells receiving Pr-MPO 
5µM. (E) siControl- or SMARTpool siBNIP3-transfected cells were treated with Pr-MPO 0 
or 10µM for 18h before measurement of SQSTM1/p62 levels by Western blotting.  
170 
 
We next questioned whether autophagy inhibition by BNIP3 knockdown translates into 
cancer resistance to Pr-MPO’s cytotoxic effect. Remarkably, silencing of BNIP3 phenocopied 
silencing of ATG genes or pharmacological intervention with 3-MA (Figure 53), all cases of 
which invalidation of the autophagic response via different approaches consistently armored 
cells to become insusceptible to Pr-MPO-triggered cell death. In a manner akin to 3-MA pre-
incubation and Atg7 ablation, BNIP3 knockdown pronouncedly rescue cells from viability 
loss (96.17 + 1.28% cell viability with siBNIP3 vs. 72.68 + 2.56% cell viability with 
siControl, both receiving Pr-MPO 5µM, p < 0.05), loss in long-term clonogenic ability and 
manifestation of classical apoptotic death feature PARP cleavage (Figure 53).  
 
Implications from these data are multi-fold; beyond merely demonstrating PPARγ activation 
as a key event required for autophagy activity, we have also identified novel functions of its 
target genes, where PPAR-γ-dependent downregulation or induction of these direct targets 
concertedly orchestrate the autophagic response. Importantly, our findings also support the 
notion that autophagy can act as a variant paradigm of cell death that is largely mitochondria- 
and caspase-independent. Even though the precise biochemical crosstalk between autophagy 
and apoptotic signaling remains to be deciphered, it is evident in our model that autophagy is 
integral to the execution of cellular demise and is also required for the appearance of 






     
 
 
Figure 53: Inhibition of autophagy by abolishing PPARγ-induced BNIP3 upregulation 
rescues cells from Pr-MPO-triggered cell death. 
In all panels, SHEP-1 cells were transfected with 50nM of either control siRNA or 
SMARTpool BNIP3 siRNA for 48h before performing subsequent experiments. siRNA-
transfected cells were treated with Pr-MPO at 0, 5, or 10µM for 18h before assessment of 
clonogenic potential by a 14-day colony-forming assay (A), evaluation of cell viability by 
MTT assay (B), and detection of PARP cleavage by Western blotting (C). For (B), the bars 
represent means + s.e.m from three independent experiments. *, p < 0.05 and **, p < 0.05 as 
compared with siControl-transfected cells receiving the same Pr-MPO treatment. 
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5 Therapeutic potential of Pr-MPO as an anticancer compound 
The identification of Pr-MPO as a novel PPARγ activator poses a few important questions 
which might yield insights into its clinical potential as an anticancer agent. Firstly, how does 
Pr-MPO distinguish itself from pre-existing “conventional” PPARγ agonists, with special 
regards to potencies and adverse therapeutic profiles? Secondly, can we avail ourselves with 
pre-clinical models in addition to cell lines, such that we can predict patients’ clinical 
response to Pr-MPO with greater confidence?  
 
5.1 Strengths of Pr-MPO compound in comparison with conventional PPARγ 
agonists 
5.1.1 Pr-MPO is significantly more potent than pre-existing PPARγ agonists  
Notwithstanding the well-documented therapeutic efficacies of conventional 
thiazolidinediones (TZDs) and 15d-PGJ2 in both cell lines and mouse models, we demonstrate 
here that Pr-MPO is remarkably more potent than these known agonists of PPARγ (Figure 
54A). At the 24h time-point of cell viability assessment, Pr-MPO, with a considerably low 
5µM concentration, achieved the same level of cell kill (~40%) that was attainable with TZDs 
only in the hundreds range of µM concentration (Ciglitazone 100µM, Rosiglitazone 200µM). 
Even with the endogenous ligand 15d-PGJ2, potency of which fared better than TZDs, 
concentrations as high as 20-50µM were required for comparable levels of cytotoxic effect.  
Analyses of long-term clonogenicity of cancer cells after treatment yielded similar results, 
whereby identical concentrations of Pr-MPO and 15d-PGJ2 elicited considerable disparities in 
efficacies, with Pr-MPO being significantly more effective (Figure 54B). When cell cycle 
profiles of ligand-treated cells were assayed by PI staining, we observed that as opposed to 
Pr-MPO 10µM, which significantly increased the fraction of cells with DNA fragmentation 
(19.71 + 4.12% cell population) (Figure 24C), equimolar concentration of 15d-PGJ2, 
Rosiglitazone and Ciglitazone exerted no detectable effect, other than approximately 6% 
increase in the G2/M population of cells treated with Ciglitazone 10µM. Pronounced effects 
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were detectable with these conventional agonists only at high concentrations; Rosiglitazone 
100µM increased the population of cells in sub-G1 fraction from 0.28 (DMSO-treated  
control) to 8.55% (Figure 54C), while Ciglitazone 100µM arrested cells at S (19.92% cell 
population) and G2/M phases (22.83% cell population) (Figure 54D), and 15d-PGJ2 20µM 
also accumulated cells in the G2/M phase (35.39% cell population) (Figure 54E). Hence, not 
only was Pr-MPO’s effect on the cell cycle profile cancer cells distinctly different from these 
known ligands of PPARγ, it is also remarkably more potent. Overall, Pr-MPO’s experimental 
efficacy at concentrations multi-fold lower than pre-existing agonists argues strongly in 
favour of its clinical potential with possibly reduced toxicity, a major impediment 
encountered by conventional TZDs chemotherapy.  
 






Figure 54: Pr-MPO is significantly more potent than  pre-existing PPARγ agonists. 
(A) SHEP-1 cells were treated with various doses of Pr-MPO, Ciglitazone, Rosiglitazone and 
15d-PGJ2 as indicated for 24h, followed by assessment of cell viability by MTT assay. The 
bars represent means + s.e.m of four independent experiments. *, p < 0.05 compared with 
vehicle control (ethanol vehicle for 15d-PGJ2, DMSO vehicle for Ciglitazone and 
Rosiglitazone, untreated cells as control for Pr-MPO as Pr-MPO is water-soluble). (B) 
Colony-forming assay was performed on SHEP-1 cells after 18h treatment of Pr-MPO or 15d-
PGJ2 at 0, 5, 10µM concentrations. (C-E) SHEP-1 cells were treated with vehicle or various 
doses of Rosiglitazone (C), Ciglitazone (D), or 15d-PGJ2 (E) for 24h. DNA content was 
analyzed by flow cytometry after staining with PI.  
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5.1.2 Potent induction of autophagy is unique to Pr-MPO compound 
In view of compelling evidence demonstrating Pr-MPO-induced autophagy that is PPARγ-
dependent, we asked if autophagy can also induced by these conventional ligands of PPARγ. 
Western blot detection of LC3-II levels revealed that Ciglitazone 5µM and 15d-PGJ2 10µM 
failed to generate any significant autophagic response in comparison to Pr-MPO at equimolar 
concentrations (Pr-MPO 5 and 10µM) (Figure 55A). Even when tested at lethal 
concentrations eliciting 20-50% cell death based on the MTT data (Figure 54A), Ciglitazone 
(20, 100µM) and 15d-PGJ2 (20, 50µM) treatment failed to result in autophagy activation 
(Figure 55B-C). On the other hand, lethal concentrations of Rosiglitazone were observed to 
increase LC3-II formation at early time-point (4h), albeit substantially milder compared to the 
levels triggered by Pr-MPO (Figure 55B). Moreover, Rosiglitazone-mediated autophagy 
appeared to be transient, as LC3-II proteins were no longer detectable after 8h treatment, 
unlike sustained autophagy displayed by Pr-MPO (Figure 55C, Figure 36). Hence, it is highly 
probable that Pr-MPO-dependent massive activation of autophagy represents a unique mode 
of cancer cell elimination not commonly attainable with pre-existing ligand compounds, 
which in turn might provide an unprecedented opportunity to target apoptosis-resistant or 






Figure 55: Potent activation of autophagic pathway is unique to Pr-MPO. 
SHEP-1 cells were treated with various doses of Pr-MPO, Rosiglitazone, Ciglitazone or 15d-
PGJ2 for 4 or 8h as shown. Rosiglitazone 0µM and Ciglitazone 0µM indicate cells treated 
with DMSO vehicle; 15d-PGJ2 0µM indicates cells treated with ethanol vehicle. Expression 




5.1.3 Pr-MPO does not elicit untoward off-target ROS/RNS production 
Multiple lines of evidence have demonstrated spontaneous generation of reactive oxygen 
species (ROS) by conventional PPARγ ligands, which notwithstanding its purported role in 
facilitating tumor cell death, is regrettably also causally linked to mitochondrial damage of 
normal organs with resultant hepatotoxicity and cardiotoxicity (Ichihara et al., 2007; Julie et 
al., 2008; Roberts et al., 2010). In fact, it has been proposed that PPARγ agonist compounds 
with little effect in ROS and oxidative stress induction would have a lower capacity to induce 
hepatotoxicity, the debilitating adverse effect that contributed to the clinical demise of 
numerous TZDs (Troglitazone, Ciglitazone, Englitazone)(Julie et al., 2008). Thus, we 
compared the production of ROS across different compounds, namely, Pr-MPO, Ciglitazone 
(TZD) and 15d-PGJ2 (endogenous ligand), used at concentrations effecting 20-40% cell death 
in 24h (Figure 54A). Kinetic analysis of intracellular ROS levels up till the point prior to 
overt manifestation of cell death (15h post-treatment) was assayed by CM-H2-DCFDA 
(DCFDA), a fluorophore widely used to measure ROS and reactive nitrogen species (RNS), 
including but not restricted to, hydrogen peroxide (H2O2),  peroxynitrite (ONOO
-
) and 
hydroxyl radical (HO·) in the cells (Myhre et al., 2003). Corroborating previous reports, 
treatment with 15d-PGJ2 led to a drastic burst in DCF fluorescence as early as 15min after 
treatment, which was sustained significantly above control levels throughout the course of 
kinetic study, with a peak (349.89 + 20.33% of vehicle control)observed at 2h time-point 
(Figure 56A). Although less potent than 15d-PGJ2, its TZD counterpart, Ciglitazone, 
nevertheless increased DCF fluorescence after 2h (148.48 + 21.89%), which peaked at 4h 
post-treatment (171.77 + 15.35%), and lasted till the 12h time-point (163.50 + 3.25%) (Figure 
56A). In stark comparison to the conventional ligands, DCFDA-responsive ROS/RNS levels 
hovered persistently at or below basal levels after Pr-MPO exposure, regardless of the 
extensive and frequent time-points investigated (Figure 56A), thus indicating sheer absence of 
ROS production by Pr-MPO prior to its  induction of cell death. In fact, Pr-MPO might even 
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assume a mild anti-oxidant role, as evidenced by the slight drop in basal DCF fluorescence at 
certain time-points (for example, 60.06 + 6.81% of untreated control at 2h) (Figure 56A).  
 
In light of the fact that Pr-MPO was tested for this assay at a concentration (5µM) capable of 
substantive cell kill, we infer that ROS/RNS production is an irrelevant concern for clinically 
efficacious doses of Pr-MPO. Nonetheless, we performed a dose-response study of Pr-MPO 
to investigate if dose augmentation of this compound would eventually drive intracellular 
ROS/RNS production. DCFDA assay revealed no increase in intracellular ROS/RNS levels 
after 4h treatment despite increasing doses of Pr-MPO, unlike dose-dependent elevation of 
DCF fluorescence in response to 15d-PGJ2 and Ciglitazone at the same time-point (Figure 
56B, C). Besides quantitative representations of DCF fluorescence in terms of percentage 
difference in G-mean value relative to vehicle control, histogram analyses also displayed 
consistent leftward shifts by various concentrations of Pr-MPO, implying a countervailing 
drop in ROS level (Figure 56C). Conversely, increasing concentrations of 15d-PGJ2 and 
Ciglitazone resulted in progressive rightward shifts in fluorescence, indicative of tremendous 







Figure 56: Pr-MPO does not increase intracellularROS/RNS, which are produced in 
copious amounts by pre-existing PPARγ ligands. 
Levels of intracellular ROS/RNS were detected by flow cytometry using the probe CM-H2-
DCFDA. For every time-point, respective vehicle controls (ethanol vehicle for 15d-PGJ2, 
DMSO vehicle for Ciglitazone, untreated cells as control for Pr-MPO ) were included. (A) 
SHEP-1 cells were treated with either Pr-MPO 5µM, Ciglitazone 20µM or 15d-PGJ2 20µM 
for various durations as indicated. Changes in ROS/RNS levels were expressed as percentage 
changes in G-Mean of treated samples relative to vehicle controls. (B-C) SHEP-1 cells were 
treated with various doses of Pr-MPO, Ciglitazone or 15d-PGJ2 as indicated for 4h. In (B), 
ROS levels were quantified by percentage changes in G-Mean of treated samples relative to 
respective vehicle controls. In (C), histograms obtained from one set of experiment are 
shown; they are representative of three independent experiments. For (A-B), data shown are 
means + s.e.m of three independent experiments. 
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Besides using the DCFDA dye, we also assayed the level of mitochondrial superoxide (O2
·-
) 
by the use of MitoSOX Red fluorogenic dye. MitoSOX Red is highly selective for the 
detection of mitochondrial O2
·-
, and once oxidized by the latter, produces an increase in red 
fluorescence measurable by flow cytometry. Fluorescence data demonstrated that kinetic 
treatment of Pr-MPO did not increase mitochondrial O2
·-
 (Figure 57), which is a ROS species 
distinct from those detected by DCFDA. On the contrary, 15d-PGJ2 and Ciglitazone triggered 
an initial burst of mitochondrial O2
·- 
at 1h (191.65 + 8.76% of vehicle control) and 2h (136.17 
+ 7.46% of vehicle control), respectively (Figure 57). Taken together, we confirmed that Pr-
MPO treatment did not engender any production of mitochondrial ROS or DCFDA-
responsive ROS/RNS, a property unique to this novel activator of PPAR-γ.  
 
 
Figure 57: Pr-MPO does not increase mitochondrial superoxide levels, unlike 
conventional PPARγ ligands. 
Mitochondrial superoxide levels of SHEP-1 cells treated with Pr-MPO 5µM, Ciglitazone 
20µM or 15d-PGJ2 20µM were assessed at indicated time-points using MitoSOX Red 
fluoroprobe. Changes in mitochondrial superoxide levels were expressed as percentage 
changes in G-Mean of treated samples relative to vehicle controls. Data shown are means + 
s.e.m of three independent experiments.  
181 
 
5.1.4 ROS/RNS production by pre-existing compounds is not PPARγ-regulated 
In the case of PPARγ activators, compounds of which cancer-specificity allegedly hinges on 
selective PPARγ overexpression in tumor cells, any colossal production of ROS in a PPARγ-
independent manner is problematic with potentially detrimental effects on non-PPARγ-
expressing normal cells. Accordingly, two lines of experimental evidence are provided here to 
substantiate the claim that ROS production by 15d-PGJ2 and Ciglitazone is an off-target effect 
independent of PPARγ. Firstly, pre-incubation of cells with PPARγ-specific antagonist 
GW9662 exerted no effect in inhibiting rightward shifts of DCF fluorescence histograms 
produced by these two compounds (Figure 58A). Quantitative analysis of fluorescence G-
means reiteratively showed comparable levels of DCFDA-responsive ROS/RNS after 
treatment of these conventional ligands with or without GW9662 (for example, 172.78 + 
20.07% with Ciglitazone 20µM alone vs. 174.18 + 2.99% with GW9662 10µM pre-
incubation before Ciglitazone 20µM treatment) (Figure 58B). The other experimental support 
of PPARγ-independent ROS/RNS production was derived from our luciferase reporter data, 
whereby effects of 15d-PGJ2 and Ciglitazone on transactivation of endogenous PPARγ were 
assessed at the point of observed DCF fluorescence elevation (4h post-agonist treatment), in 
the absence or presence of GW9662. We found that treatments with these compounds were 
not accompanied by any appreciable PPARγ activation (1.12 + 0.04 and 1.14 + 0.04 fold 
increases of control for 15d-PGJ2 20µM and Ciglitazone 20µM, respectively), whereas pre-
incubation with GW9662 managed to further suppress PPARγ activity below basal level (0.89 
+ 0.06 fold with GW9662 10µM pre-incubation before 15d-PGJ2 20µM treatment), in line 
with previous reports demonstrating its antagonistic function (Figure 58C) (Leesnitzer et al., 
2002). Although unexpected, the paradoxical lack of PPARγ agonism witnessed with these 
conventional ligands nonetheless supports the notion that ROS/RNS production by these 







Figure 58: ROS/RNS production by conventional ligands is not PPARγ-dependent. 
SHEP-1 cells were treated with vehicle, Ciglitazone 20µM or 15d-PGJ2 20µM for 4h with or 
without 2h pre-incubation of GW9662 10µM . Intracellular ROS levels were detected by flow 
cytometry using CM-H2-DCFDA fluoroprobe. (A) Histograms obtained from one set of 
experiment are shown here; they are representative of three independent experiments. (B) 
Quantitative representation of percentage changes in G-Mean values relative to vehicle 
control samples.*, p < 0.05 and **, p < 0.005 as compared with vehicle control. (C) SHEP-1 
cells were transfected with 3 x PPRE luciferase reporter plasmids. Transfected cells were pre-
incubated with GW9662 10µM for two hours before exposure to vehicle, or various doses of 
Ciglitazone or 15d-PGJ2 for 4h. Data were calculated as luciferase RLU/renilla/µg total 
protein and expressed as fold increase relative to untreated control. For (B-C), the bars 
represent means + s.e.m from three independent experiments. 
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5.1.5 Unlike conventional ligands, efficacy of Pr-MPO is not limited by high 
serum conditions 
Intrigued by the above data, we sought for logical reasons to account for the inability of 15d-
PGJ2 and Ciglitazone to activate PPARγ in our model. One possible explanation is premised 
on the differences in serum conditions used in our system (specifically, “full”, or 10% serum 
in complete media), as opposed to those used in numerous reports demonstrating PPARγ 
agonistic activity of these compounds in either serum-free or serum-depleted media. To test 
this hypothesis, we serum starved SHEP-1 cells with DMEM containing only 0.5% serum for 
18h before administration of compounds. In another set of cells handled in parallel, serum 
level was kept constant at 10% throughout the experiment. As illustrated by Figure 59A, 
deprivation of serum from 10 to 0.5% markedly enhanced both 15d-PGJ2 and Ciglitazone-
induced PPARγ activation (4.19 + 0.44 and 2.19 + 0.27 fold increases for 15d-PGJ2 10µM 
and Ciglitazone 20µM, respectively).  
 
Even if we agree with the necessity for such manipulated experimental conditions to unmask 
agonistic effects of conventional ligands in research settings, the unpalatable issue remains 
that cellular responses to these compounds appear to be dictated by serum conditions, 
contents of which are inconceivable to be controlled in vivo. Moreover, serum deprivation per 
se exerts confounding effects, as evidenced by cell cycle profile analysis of SHEP-1 cells 
being maintained in full serum condition or serum-free media for 24h with no additional drug 
treatments (Figure 59B). Serum starvation alone was able to prominently increase sub-G1 
population (2.90% in full serum vs. 20.07% sub-G1 population with serum-deprivation) 
(Figure 59B), hence rendering it an inapplicable experimental condition for cell lines which 
are not viable in low or depleted serum conditions. Bearing these considerations in mind, it is 
an advantage that Pr-MPO is potent and effective even in the presence of relatively high 
prostaglandin levels (in full serum), which tend to elevate constitutive levels of PPARγ 
activation. Our preliminary data with Pr-MPO 5µM showed that this novel compound also 
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activates PPARγ receptor in 0.5% serum to a degree comparable with that in full serum (1.51 
+ 0.07 fold increase in 0.05% serum vs. 1.46 + 0.06 fold increase in 10% serum) , suggesting 
that serum conditions are unlikely to limit its efficacy (Figure 59C).  
      
 
Figure 59: Efficacies of conventional ligands are severely limited by high serum 
conditions, which do not affect Pr-MPO. 
(A) SHEP-1 cells were transfected with 3 x PPRE luciferase reporter plasmids. One set of 
transfected cells was exposed to various doses of Ciglitazone or 15d-PGJ2 for 4h in complete 
media with 10% FBS. The other set of transfected cells was subjected to serum starvation by 
changing to media containing 0.5% FBS for 18h, followed by treatment of vehicle or various 
concentrations of Ciglitazone or 15d-PGJ2 for 4h. (B) Cell cycle profiles of SHEP-1 cells 
cultured in media with 10% or 0% FBS(serum-deprived) for 24h were assayed by flow 
cytometry after PI staining. (C) 3 x PPRE luciferase reporter-transfected SHEP-1 cells were 
serum-starved by incubation in media with 0.5% FBS for 18h before 2h treatment of GW9662 
1µM, followed by 4h treatment of Pr-MPO 5µM. Another set of transfected cells was treated 
with Pr-MPO 5µM in media with 10% FBS without prior serum starvation. For (A) and (C), 
data were calculated as luciferase RLU/renilla/µg total protein and expressed as fold increase 
relative to untreated control. The bars represent means + s.e.m from two independent 
experiments with duplicates. 
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5.2 Pr-MPO is efficacious in clinical samples and xenograft model 
5.2.1 Pr-MPO exerts potent cytotoxicity in clinical malignant lymphoma  
To validate the clinical relevance of Pr-MPO as an effective PPARγ-dependent anticancer 
compound, we studied therapeutic effects of Pr-MPO on lymphoma cells of malignant clinical 
samples derived from three independent biopsies. In fact, we were provided with four 
different biopsies (patient 93-96), two of which were pathologically characterized as follicular 
lymphoma (patient 93 and patient 96), and one as diffused B-cell lymphoma (patient 94). The 
sample from patient 95 was later excluded from our study of clinical lymphoma samples 
because it was later diagnosed as metastasized ovarian carcinoma. We treated these malignant 
lymphoma cells with various doses of Pr-MPO for 18h, followed by assessment of cell 
viability loss by MTT assay. Our data confirmed Pr-MPO to be therapeutically effective in 
these clinical samples, as evidenced by Pr-MPO 5µM inducing a potent loss of approximately 
50% cell viability in follicular lymphoma samples (59.01% viability of control in sample 93 
and 54.97% viability in sample 96), and 20% cell viability loss in diffused B-cell lymphoma 
sample (78.60% viability of control in sample 94) (Figure 60A). Western blot analyses of 
whole cell lysates confirmed the expression of endogenous PPARγ in these malignant 
lymphoma cells, which in comparison was not detectable in normal PBMCs (Figure 60B). 
Taking the viability data obtained from normal PBMCs into consideration, where equivalent 
concentration of Pr-MPO had negligible effect on the survival of non-cancerous lymphocytes 
(90.11 + 6.20% cell viability with Pr-MPO 5µM) (Figure 16D), the compound’s selectivity 
for PPARγ-overexpressing transformed cells is remarkable. Incidentally, PPARγ level in 
Patient 94 (P94) diffused B-cell lymphoma appeared to be lower relative to P93 follicular 
lymphoma sample (Figure 60B), which might explain Pr-MPO’s reduced potency in the 
former (Figure 60A). We also observed Pr-MPO-responsive degradation of PPARγ in these 
malignant samples, which is suggestive of PPARγ activation (Floyd and Stephens, 2002) 
(Figure 60B). These data support the notion that Pr-MPO’s clinical efficacy as a cancer-







Figure 60: Pr-MPO is effective in reducing cell viability of PPARγ-expressing 
lymphoma cells derived by patient samples. 
(A) Histopaque-separated lymphoma cells obtained from three independent biopsies (patient 
93, 94, and 96) were treated with Pr-MPO at 0, 5, or 10µM  for 18h before assessment of cell 
viability loss by MTT assay. Each data point represents mean of five replicates. (B) 
Malignant lymphoma cells from patient samples and normal PBMCs isolated by buffy coat 
were treated with Pr-MPO at 0, 5, or 10µM for different durations as indicated. Expression 




5.2.2 Autophagy induction is specific to clinical lymphoma cells, sparing non-
cancerous PBMCs 
In order to confirm the ability of Pr-MPO to induce autophagy in clinical samples, we treated 
lymphoma cells derived from patients’ biopsies with Pr-MPO in a kinetic study, after which 
LC3-II formation was measured by Western blotting. In close association with our viability 
data, Pr-MPO effectively activated autophagy in malignant lymphoma cells (Figure 61A). In 
contrast, normal PBMCs were spared from Pr-MPO’s autophagy induction (Figure 61B). 
These data are consistent with our observations of the cancer cell lines, whereby Pr-MPO 




Figure 61: Pr-MPO induces in clinical lymphoma samples but not in normal PBMCs. 
(A) Malignant lymphoma cells derived from patient samples were treated with Pr-MPO at 0, 
5, or 10µM for the indicated durations before being harvested for Western blotting. (B) 
Normal PBMCs isolated from buffy coat and malignant lymphoma cells obtained from 
clinical sample 93 were treated with Pr-MPO at 0, 5, or 10µM for 8h. In all panels, LC3-II 
levels were assessed by Western blot analysis, and GAPDH was used as a loading control.  
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5.2.3 Pr-MPO is effective against tumor growth of HCT116 xenografts in nude 
mice 
To ascertain whether the antitumor effect we observed with Pr-MPO in vitro could also be 
reproduced in vivo, our colleagues in the laboratory used a proof-of-concept HCT116 
xenograft model in nude mice
1
. To note, Pr-MPO-induced cytotoxicity and autophagy 
activation in HCT116 cell line was previously established in vitro in Figure 16B and Figure 
36. Moreover, prior to the start of the tumor xenograft experiment, we verified the 
responsiveness of HCT116 to Pr-MPO-mediated PPARγ transactivation which was 
determined by the luciferase reporter assay (Figure 62), thus establishing PPARγ as a valid 
target responding to Pr-MPO in this colorectal carcinoma cell line.  
 
 
Figure 62: Transcriptional activation of PPARγ by Pr-MPO in HCT116 colorectal 
cancer cells as determined by luciferase activity. 
HCT116 cells were transiently co-transfected with 3 X PPRE luciferase reporter and renilla 
plasmids as previously described in Figure 3, and subsequently exposed to various doses of 
Pr-MPO for 6h. Data were calculated as luciferase RLU/renilla/µg total protein and expressed 
as fold increase relative to untreated control. The bars represent means + s.e.m from two 
independent experiments with duplicates. 
                                                   
1 In vivo mice work was conducted by lab colleagues Agnes Maillet and Karishma Sachaphibulkij, who 
also kindly provided the data for Appendix A.  
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As summarized in Appendix A.I, tumor inoculation was performed by injecting HCT116 
cancer cells subcutaneously into female nude mice (n = 5). After the tumors had reached a 
mean volume of approximately 50mm
3
, Pr-MPO was administered to the recipient nude mice 
at a dosage of either 100µg/mouse (7.5mg/kg) or 200µg/mouse (13mg/kg, corresponding to 
75µM, IC50 for HCT116, Figure 16B) by intraperitoneal injection, while control group was 
injected with water as vehicle control. All treatments were continued for 16 days, during 
which tumor volumes were constantly measured. Figure 63B showed that Pr-MPO-mediated 
reduction of tumor volume was detectable 8 days after treatment initiation, with the higher 
dosage of Pr-MPO being more effective. Antitumor effect of Pr-MPO became increasingly 
pronounced with longer durations of treatment, and by the end of the study, 200µg Pr-MPO 
resulted in a staggering 80% reduction of average tumor volume as compared to vehicle-
treated xenografts, while 100µg Pr-MPO inhibited average tumor growth by approximately 
50% (Appendix A.II-III). Analysis of individual tumors indicated that most tumors in the Pr-
MPO-treated groups, especially those receiving 200µg Pr-MPO, were dramatically reduced in 
size relative to the xenografts in vehicle control group (Appendix A.III). Importantly, Pr-
MPO treatment was well tolerated by the nude mice, which did not display any discomfort or 
noticeable side effects in terms of diet intake or overall body weight during the course of 
study.  
 
To confirm the effect of Pr-MPO on transactivation status of PPARγ in the xenografts tumors, 
we examined the expression levels of a few PPARγ target genes by Western blot analysis. 
Consistent with the response observed in cancer cell lines, PTEN and RhoB expressions were 
upregulated in Pr-MPO-treated tumors, whereas MnSOD levels were downregulated 
correspondingly (Figure 63). Modulations of these target genes reflect in vivo activation of 
PPARγ, which is conceivably responsible for Pr-MPO compound’s potent anticancer effect 







Figure 63: Pr-MPO modulates PPARγ transcriptional targets in vivo. 
Expression levels of PPARγ target genes in vehicle-, 100µg Pr-MPO- or 200µg Pr-MPO-
treated tumors were assayed by Western blotting. The relative differences in expression were 
obtained by densitometry and expressed as fold increase with 1 being the control expression 




1 Timely discovery of a novel PPARγ activator 
In this study, we present the identification of a novel praseodymium-based metal complex, Pr-
MPO, that act as a potent activator of PPARγ. At the onset of the project, a combination of 
varying experimental techniques was employed to ascertain cell-based activation of PPARγ 
receptor as a result of compound treatment. Specifically, we applied two different 
transactivation plasmid systems that are commonly used in the literature for the identification 
of new PPARγ agonists. Dose-dependent PPARγ agonism by Pr-MPO was conclusively 
demonstrated by both GAL4-mPPARγ LBD reporter system (Figure 2) and 3xPPRE-tk-luc 
reporter plasmid (Figure 3). Moreover, positive readouts for endogenous PPARγ activation 
were consistently observed in several PPARγ-overexpressing cell lines, namely SHEP-1, 
SHSY5Y, MDA-MB-231, MCF7 and HCT116 (Figure 3, Figure 7B, Figure 10B, Figure 62), 
illustrating the robustness of Pr-MPO-mediated receptor transactivation independent of cancer 
cell lineages. Positive and negative controls via wildtype PPARγ overexpression, mutant 
PPARγ transfection, pharmacological antagonism of PPARγ and transient knockdown of 
PPARγ protein in SHEP-1, MDA-MB-231 or T47D cell line further corroborated the notion 
that Pr-MPO depends specifically on PPARγ to activate PPRE reporter gene (Figure 4-6, 
Figure 8-9). Of note, in a few previously described models, RXR was co-transfected with 
PPARγ to augment PPARγ transactivation (Camp and Tafuri, 1997; Hu et al., 1996). 
However, it has also been demonstrated that co-transfection of RXR with PPARγ may exert 
confounding effects because binding of cognate ligands at either subunits (RXR or PPARγ) 
can influence transactivation status of the PPAR:RXR heterodimer (Mukherjee et al., 1997a; 
Schulman et al., 1998). Thus, in this study, experimental manipulations were focused solely 
on PPARγ without any artificial modulation of its binding partner RXR in the heterodimer, in 
order to assess specificity of Pr-MPO for the PPAR receptor. This ensures that any alterations 
in the reporter activity or transcription of target genes were truly mediated by PPARγ and not 
RXR. Nevertheless, given the critical involvement of RXR in classical PPARγ-mediated 
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transcriptional regulation of target genes, further studies may be performed to elucidate a 
possible role of RXR in modulating cellular responses to Pr-MPO.  
 
In addition, we, in this study, as with most studies concerned with biological roles of PPARγ 
in various pathologies, do not explicitly distinguish between PPARγ-1 and PPARγ-2 protein 
isoforms. It is known that PPARγ-2 expression is restricted to adipose tissues, while PPARγ-1 
may be expressed in other tissue types (Tontonoz et al., 1994b). Currently, there is no specific 
antibody available to determinately discern one isoform from the other. Hence, by addressing 
PPARγ in general throughout the present study, we avoid making unqualified claims 
regarding isoform-specific effects. Given that these two protein isoforms are bound and 
activated by well-established synthetic PPARγ ligands in an almost identical manner 
(Elbrecht et al., 1996), the lack of differentiation between PPARγ-1 and PPARγ-2 activation 
by Pr-MPO will not diminish the impact of our findings. 
 
1.1 Relevance of Pr-MPO in the search for new generation PPAR 
modulators: implications in cancer and diabetes 
1.1.1 Pr-MPO as a dual PPARγ/α agonist 
Even though this study was focused on the PPARγ-dependent physiological properties of Pr-
MPO in cancer, this compound was also found to activate the –α isoform with no effect on the 
third isoform, PPARδ. Against a backdrop of intensive search for new PPAR agonists with 
less adverse therapeutic profiles, our identification of this novel dual PPARγ/α activator is 
particularly pertinent. The infamous clinical misadventure of Troglitazone more than a decade 
ago still serves as an instructive example cautioning against the application of other PPAR 
agonists structurally related to TZDs (Julie et al., 2008). Since then, an enormous amount of 
pharmaceutical research effort has focused on the development and optimization of safer and 
improved PPAR modulators, leading to the emergence of a new class of agents known as the 
PPARγ/α dual agonists. Such dual agonists hold promising potential as they are tailored to 
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temper PPARγ-induced weight gain in diabetic patients by stimulating lipid catabolism via 
PPARα activation (Chaput et al., 2000; Guerre-Millo et al., 2000). In addition, tandem 
targeting of PPARγ and -α with a single compound enables concomitant treatment of 
hyperglycemia as well as secondary cardiovascular complications. Beneficial effects of 
PPARγ/α agonists have been exemplified by Muraglitazar which reduced triglycerides levels, 
increased HDL levels and simultaneously improved glycemic control (Kendall et al., 2006). 
Thus, the ability of Pr-MPO to activate both -γ and –α subtypes signals potential application 
of this novel compound in the treatment of metabolic syndrome.  
 
In the context of cancer treatment however, it is far less clear whether Pr-MPO’s improved 
efficacy over pre-existing PPARγ agonists is by virtue of its dual PPARγ/α agonistic property. 
To date, pharmacological exploitation of PPAR receptor as an anticancer strategy has largely 
been PPARγ-centric. In fact, our literature review uncovered only two research groups which 
reported tumoricidal activity of novel dual PPARγ/α agonists. The first example is a high 
potency PPARγ/α agonist TZD18 compound, which inhibited cell growth and induced 
apoptosis in glioblastoma, Ph
+
-(Philadelphia chromosome positive) lymphoblastic leukemic 
cells and breast carcinoma (Liu et al., 2004; Liu et al., 2006; Zang et al., 2009). The other 
novel dual agonist compound BPR1H0101 functioned as an inhibitor of topoisomerase II in 
human oral carcinoma (Kao et al., 2008). Even though it was initially proposed that dual 
PPARγ/α agonists could wield greater anticancer efficacy than specific agonists of PPARγ or 
PPARα alone, direct evidence linking dual agonism to therapeutic advantages was however 
absent. To begin with, the true physiological importance of PPARα activation in cancers 
remains debatable as the endogenous expression of this receptor is limited to very few cancer 
types (Liu et al., 2006; Suchanek et al., 2002) (Table 1). Furthermore, knockdown of PPARα 
receptor in MCF-7 and MDA-MB-231 cells did not have any significant impact on dual 
PPARγ/α agonist TZD18-mediated cancer growth inhibition (Zang et al., 2009). In this study, 
our main experimental model SHEP-1 neuroblastoma expresses PPARγ and –δ, with no 
detectable PPARα expression (Figure 4A). As a result, pre-incubation of SHEP-1 cells with 
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MK886, a PPARα antagonist, expectedly failed to rescue cells from Pr-MPO-mediated cancer 
cell death (Appendix B). We concur that tumoricidal property of this novel compound is 
unlikely to be a function of dual agonism, but rather an outcome of modulation at the PPARγ 
receptor alone. Nevertheless, the ability of Pr-MPO to activate PPARα may present an 
unprecedented opportunity to offset side effects of PPARγ such as cardiovascular risks, thus 
preventing adverse drug-related events. On the other hand, a recent report showed that ligand-
activated PPARδ attenuates pro-apoptotic effects of PPARγ in PPARγ/δ-expressing colorectal 
carcinoma cells by opposing PPARγ’s effects on survivin expression and caspase-3 activity 
(Wang et al., 2011). In light of these findings, the specificity of Pr-MPO for PPARγ and α 
receptors without affecting the δ subtype confers promising benefits in the treatment of 
cancer. 
 
1.2 Establishing compound-mediated functional transactivation of PPARγ in 
cancer: a challenge 
Transcriptional readouts from chimeric receptors and PPRE-containing reporter plasmids are 
indeed practical tools in identification of lead compounds with PPAR-agonistic activity. 
However, such reporter systems are handicapped by certain shortcomings. With regards to 
chimeric receptors, these constructs include only the LBD of the PPAR receptor, and is thus 
unrepresentative of modulations exerted by the rest of the functional domains of PPAR on the 
receptor activity. As for the 3 x PPRE-tk-luc reporter plasmids, target promoters are 
exogenous and do not represent native chromatin environment or physiological controls by 
other cellular factors. Based on these considerations, we sought for direct molecular readouts 
that will more closely reflect in vivo cellular responses. Conventionally, cellular phenotypic 
assays employed to demonstrate functional PPARγ agonism of novel compounds are 
primarily based on differentiation of pre-adipocytes or stem cell lines to adipocytes. Since this 
study is focused on the effect of PPARγ activation in cancer models, we endeavored to assess 
modulations of representative PPARγ-responsive transcriptional targets in cancer cells as a 
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litmus test for activation of classical PPARγ receptor function by Pr-MPO(Tontonoz et al., 
1994b). This investigation, however, proved to be a major research challenge to our study. 
Regrettably, during the course of our study, there was a dearth of comprehensive and 
systematic studies to identify de novo cancer-specific gene network of PPARγ. As such, even 
though the literature is replete with studies identifying and experimentally validating PPARγ 
target genes implicated in adipogenesis and fatty acid metabolism (reviewed in our 
introduction), only a few reports demonstrated isolated transcriptional targets of PPARγ in 
mediating anticancer effects. Eventually, based on an extensive literature search and several 
preliminary investigations, we narrowed down our panel of PPARγ signature targets to six 
different genes, as detailed in Table 2. Quantitative mRNA transcript analyses by real-time 
PCR confirmed that these genes are modulated by Pr-MPO at the transcriptional level (Figure 
12), and are amenable to inhibition by Actinomycin D, an inhibitor of transcription (Figure 
13). Our data also demonstrate that modulations of these gene transcripts are further 
translated into corresponding changes at the protein level, which are abrogated by GW9662, a 
PPARγ specific antagonist (Figure 14A-B). We also rigorously demonstrated PPARγ-
dependence of these modulations by PPARγ knockdown and overexpression studies in 
different cell lines (Figure 14C-E). All these findings serve to validate Pr-MPO-triggered 
functional activation of PPARγ as a transcription factor. To our knowledge, this is the first 
study testing PPARγ agonistic properties of a novel compound using a cancer model without 
prior investigation in adipocytes. Thus, the use of these six cancer-relevant PPARγ target 
genes as a molecular readout for PPARγ’s transactivation status in a transformed state is 
unprecedented and represents a new strategy for discovery of PPARγ agonist compounds 
intended for cancer therapy. This approach conceptually disputes the traditional idea that 
PPARγ target genes are only important for adipocyte differentiation and lipid metabolism, 
and corroborates a recent paper reporting that PPARγ target genes are in fact highly 




1.3 Possible mechanism of Pr-MPO-mediated PPARγ receptor activation 
Several lines of evidence demonstrate that Pr-MPO treatment results in potent activation of 
PPARγ. In most cases, compounds with PPARγ-activating ability are found to be direct 
ligands of the receptor; physical binding to the receptor thus constitutes the most likely 
mechanism for potent induction of receptor activity. Thus far, some of our preliminary 
findings suggest that Pr-MPO is a ligand of the PPARγ receptor. Computational docking with 
the crystal structure of PPARγ showed promising results of Pr-MPO binding to the receptor at 
a pocket distinct from the known agonist ligands (personal communication with Dr. Sanjiv 
Yadav). In this regard, recent research findings have revealed that non-TZDs-related 
compounds that bind the nuclear receptor at alternative binding sites can differ in their ability 
to produce stable receptor conformations, thus triggering altered recruitment of corepressor 
and coactivator proteins, resulting in differential gene regulatory effects (Oberfield et al., 
1999; Zhang et al., 2007). Thus, Pr-MPO may represent a novel nuclear receptor ligand that is 
structurally and hence mechanistically distinct from conventional agonists, holding promise 
for improved efficacy and reduced side effects. Currently, we are validating the 
computational docking data to confirm that Pr-MPO binds to the PPARγ receptor by using the 
LanthaScreen time-resolved fluorescence resonance energy transfer (TR-FRET) PPARγ 
competitive binding assay (Invitrogen, Carlsbad, CA). This assay quantitatively determines 
the ability of test compounds to bind to purified hPPARγ LBD in vitro.  
 
Although uncommon, precedences of non-ligands activating PPARγ receptor have also been 
documented (Yano et al., 2007). One possible mechanism is through the upregulation of 
PPARγ expression. For example, cholesterol depletion increases PPARγ expression in HepG2 
and 3T3-L1 cells, giving rise to increased PPRE-driven transcription (Fajas et al., 1999). 
However, Pr-MPO treatment did not increase PPARγ expression; in fact, transactivation-
dependent decrease in PPARγ protein was consistently observed at all time-points 
investigated (Figure 11). Thus, we speculate that elevated expression of the receptor is not 
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critical for Pr-MPO-mediated PPARγ activation. Another possible mode of PPARγ activation 
is the production of endogenous ligands. In accordance to the description of 15d-PGJ2 
production in Figure D, net levels of prostaglandins are contingent on the expression and 
activity of cyclooxygenases, COX-1 and COX-2. As such, induced expression of COX has 
been advanced as a possible route of activating PPARγ by increasing intracellular production 
of ligands (Birnbaum et al., 2005; Yano et al., 2007). It was reported that statins induce COX-
2 expression via a p38- and MAPK-dependent pathway (Chen et al., 2004). Other reports also 
demonstrated COX-2 induction by inhibition of RhoA and Cdc42 (Degraeve et al., 2001; 
Yano et al., 2007). However, some may argue that given the controversial role of COX-2 in 
inflammatory responses, direct ligation of an agonist to the PPARγ receptor may represent a 
preferred mechanism of PPARγ activation rather than through elevated production of 
prostaglandins. Hence, whether Pr-MPO treatment increases generation of COX, thereby 
activating PPARγ, remains an avenue for future investigations.  
 
Lastly, several studies demonstrate that phosphorylation of PPARγ at a consensus MAP 
kinase site (serine 84) inhibits both its ligand-dependent and -independent transcriptional 
activity (Adams et al., 1997; Camp and Tafuri, 1997). In theory, compounds which suppress 
the MAP kinase cascade can potentially alleviate the suppression of PPARγ transactivation, 
priming the receptor for transactivation. However, our experimental data do not defend this 
hypothesized mechanism of activation, because Pr-MPO treatment did not depress, but rather 
activated ERK1/2 and JNK kinases (Appendix C). Moreover, administration of Pr-MPO to 
SHSY5Y, a cell line in which basal PPARγ receptor is highly phosphorylated, failed to 
modulate the phosphorylation status of PPARγ (Appendix D). In fact, we speculate that the 
maximal effect of Pr-MPO may be limited by an inherently abundant amount of 
phosphorylated PPARγ in SHSY5Y (Figure 10). Interestingly, with the exception of 
SHSY5Y, total PPARγ expression alone has thus far been predictive for Pr-MPO sensitivity 
in all other tested cancer cell lines. Hence, the question remains if the phosphorylation status 
of PPARγ in other cancer types affects cellular responses to Pr-MPO. It is clear, however, that 
198 
 
Pr-MPO does not trigger PPARγ receptor activation via inhibition of MAPK-mediated 
receptor phosphorylation, at least not in the SHSY5Y cell line.  
 
Taking into consideration the abovementioned possible routes of PPARγ activation, direct 
ligation of the receptor remains the most likely mechanism mediated by Pr-MPO. Our kinetic 
observations of Pr-MPO activation, which is as rapid as within 30min post- treatment (Figure 
11), are in line with our speculation that Pr-MPO compound binds directly to PPARγ, thereby 
activating the receptor. This is further corroborated by our computational modeling data, 
details of which are beyond the scope of this thesis.  
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2 Anticancer effects of Pr-MPO as a function of PPARγ activation  
As reviewed in the introductory section, mounting experimental data have demonstrated the 
anticancer properties of PPARγ agonists. Having witnessed the ability of Pr-MPO to activate 
PPARγ receptor in a rapid and sustained manner (Figure 3), we proceeded to test its cytotoxic 
potential in cancer models. As hypothesized, Pr-MPO caused significant reduction in cell 
survival of eight different PPARγ-overexpressing cell lines from disparate cancer origins 
(Figure 16). Moreover, Pr-MPO treatment also drastically compromised long-term clonogenic 
ability of cancer cells as evidenced by the colony-forming assay (Figure 17). Cell cycle 
profile analysis further confirmed the accumulation of cells with DNA fragmentation (Figure 
24), which is indicative of programmed cell death, and not merely a cytostatic effect. Even 
more encouraging results are obtained with our in vivo xenografts model, where Pr-MPO 
significantly inhibited growth of grafted tumors, in comparison with vehicle-treated 
xenografts (Appendix A). 
 
2.1 Potential of rare earth metal compounds as a cancer treatment modality 
Our observations on the tumoricidal effect of Pr-MPO point not only to the potential of 
PPARγ activators as a cancer therapeutic strategy; they also present new insights implying the 
potential use of praseodymium coordination complexes as prospective anticancer drugs. Over 
the past few decades, platinum-based compounds are the most commonly used metal-based 
compounds in cancer treatment. However, it is well-documented that undesirable toxicity and 
tumor resistance persist even with new generation platinum-based compounds (Galanski et 
al., 2003), stimulating researchers to explore the therapeutic potential of lanthanide (Ln)- or 
rare-earth metal-based anticancer agents as alternatives. Moreover, worthy to note, the choice 
of lanthanide in most investigations is by tradition lanthanum and gadolimium, therefore little 
is known of the therapeutic effects of other Ln (Kostova, 2005), such as praseodymium (Pr). 
Therefore, the novelty of our study is underlined by the first-time report of a newly synthesis 















 retarded growth of cultured B16 
melanoma cells by impeding transition of cancer cells from G0/G1 to the S phase (Sato et al., 
1998). According to Dai et al., millimolar concentrations of LaCl3 and CeCl3 induced 
apoptosis of leukemic cells without affecting normal bone marrow hematopoietic progenitor 
cells (Dai et al., 2002), while Weiss et al. showed that La
3+
 exerted antiproliferative effect on 
human colon carcinoma cell line HRT-18 by reducing Ca
2+
 supply (Weiss et al., 2001). 
However, it is conceivable that toxicity is significant with such high doses of Ln. The efficacy 
of Pr-MPO is observed at a micromolar range, thus giving it great advantage over the 
previously reported Ln. The superior therapeutic profile of this compound may be attributed 
to its coordination complex structure, with the Pr metal center organizing surrounding atoms 
to attain pharmacophore geometries specific for certain molecular targets (Kostova, 2005), 
which in our case are the PPAR receptors. In fact, in the last decades Ln complexes have 
attracted attention in cancer therapy, because they were discovered to be more effective and 
possibly better tolerated than inorganic salts. For an instance, cerium complexes of Warfarin, 
Coumachlor, and Niffcoumar have been discovered to be cytotoxically more potent than the 
Ce
3+
 counterpart (Manolov et al., 2000). Pr-MPO thus exemplifies a judiciously designed 
metal complex compound, which may be a potential lead for prospective synthesis of 
improved Pr-based cancer-targeting agent. 
 
Previously, Gunanathan et al. designed and synthesized a new series of selective estrogen 
receptor modulators (SERMs), composed of Ln chelates of estradiol-pyridine tetra acetate 
(EPTA), with good binding affinities to ERα (Li et al., 2011). Unique properties of such metal 
complexes allow them to target ER-positive cells, with strong implications in chemotherapy 
and imaging diagnostics. On the other hand, novel gadolinium-based mifepristone conjugates 
were synthesized and observed to exert antiprogestagenic activity in human breast cancer 
cells (Saha et al., 2010). Similar efforts were carried out in other research groups designing 
Ln chelates targeting progesterone receptor to be applied as MRI contrast agent (Lee et al., 
2007). Nevertheless, such reports are exceptions because the molecular targets of most Ln 
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complexes remain unidentified. Here, the ability of Pr-MPO to activate PPARγ represents 
first of its kind in the category of Ln complexes. Our discovery opens a new vista for the 
design and synthesis of Ln-based compounds to act as more specific agonists of PPAR 
receptors with less adverse side effects.  
 
2.2 Receptor-dependent vs. receptor-independent anticancer effects 
No doubt we have conclusively demonstrated Pr-MPO-induced PPARγ activation and the 
attendant antineoplastic effects. Nevertheless, mere concomitant observations of these two 
disparate events do not qualify the claim of PPARγ receptor-dependent cancer cell death. In 
fact, TZDs and 15d-PGJ2 have been reported to mediate antitumorigenic effects via receptor-
independent pathways. For example, troglitazone (Trog) mediated MAPK activation-
dependent induction of early growth response-1 gene (EGR-1). The authors argue that this 
antiproliferative mechanism of Trog is independent of PPARγ because other PPARγ ligands 
could not induce EGR-1 (Baek et al., 2003). In addition, Laurora et al. reported that Trog-
induced cell arrest in leukemic cells followed by cell death was linked to c-myc, c-myb and 
cyclin D2 downregulation, genes which lack putative PPRE in their promoter regions 
(Laurora et al., 2003). Nevertheless, these cases are in contrast to Pr-MPO, treatment of which 
lead to induction of PTEN, RhoB, HIF1-α, BNIP3, and downregulation of NHE-1 and 
MnSOD (Figure 12). All these cancer-relevant target genes contain PPRE motifs and are 
previously reported to be modulated by other PPARγ ligands (Table 2-3) (Kumar et al., 2009; 
Marlow et al., 2009; Patel et al., 2001; Venkatachalam et al., 2009; Zhou et al., 2009), 
building a case of PPARγ-dependent effects of Pr-MPO.  
 
In another study, ciglitazone and rosiglitazone caused cell death in human and rodent glioma 
cell lines but these effects were not reverted by GW9662 (Perez-Ortiz et al., 2004). 
Meanwhile, a more direct evidence of PPARγ-independent effect is provided by a PPARγ 
knockout study, where Trog suppressed growth of both PPARγ+/+ and PPARγ-/- mouse 
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embryonic stem cells-derived tumors (Palakurthi et al., 2001). Juxtaposed with these findings, 
our data obtained from pre-incubation of SHEP-1 and MDA-MB-231 cells with GW9662 
(Figure 21-22), as well as PPARγ knockdown experiment in SHEP-1 cells clearly indicate 
requirement of PPARγ expression and activation for antineoplastic effects (Figure 18). In line 
with these observations, loss of either PPARγ function (by GW9662-mediated antagonism) or 
expression (by transient knockdown) abrogated Pr-MPO-activated autophagy (Figure 46B, 
Figure 47), a mechanism confirmed by our study to be crucial for mediating cancer cell death. 
We acknowledge that GW9662 did not completely rescue cancer cells from Pr-MPO-
triggered cellular insult (Figure 21). At first glance, this may imply a component of Pr-MPO’s 
cytotoxic effect that is PPARγ-receptor independent. However, we also observed a greater 
extent of protection conferred by PPARγ knockdown (Figure 18) or DBD mutation (Figure 
23), as compared to pharmacological antagonism. Bearing in mind that PPARγ possesses 
basal ligand-independent repression and activation functions (Feige et al., 2006; Pascual and 
Glass, 2006), it is possible that in addition to direct ligation to the LBD, Pr-MPO also 
influences PPARγ’s ligand-independent activation domain. More structural studies will be 
required to confirm this speculation. Besides, it is worth noting that as with most 
pharmacological inhibitors, GW9662 may exert confounding effects unconnected to 
antagonism of PPARγ receptor. In fact, reports have previously demonstrated anticancer 
properties of PPARγ inhibitors mediated by PPARγ-independent reduction of tubulin protein 
levels (Schaefer, 2008; Schaefer et al., 2007). Thus, it is credible that PPARγ antagonism 
endows cells with less chemo-resistance opposed to PPARγ knockdown or loss-of-function 
mutation. 
 
 Despite so, we have ample lines of evidence to justify the claim that PPARγ is a crucial 
determinant and mediator of Pr-MPO-exerted anticancer effects. This is corroborated by data 
derived from breast carcinoma and lymphoma cell line models, as well as clinical samples of 
malignant lymphoma and isolated normal PBMCs (Figure 15, Figure 60). These data show 
that high PPARγ expressions consistently rendered cancer cells more susceptible to Pr-MPO, 
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as opposed to their low-PPARγ-expressing non-cancerous counterparts. When PPARγ was 
experimentally overexpressed in low receptor-expressing cancer cell line T47D, significant 
sensitization to Pr-MPO-mediated receptor activation and antineoplastic effects were 
observed (Figure 9, Figure 14E, Figure 19, Figure 46A), thus highlighting physiological 
relevance of this molecular target.  
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3 Unorthodox anticancer mechanism mediated by Pr-MPO: induction of 
autophagic cell death 
Most previous cases of PPARγ-mediated cell death were designated as apoptosis, which in 
some occasions were preceded by cell cycle arrest. Extensive studies demonstrated the 
induction of PPARγ-dependent apoptosis in thyroid cancer(Kato et al., 2006; Ohta et al., 
2001), colorectal carcinoma(Shimada et al., 2002), non-small cell lung carcinoma (Li et al., 
2006; Satoh et al., 2002), among several other cancers. In classical apoptosis, activation of 
caspases, PARP (caspase-3 substrate) cleavage, and MOMP commonly occur as early signal-
transducing events that precede and are required for eventual full-blown cell death. 
Additionally, pro- and antiapoptotic members of the Bcl-2 family, such as Bax/Bak and Bcl-2 
respectively, represent important players that determine the propensity to MMP and hence 
influence cell fate decisions in apoptosis. In this study, however, our investigations revealed 
prominent differences between the molecular events in Pr-MPO-induced cell death and 
classical apoptosis. Observations that deviate from typical apoptotic cell death are as follows, 
(1) activation of caspase-8 and -9 was consistently minimal (below 2-fold activation) and 
detected only at late stages of cell death (Figure 27-28); (2) nuclear PARP cleavage was 
evident only when substantive cell death has occurred (after 18h of treatment) (Figure 27B); 
(3) PARP cleavage was weak and incomplete, unlike the response induced by apoptotic 
trigger staurosporine (Figure 27B); (3) MMP modulator proteins Bax and Bcl-2 were not 
critically involved in cell death (Figure 30B, Figure 31); (5) pan-caspase inhibitor zVAD-fmk 
only conferred partial protection (Figure 29).  
 
A breakthrough was achieved in unraveling the mechanism of Pr-MPO-induced cell death 
when we observed that Pr-MPO-treated cancer cells displayed a striking autophagic 
phenotype early in the death process and prior to the manifestations of apoptotic hallmarks. 
Pr-MPO-induced autophagosomes formation was evidenced by observation of autophagic 
structures through transmission EM analysis (Figure 35), increased LC3-II levels (Figure 36) 
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and elevated GFP-LC3 punctate staining (Figure 37). Further experiments monitoring 
autophagic flux demonstrated that Pr-MPO-triggered increase in autophagosomes number 
reflects a true upregulation of autophagic activity (Figure 38) rather than downstream defects 
in autophagosomal maturation. Notably, among the methods used to measure autophagic 
activity, immunoblotting of LC3 represents the most widely used technique to monitor 
autophagosomes number. Even though in this study we present immunoblots of both LC3-I 
and LC3-II, only LC3-II is interpreted as the reliable indicator of autophagy. As discussed in 
detail by Mizushima et.al., a comparison of the levels of LC3-II alone between samples of 
different treatment is the most accurate way of measuring autophagy (Mizushima and 
Yoshimori, 2007). It is now known that the anti-LC3 antibody is more sensitive towards the 
detection of LC3-II than LC3-I, possibly because of certain conformational alterations at the 
N-terminal of LC3 after PE conjugation that allows exposure of an antibody-reactive epitope 
(Ichimura et al., 2004; Mizushima and Yoshimori, 2007). Since the detection of LC3-I is less 
sensitive and hence not always accurate, it is not recommended to use the ratio of LC3-II to 
LC3-I (LC3-II/LC3-I), or the ratio of LC3-II to the summation of LC3-I and –II (LC3-II/ 
(LC3-I + LC3-II)) as an indicator of autophagy (Mizushima and Yoshimori, 2007). In our 
study, a clear increase in LC3-II levels was consistently observed with Pr-MPO treatment in a 
variety of cell lines (Figure 36), which was further increased in the presence of lysosomal 
protease inhibitors (Figure 38A), thus demonstrating a genuine increase in autophagic flux.  
 
3.1 Canonical vs. non-canonical autophagy 
Interestingly, Pr-MPO-mediated autophagy is independent of Beclin 1, a tumor suppressor 
protein important for autophagosomes formation (Cao and Klionsky, 2007; Liang et al., 1999; 
Pattingre et al., 2008). This deduction was inferred from the insensitivity of Pr-MPO-induced 
LC3II formation to the knockdown of Beclin 1, which in turn is associated with the inability 
of Beclin 1 knockdown to rescue cancer cells from eventual cell death (Figure 41-42). In line 
with our hypothesis of Beclin 1-indepedendent autophagic cell death, overexpression of Bcl-
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2, which was established to inhibit autophagy by physically interacting with Beclin 1 
(Pattingre et al., 2005), failed to revert cellular demise (Figure 31). Notably, autophagy 
stimulated by C2-ceramide treatment (Figure 41B) in SHEP-1 cells was also unaffected by 
Beclin 1 silencing. It remains to be investigated if the redundancy of Beclin 1 in autophagy 
activation is an inherent feature of SHEP-1 cell line, or/and whether this is a general 
phenomenon applicable for other cancer cell lines.  
 
In fact, in recent years, more experimental data have surfaced to demonstrate “non-canonical” 
autophagy, a process in which autophagosomes formation bypasses the need for Beclin 1 or 
its binding partner hVps34. This alternative form of autophagy was demonstrated in 
neurotoxin-exposed SHSY5Y cells (Zhu et al., 2007), Bcl-XL/Bcl-2 inhibition in HeLa cells 
with a novel compound (Tian et al., 2010), and resveratrol treatment in MCF7 cells (Scarlatti 
et al., 2008). Last year, our laboratory also published findings on non-canonical autophagy 
triggered in HCT116 cells by a novel compound C1 (Wong et al., 2010). In all these cases 
(Scarlatti et al., 2008; Tian et al., 2010; Wong et al., 2010; Zhu et al., 2007), non-canonical 
autophagy was invariantly observed to be independent of both Beclin 1 and hVps34. Same as 
with Beclin 1 silencing, knockdown of hVps34 did not attenuate autophagic activity in these 
studies, and neither did 3-MA treatment, which inhibits the activity of hVps34, had any effect 
(Scarlatti et al., 2008; Tian et al., 2010; Wong et al., 2010). Unlike these reported systems, 
even though Pr-MPO-activated autophagy was Beclin 1-independent, pre-incubation of 
SHEP-1 and MDA-MB-231 cells with class III PI3-K inhibitor 3-MA effectively inhibited 
autophagy induction. Since Beclin 1 and hVps34 are both components of the class III PI3-K 
core complex required for autophagosomes formation, it is interesting that we observed 
dependence of autophagy on hVps34 but not Beclin 1. We infer that it is possible for distinct 
Beclin 1-independent class III PI3-K complexes to exist for autophagosomes formation, 
especially in view of literature reporting that only half of total PI3-K was observed to be 
associated with Beclin 1 during autophagy (Kihara et al., 2001). This speculation is further 
supported by a report demonstrating that MCF-7 cells, in spite of being haploinsufficient in 
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Beclin 1 (Liang et al., 1999), are able to mount Beclin 1-independent autophagic response that 
is reversible by 3-MA (Cheng et al., 2010). We concur that Pr-MPO-mediated autophagy falls 
into neither canonical nor non-canonical form of autophagy, due to concomitant redundancy 
of Beclin 1 and dependence on PI3-K.  
 
3.2 Autophagy induction by Pr-MPO mediates cell kill 
A criticism often levied in the field of autophagy research is that the mere observation of 
large scale autophagosomes formation in dying cells does not qualify for autophagic cell 
death (Eisenberg-Lerner et al., 2009; Kroemer and Levine, 2008). In fact, in glioblastoma 
cells where certain antineoplastic agents, such as temozolomide and SAHA, were initially 
reported to induce autophagic cell death, autophagy stimulation was later found to be a stress-
induced cytoprotective response instead (Kanzawa et al., 2004; Shao et al., 2004). Hence, it is 
still an ongoing conundrum as to whether autophagy induction mediates cell death or 
promotes cell survival in cancer cells. Difficulty in deciphering the exact role of autophagic 
response in cancer cells is compounded by the fact that we still lack highly specific genetic or 
pharmacological inhibitors of autophagy. Currently, the most commonly used 
pharmacological inhibitor of autophagy is 3-MA. However, it is now known that besides 
inhibiting class III PI3-K, 3-MA might also inhibit class I PI3-K (Wu et al., 2010), a negative 
regulator of autophagy. Besides, 3-MA can also affect mitochondrial permeability transition, 
glycogen metabolism, endocytosis and lysosomal acidification (Cao and Klionsky, 2007; 
Punnonen et al., 1994; Xue et al., 2002). Thus, genetic ablation of different Atg genes may be 
a preferred method to achieve higher specificity in autophagy inhibition. Nonetheless, many 
Atg proteins are now discovered to have alternative functions other than mediation of 
autophagy. For example, full-length Atg5 (33 kDa) can be proteolytically cleaved to generate 
a 24 kDa fragment that loses it autophagy-inducing function, and instead translocates to 
mitochondria where it triggers MOMP (Yousefi et al., 2006). Also, Beclin 1 is implicated in 
vesicular trafficking(Cao and Klionsky, 2007); its interaction with Bcl-2 and Bcl-XL also 
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raises theoretical speculations of a putative pro-apoptotic role (Maiuri et al., 2007b; Pattingre 
et al., 2005).  
 
Bearing all these limitations in mind, we rely on not just one, but a combination of methods to 
inhibit autophagy and to evaluate the effect of autophagy inhibition on cell death. Aside from 
the use of 3-MA (Figure 40-41), we knocked down Atg7, ULK1 and Beclin 1 (Figure 43-43). 
Notably, Atg7 knockdown is more specific towards autophagy inhibition than Atg5 
knockdown(Eisenberg-Lerner et al., 2009) because of the autophagy-independent roles of 
Atg5 as mentioned above. Moreover, since Atg7 is indispensable for both conjugation 
systems during membrane elongation, this gene is often a first choice RNAi target for 
autophagy inhibition. Corroborating previous findings (Chan et al., 2007; Komatsu et al., 
2005), ULK1 silencing also blocked autophagic response after Pr-MPO treatment (Figure 43-
43), even though its effectiveness in autophagy inhibition as well as clonogenic rescue was 
somewhat milder compared to Atg7 knockdown. This observed milder phenotypic rescue 
mediated by ULK1 knockdown was consistent with other published studies (Kundu et al., 
2008), plausibly because related isoforms may compensate for its gene deficiency 
(Mizushima et al., 2010).  
 
Consistently, abrogation of autophagy in our model via different approaches invariably 
rescued cancer cells from Pr-MPO-induced cell death (Figure 40, Figure 42). In addition to 
direct methods of autophagy inhibition mentioned above, attenuation of autophagic response 
by loss of PPARγ expression or function (Figure 46B, Figure 47), BNIP3 silencing (Figure 
53), NHE-1 (Figure 51) or MnSOD overexpression (Figure 50) also endowed cancer cells 
with survival advantage in the wake of Pr-MPO treatment. The converse was also observed; 
silencing of Beclin 1, PTEN, RhoB, and HIF1-α, which failed to prevent the induction of 




It is important to note that very often, a delay in the appearance of biochemical death markers 
caused by autophagy inhibition is misconstrued as a rescue from eventual cell death (Kroemer 
and Levine, 2008). In this study, the operational readout of rescue from cell death is not based 
on biochemical events such as DNA degradation or plasma membrane permeabilization. 
Instead, we demonstrate that autophagy invalidation substantially restored metabolic activity 
and clonogenic survival of cancer cells after Pr-MPO treatment, which were assessed by MTT 
and long-term colony-forming assay respectively. In particular, long term clonogenic survival 
is often deemed as the gold standard for attesting cytoprotection from cell death (Thorburn, 
2008). Since our data unambiguously show that inhibition of autophagy mediates a pro-
survival effect in cancer cells, we deduce that the induction of autophagy is required for Pr-
MPO-mediated cell death.  
 
3.3 How does autophagy kill cancer cells? 
An intriguing paradox is that autophagy, although regarded as an alternative form of PCD 
known as type II or autophagic cell death, functions in fact as a stress adaptation response in 
most settings of metabolic or cellular stress. According to Katayama et al., autophagic 
induction following treatment of DNA-damaging agents plays an adaptive pro-survival role to 
mitigate cell death. In that model, autophagic response led to a surge of cytoprotective ATP 
levels, possibly by supplying substrates from catabolized cellular components for oxidative 
phosphorylation (Katayama et al., 2007). This begs the question of whether autophagy was 
first stimulated to salvage the cancer cells from Pr-MPO-mediated cellular insult or was it 
directly triggered to execute cell kill. One possibility is that even if autophagy is originally 
intended as a compensatory cytoprotective response, sustained and massive upregulation of 
this pathway by Pr-MPO paradoxically led to cell death due to excessive self-cannibalism, 
resulting in a complete shutdown of essential cellular functions (Levine and Kroemer, 2008) 
(Figure 64). However, data from our kinetic study of 3-MA treatment after Pr-MPO exposure 
do not seem to support this hypothesis. We observed that autophagy inhibition 2h after Pr-
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MPO treatment was no longer effective in reversing cell death (Figure 43). This 2h time-
point, which marks “the point of no return”, is too short a duration to envisage any massive 
loss of cellular content, considering autophagic activity was first detectable only shortly 
before (at the 90min time-point) (Figure 43D). Hence, we deduce that Pr-MPO-induced 
autophagic cell death is not simply a consequence of achieving certain degree of cellular 
destruction; otherwise, inhibition of autophagy at any time before crossing the quantitative 
threshold of excessive cellular atrophy should still allow the cells to survive (illustrated in 
Figure 64). Moreover, previous reports have demonstrated that cells can lose the majority of 
their mass through autophagy-mediated catabolism and yet still fully recover once returned to 
favorable culture conditions (Degenhardt et al., 2006; Lum et al., 2005a). In sum, self-
cannibalism is unlikely to be the only mechanism governing Pr-MPO-induced autophagic cell 
death.  
 
As mentioned above, we found that LC3-II level first increased 90min after Pr-MPO 
treatment (Figure 43D). Remarkably, inhibition of autophagy by 3-MA at any point before 
but not after this first appearance of LC3-II accumulation was able to avert Pr-MPO-triggered 
cancer cell death. A likely explanation is that once set in motion, autophagy acts as a trigger 
for activating apoptosis. Hence, even when autophagy was inhibited at later stages in the 
course of Pr-MPO treatment (2h onwards), cancer cell fate was already sealed and treated 
cells were destined to die, at least in part via the apoptotic machinery (illustrated in Figure 
64). This hypothesis is further supported by the late appearances of apoptotic hallmarks 
(Figure 27-28), and the observation that pan-caspase inhibitior, zVAD-fmk, granted cancer 





Figure 64: How does autophagy kill cancer cells? 
Illustrated here in the diagram are two possible mechanisms by which Pr-MPO-induced 
autophagy mediates cancer cell death (Mechanism I & II). As shown in Figure 43D, 90min 
marks the first time-point at which activated autophagy is observed. Autophagy inhibition 2h 
prior to and up to 90min after Pr-MPO treatment rescues cells from death, but autophagy 
inhibition 2h after Pr-MPO treatment no longer confers protection (Figure 40, Figure 43). 
Autophagy-mediated signaling to apoptotic or other executioner machinery (Mechanism I) is 
likely to be the key mechanism of autophagic cell death in this model (see description
1
 above 
for details).  
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3.4 The crosstalk between autophagy and apoptosis 
3.4.1 Pr-MPO-induced autophagy is required for apoptotic features and is 
independent of caspase activation  
As reviewed in the introductory section, the intricate connection between autophagy and 
apoptosis is fascinatingly complex. Depending on the cellular context and stimulus, 
autophagy may be imperative for triggering apoptosis, or it may, instead, antagonize or inhibit 
apoptosis (Figure I). In other instances, these two pathways are activated in a mutually 
exclusive manner, thereby serving as backup mechanisms to each other to ensure failsafe 
execution of cellular demise (Gozuacik and Kimchi, 2004) (Figure I). What is of particular 
relevance to our study, however, is the postulation that autophagy may be activated as a 
primary response that is indispensable for the activation of the apoptotic pathway (Maiuri et 
al., 2010) . We observe here that Pr-MPO-induced autophagy (Figure 36) preceded the 
appearance of apoptotic hallmarks (caspase activation, cytochrome c release, Bax 
translocation, DNA fragmentation, PARP cleavage). Importantly, inhibition of autophagy by 
both 3-MA and Atg7/ULK1 silencing abolishes PARP cleavage (Figure 44A-B). Prevention 
of caspase activation with zVAD-fmk, on the other hand, did not affect autophagy (Figure 
44C). These findings corroborate several previous studies showing that autophagy can be 
required for apoptosis (Canu et al., 2005; Guimaraes et al., 2003; Hoyer-Hansen et al., 2005; 
Jia et al., 1997; Uchiyama, 2001; Xue et al., 1999). For example, HIV-1 envelope 
glycoproteins (Env) induced autophagy in CD4/CXCR4-expressing T cells, followed by 
apoptosis; inhibition of autophagy totally abrogated cell death and apoptotic features 
including caspase 3 activity. Analogous to our findings, zVAD-fmk partially protected T cells 
from cell death, even though it did not affect autophagy induction. In another case, 
constitutive induction of autophagy by enforced expression of Atg1 also triggered cell death, 





In view of the observation that zVAD-fmk endowed cells with partial protection (Figure 29), 
it is likely that caspase-dependent apoptosis is at least in part responsible for Pr-MPO’s 
cytotoxic effect. Pr-MPO-mediated cell death, however, should not be characterized as 
classical apoptosis due to at least two reasons. Firstly, the induction of apoptotic features 
requires autophagy. Secondly, autophagy inhibition granted cancer cells with near complete 
protection (Figure 40, Figure 42), unlike caspase inhibition which provided only partial 
resistance (Figure 29). Thus, it seems likely that autophagy causes cell death by mechanisms 
other than activating the apoptotic machinery. Furthermore, we provide unprecedented 
experimental evidence with kinetic inhibition of autophagy (Figure 43) to show that once 
activated, Pr-MPO-induced autophagy commits cancer cells towards cellular demise.  
 
Currently, one unanswered question concerns how exactly does autophagy activate the 
apoptotic machinery? This enigma continues to baffle researchers in the field, but two studies 
have proposed lysosomal proteases, particularly cathepsins, as the molecular link between 
autophagy and apoptosiss (Bhoopathi et al., 2010; Uchiyama, 2001). Both studies agree that 
active autophagy results in the induction of cathepsins expression or activity, which is 
required for downstream activation of apoptotic cell death. Inhibition of autophagy was 
shown to abolish cathepsin activity as well as apoptotic features. The discrepancy between 
these two studies however, lies in the type of cathepsin involved; Uchiyama claimed that 
cathepsin D (aspartic proteinase) is the death effector, which can be inhibited by cathepsin B 
(cysteine proteinase) (Uchiyama, 2001), while Bhoopathi et al. proposed cathepsin B as the 
death-inducing factor (Bhoopathi et al., 2010). Further investigation will be required to test if 




4 Novel role of PPARγ activation in regulation of autophagy 
4.1 PPARγ expression and transcriptional function are required for 
autophagy 
It is significant to note that this is the first study providing direct evidence of autophagic cell 
death induced by an activator of PPARγ. To the best of our knowledge, only four studies have 
reported activation of autophagy after treatment of cancer cells with 15d-PGJ2 (Butler et al., 
2000) and TZDs (Wei et al., 2010; Yan et al., 2010; Zhou et al., 2009). These reports, 
however, fail to avoid two major pitfalls in autophagy research. Firstly, in the studies by Shuo 
et al., Butler et al., Zhou et al., only an increase in autophagosomes number were shown by 
transmission EM or LC3-II accumulation. No experiments monitoring autophagic flux were 
conducted to show a true upregulation of autophagic activity. Secondly, most studies showed 
that PPARγ agonists activated autophagy, followed by cell death, but did not show the exact 
role of autophagy in cellular demise. In fact, there was no experimental data to demonstrate if 
autophagy was the cause of cell death in those models. The only attempt to study the role of 
autophagy in cell death was made by Wei et al (Wei et al., 2010). In that study, ectopic 
expression of dominant-negative AMPK suppressed drug-induced anti-proliferative effects, 
which was claimed by the authors to demonstrate the requirement of autophagy for cell death. 
However, since AMPK has functions in many other cellular processes other than autophagy, 
more specific methods of autophagy inhibition such as Atg silencing would have been 
preferred. Besides these four papers, a fifth study showed that 15d-PGJ2 induced non-
apoptotic cell death characterized by non-autophagic cytoplasmic vacuolation and ER 
dilatation(Kar et al., 2009). As opposed to Pr-MPO-increased cytoplasmic vacuoles 
containing partially degraded cytoplasmic materials (Figure 35), 15d-PGJ2 induced vacuoles 
in this particular study appeared completely clear and carried no visible cellular material (Kar 
et al., 2009). Interestingly, a non-autophagic function of LC3 appeared to be crucial for cell 




Among these previous studies, only Zhou et al. demonstrated involvement of PPARγ 
activation in autophagy (Zhou et al., 2009). According to the authors, enforced expression of 
constitutively active mutant PPARγ cDNA in MCF10a cells induced autophagy, based on an 
increased number of cells forming acidic vesicular organelles detected by acridine orange 
staining. Unfortunately, acridine orange staining is a poor choice of method as acidic vacuoles 
are not direct indicators of autophagosomes. Here, with the use of varied autophagy-specific 
techniques, we provide direct evidence establishing a critical role of PPARγ for autophagy 
induction. We observed that endogenous expression level of PPARγ was predictive of Pr-
MPO-induced autophagic response in at least two different models (Rajiv vs. PBMCs, and 
MDA-MB-231 vs. MCF10a) (Figure 45). Moreover, we showed that modulation of PPARγ 
levels has a direct effect on Pr-MPO-induced autophagy; PPARγ knockdown with either 
shRNA or siRNA both attenuated autophagic response, while PPARγ overexpression 
enhanced autophagic activity (Figure 46). Lastly, specific inhibitor of PPARγ, GW9662, 
efficiently abrogated autophagy activated by Pr-MPO, as determine by four different 
experimental techniques (transmission EM, GFP-LC3 punctate staining, LC3-II formation, 
p62 degradation, Figure 47). Our data contrast against previous findings of troglitazone-
induced autophagy, which was allegedly independent of PPARγ. The authors showed that 
pre-incubation of cells with GW9662 antagonist did not affect troglitazone-induced LC3-II 
accumulation (Yan et al., 2010). An obvious question would be, why do Pr-MPO and 
troglitazone induce PPARγ-dependent and –independent autophagy, respectively, when they 
are both activators of PPARγ? This might be explained by the different models in which these 
observations are made; while Pr-MPO-induced autophagy was observed in PPARγ-
overexpressing cancer cells, troglitazone-induced PPARγ-autophagy was demonstrated in 
non-cancerous PAE (porcine aortic endothelial) cells. Thus, it is probable that autophagy 
induction represents an off-target effect of troglitazone (through activation of AMPK) in 





4.2 Critical involvement of PPARγ-target genes in autophagy: a novel finding 
Autophagy inhibition by PPARγ antagonism suggests that Pr-MPO-induced autophagy is 
dependent upon transcriptional function of the nuclear receptor. Hence, we explored the 
possibility of PPARγ target genes being involved in the autophagic pathway. In our panel of 
six cancer-relevant PPARγ signature targets, PTEN, BNIP3, HIF1-α and MnSOD have been 
implicated in the regulation of autophagy by previous studies (Arico et al., 2001; Bellot et al., 
2009; Chen et al., 2009; Chiavarina et al., 2010) , whereas the role of NHE-1 and RhoB in 
autophagy have never been addressed. In this study, RNAi-directed silencing of BNIP3, 
PTEN, RhoB and HIF1-α, as well as enforced expression of NHE-1 and MnSOD overrode 
PPARγ-mediated modulation of these target genes expression (Figure 48A.II, Figure 48B.II, 
Figure 49A.II, Figure 50A.II, Figure 51A.II, Figure 52A.II) to an effect similar to that 
achieved by PPARγ antagonism with GW9662 (Figure14A). We observed that BNIP3-
silenced SHEP-1 cells phenocopied those pre-incubated with GW9662 (Figure 53, Figure 47), 
in which Pr-MPO-induced autophagic cell death was strongly inhibited. Moderate protective 
effect against autophagic cell death was also attained by enforced expression of NHE-1 and 
MnSOD, respectively (Figure 50-51). Conversely, knockdown of PTEN, HIF1-α and RhoB 
did not attenuate Pr-MPO-activated autophagy, which in turn was associated with the inability 
of these target genes silencing to rescue cancer cell death (Figure 48-49). 
 
4.2.1 Challenging the predefined role of PTEN as a positive regulator of 
autophagy 
Previously, Arico et al. showed that overexpression of wildtype PTEN abolished interleukin-
13 (IL-13)-mediated downregulation of autophagy in HT29 colorectal carcinoma cells (Arico 
et al., 2001). The authors also observed that this specific effect of PTEN overexpression was 
dependent upon its lipid phosphatase function, which is known to antagonize the PI3-K/PKB 
pathway (Downes et al., 2001). Since the activation of class I PI3-K-Akt-mTOR pathway 
suppresses autophagy, it is conceivable that PTEN positively regulates autophagy by 
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inhibiting class I PI3-K/Akt activation. At first glance, our negative findings on the role of 
PTEN appear inconsistent with the previous study. Upon closer scrutiny, we remarked a 
significant aspect of their study which might explain the apparent disagreement between our 
findings and theirs. It was demonstrated that PTEN overexpression mitigates IL-13-induced 
downregulation of basal autophagy in HT29 cells. Notably however, PTEN overexpression 
alone did not increase basal activity of autophagy as indicated by the reported experiments of 
long-lived protein degradation and autophagic sequestration of lactate dehydrogenase. It is 
thus likely that Pr-MPO-induced autophagy was not mediated by an upregulation in PTEN 
expression, akin to enforced overexpression in that system. In fact, even though adenovirus-
mediated transfer of PTEN was previously shown to exert in vitro and in vivo antitumor 
effects on malignant glioma and prostate cancer (Cheney et al., 1998; Davies et al., 2002), 
until now no experimental evidence is available to demonstrate modulations of autophagy by 
PTEN upregulation per se.  
 
4.2.2 Uncoupling the functions of HIF1-α and BNIP3 in autophagy induction 
The irrelevance of HIF1-α in Pr-MPO-induced autophagic activity is surprising, in view of an 
earlier study showing that rosiglitazone-induced autophagy in MDA-MB-231 cells was 
blocked by silencing of HIF1-α (Zhou et al., 2009). Abundant literature show that HIF1-α is a 
well-established mediator of hypoxia-induced autophagy via induction of BNIP3/BNIP3L 
(Mazure and Pouyssegur, 2010; Zhang et al., 2008); both BNIP3 and BNIP3L contain a 
functional HIF-1-responsive element (HRE) in their promoter regions, thus enabling induced 
expression of these proteins under hypoxic conditions or upon enforced expression of HIF1-α 
(Bruick, 2000). Since HIF1-α mediated autophagy is largely dependent upon BNIP3/BNIP3L 
induction, it is possible that HIF1-α may be rendered redundant if another regulator is in place 
to potently induce BNIP3/BNIP3L. We postulate that upon Pr-MPO treatment, PPARγ, 
instead of HIF1-α, is the dominant transcription factor upregulating BNIP3 expression, which 
in turn is critically involved in the regulation of autophagy. This speculation is based on a few 
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experimental observations; even though BNIP3 knockdown efficiently inhibited autophagy 
induced by Pr-MPO, silencing of HIF1-α had no inhibitory effect, implying that BNIP3 is 
induced by another transcriptional factor in the absence of HIF1-α. Additionally, 
transcriptional upregulation of BNIP3 preceded induction of HIF1-α after Pr-MPO treatment 
(Figure 12C-D). Lastly, our sequence alignment analysis revealed the presence of a PPRE in 
the promoter region of BNIP3 (Table 3), which corroborates previous reports of TZDs driving 
luciferase activity of BNIP3-promoter-luciferase reporter (Zhou et al., 2009). Further studies 
are required to determine if PPARγ activation by Pr-MPO exerts a similar inductive effect on 
BNIP3L, a homologous gene of BNIP3. Perhaps double knockdown of BNIP3 and BNIP3L 
could endow cells with complete resistance against Pr-MPO-induced autophagic cell death.  
 
4.2.3 BNIP3, NHE-1 and MnSOD are newly identified molecular effectors of 
PPARγ-regulated autophagy 
Identification and experimental validation of BNIP3, MnSOD and NHE-1 as molecular links 
between PPARγ activation and the autophagic pathway constitutes a major contribution of 
this study. These findings are significant because therapeutic modulation of BNIP3, MnSOD 
and NHE-1 by Pr-MPO represents a more cancer-specific approach of inducing autophagy, 
instead of targeting ubiquitous core autophagic components that can also affect basal 
autophagy in normal cells. Interestingly, we observed that even though mitigation of PPARγ’s 
effects on MnSOD and NHE-1 through enforced expression of these two target genes did 
confer cancer cells with resistance to autophagic cell death (Figure 50-51), their inhibitory 
effects were not as pronounced as that mediated by BNIP3 silencing (Figure 52-53). We 
speculate that BNIP3, being upregulated in a rapid yet sustained manner throughout Pr-MPO 
treatment (Figure 12C), plays an indispensable role in the potent and prolonged induction of 
PPARγ-dependent autophagic activity. Meanwhile, downregulation of MnSOD and NHE-1 
was only observed at certain phases during Pr-MPO treatment (Figure 12E-F). Thus, 
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downregulation of these two genes may exert a cooperative function, rather than acting as 
dominant inducers of autophagy.  
4.2.3.1 BNIP3 is a primary modulator of PPARγ-dependent autophagy 
To date, the primary hypothesis raised to account for BNIP3-induced autophagy is its ability 
to displace Beclin 1 from Bcl-2 and Bcl-XL, hence relieving Beclin 1 from its inhibitory 
association with these proteins to form autophagic-specific class I PI-3K complexes (Bellot et 
al., 2009). It would hence be particularly interesting to address the paradoxical requirement of 
BNIP3 in Beclin 1-independent autophagy induced by Pr-MPO. Another possibility proposed 
in literature claims that BNIP3 may trigger mitochondrial depolarization and dysfunction, 
which in turn accumulates ROS, leading to autophagy (Scherz-Shouval and Elazar, 2011). 
This is unlikely to be relevant to our model due to the absence of discernible ROS production 
at the point of autophagy induction (Figure 56-57). A third suggested mechanism is based on 
the ability of BNIP3 to bind and inhibit Ras Homolog Enriched In Brain (RheB), an upstream 
activator of mTOR, thereby inhibiting mTOR activity and inducing autophagy (Li et al., 
2007). Future studies determining if BNIP3 operates in a similar mode in Pr-MPO-mediated 
autophagy are essential requisites for deeper molecular understanding.  
 
4.2.3.2 MnSOD downregulation is required for PPARγ-dependent autophagy 
With regards to MnSOD overexpression, our findings corroborate a previous study by Chen 
et al. demonstrating that MnSOD overexpression attenuated autophagy and cell death induced 
by mitochondrial electron transport chain inhibitors (Chen et al., 2007). As MnSOD is an 
anti-oxidant enzyme responsible for converting mitochondrial O2
·-
 to H2O2, the authors argue 
that O2
·- 
is the specific ROS species implicated in autophagy induction. Hence, synonymous 
with PPARγ-downregulation of MnSOD expression in our study, MnSOD inhibition with 2-
methoxyestradiol (2-ME) in HEK293, U87 and HeLa cells induced autophagy (Chen et al., 
2008). Given that mitochondrial O2
·- 
production was not detected in SHEP-1 cells after Pr-
MPO treatment, it seems unlikely that the O2
·-
-dependent mechanism is operative in our 
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system. Nevertheless, more experiments assessing total intracellular O2
·- 
levels (such as 
lucigenin assay) are required to definitively rule out this possibility. Very recently, another 
research group claimed that overexpression of MnSOD, instead of conferring protection, 
induced premature senescence and subsequently autophagic cell death in young keratinocytes 
(Deruy et al., 2010). These reported findings contrast against ours, where MnSOD 
overexpression exerted an inhibitory effect on PPARγ-activated autophagic response in 
cancer cells; also, we did not observe an upregulation of basal autophagy upon MnSOD 
overexpression alone (Figure 50A). One plausible explanation is that modulations of an 
intracellular antioxidant defense such as MnSOD might trigger a response in cancer cells that 
is different from non-transformed cells, since cancer cells inevitably acquire changes in their 
intracellular redox balance during the process of transformation. Then again, in the 
keratinocytes model, MnSOD overexpression was only shown to induce senescence followed 
by cell death, which the authors infer to be executed via autophagic induction based on their 
correlative observations of H2O2-induced autophagic cell death (Deruy et al., 2010). Hence, 
more direct experimental evidence is required before accurate interpretations could be made 
pertaining to the actual effect of MnSOD overexpression on autophagy in keratinocytes.  
 
4.2.3.3 NHE-1 downregulation is required for PPARγ-dependent autophagy 
On the other hand, ours is the first study to demonstrate a regulatory role of NHE-1 in 
autophagy. One intuitive mechanism by which NHE-1 repression positively regulates 




 across the 
plasma membrane (Pedersen, 2006), hence allowing intracellular acidification and formation 
of autolysosomes. A second postulation is premised on the knowledge that interaction of 
NHE-1 with phosphorylated ezrin/radixin/moesin (ERM) proteins recruits PI3-K and 
activates downstream Akt/PKB pathway (Wu et al., 2004). In line with this notion, inhibition 
of NHE-1 was found to antagonize Akt/PKB (Cho et al., 2005), which might provide 
mechanistic explanations for NHE-1 downregulation-mediated autophagy.  
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In summary, by narrowing the search on downstream PPARγ-regulated effector proteins from 
a plethora of transcriptional targets down to three molecules, findings from this study pave the 




5 Further insights into clinical potential of Pr-MPO as a novel PPARγ-
targeted anticancer compound 
For a substantial part of this study, we have capitalized on PPARγ-activating properties of a 
novel compound to decipher a different facet of PPARγ biology in regulating cancer cell 
death. Clearly, Pr-MPO is a valuable addition to the present artillery of drug-based models 
aimed at furthering mechanistic understanding of PPARγ and autophagy regulation. In 
parallel however, we are also interested in unveiling its therapeutic potential as a drug 
candidate or lead compound for cancer treatment. As with all other newcomer drug 
compounds, there is an imperative need to compare Pr-MPO against known agonists of 
PPARγ in in vitro studies before any application in the clinical setting can be envisaged.  
 
5.1 Pr-MPO holds promise as a new generation PPARγ-activator with 
improved efficacy and reduced toxicity 
In general, we recognize three shortcomings encountered with the use of TZDs and 15d-PGJ2 
in cancer therapeutics and cancer biology research. Firstly, many of the studies demonstrating 
PPARγ activation and antiproliferative effects of TZDs and 15d-PGJ2 were conducted in 
serum-depleted experimental conditions. In some cases, cells were incubated in serum-free 
medium for designated number of hours before drug treatment in the absence of serum 
(Butler et al., 2000; Kang et al., 2008; Kwon et al., 2008; Lin et al., 2007; Rohn et al., 2001). 
In other studies, normal FBS was replaced by charcoal-stripped FBS (Armoni et al., 2003; 
Gupta et al., 2001; Sarraf et al., 1998). Charcoal treatment of serum serves to remove steroids 
(Darbre et al., 1983), as well as reduce levels of estradiols and prostaglandins (Product sheet, 
Hyclone) . Theoretically, the presence of high levels of prostaglandins in normal FBS triggers 
constitutive activation of PPARγ in cancer cells, thus masking the effect of TZDs or 15d-PGJ2 
treatment. In addition, a published report showed that the effect of 15d-PGJ2-induced PPARγ 
activation and cell viability loss in neuroblastoma cells was much more pronounced in 
delipidated media (media with delipidated Fetal Calf Serum, FCS) than in complete media 
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supplemented with normal FCS (Rodway et al., 2004). The authors identified 
lysophosphatidic acid (LPA) as the lysolipid responsible for limiting 15d-PGJ2-induced 
PPARγ activation through a Gi/PI3-K/MEK/MAPK-dependent pathway. Consistent with 
Rodway et al.’s observations, our data revealed that both 15d-PGJ2 and ciglitazone failed to 
stimulate PPARγ activation in SHEP-1 cells cultured in complete media (Figure 58C, Figure 
59A). Once FBS content was lowered from 10 to 0.5% (of total media volume), we witnessed 
a restored activation of PPARγ receptor after drug treatment (Figure 59A). Clearly, as shown 
by others and our study, the efficacy of known PPARγ agonists is limited by the presence of 
serum. This limitation poses a serious and valid concern because manipulations of in vitro 
culture conditions may exert confounding effects on cancer cell growth and cellular response. 
For example, serum withdrawal or serum delipidation alone have been shown to trigger 
spontaneous differentiation of neuroblastoma cells, even in the absence of additional drug 
treatment (Evangelopoulos et al., 2005; Monard et al., 1977). In our laboratory, we observed 
that SHEP-1 cells do not tolerate serum-deprived conditions well, as evidenced by changes in 
the cell cycle profile (Figure 59B). Furthermore, even if the in vitro setting can be optimized 
to allow healthy growth of cultured cells in serum-manipulated conditions, data yielded may 
not reflect effectiveness in vivo, where the balance of lysolipids in cancer milieu are most 
likely variable. In view of these considerations, Pr-MPO, efficacy of which is proven in 
physiological culture conditions, is preferred over known agonists due to its infallibility in 
different serum conditions (Figure 59C).  
 
The second disadvantage of conventional TZDs and 15d-PGJ2 is that high concentrations of 
these compounds are required to exert antiproliferative effects on cancer cells (Figure 54), 
due to their low potency in complete media (10% FBS). In the present study, the same extent 
of cell kill achieved by 5µM of Pr-MPO required approximately 100µM of Ciglitazone, 
200µM of Rosiglitazone and more than 20µM of 15d-PGJ2. To circumvent the problem of 
narrow therapeutic index commonly associated with compounds requiring high doses, Pr-
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MPO may be favored for cancer therapeutics because of its efficacy at low concentrations 
(IC50 ~ 10µM with 24h treatment).  
 
Thirdly, PPARγ agonists are well-known potent inducers of oxidative stress (Kondo et al., 
2001; Lennon et al., 2002). Mounting experimental evidence show that some of the 
antineoplastic effects are intricately linked to these compounds’ ability to stimulate ROS 
production (Kang et al., 2008; Kim et al., 2007; Narayanan et al., 2003). Granted, ROS 
induction is a legitimate therapeutic strategy for cancer treatment by exploiting the 
vulnerability of transformed cells to increased oxidative stress (Ahmad et al., 2004; Hileman 
et al., 2004). However, the concern posed by known TZDs and 15d-PGJ2 is the indiscriminate 
production of ROS that is independent of PPARγ. Colossal ROS production that is 
unregulated by PPARγ undermines the initial premise of targeting PPARγ-overexpressing 
tumors with these compounds. Consistent with previous results (Lennon et al., 2002; Wang 
and Mak, 2011), our study shows that both TZD and 15d-PGJ2 treatment give rise to elevated 
levels of ROS/RNS in the absence of PPARγ activation (Figure 56-58). Of note, a dose-
response assay revealed that increased concentrations of these compounds progressively 
increased ROS/RNS generation (Figure 56C), evoking the conjecture that effective working 
doses of these compounds, which are considerably high, will inevitably trigger oxidative 
stress. In fact, these established agonists of PPARγ trigger massive ROS production even in 
non-PPARγ-expressing normal cells (Jozkowicz et al., 2008; Li et al., 2001; Narayanan et al., 
2003). This phenomenon is surmised to account for troglitazone-induced hepatotoxicity even 
though PPARγ is usually not expressed at functionally relevant levels in normal liver (Deng 
et al., 2009; Julie et al., 2008; Narayanan et al., 2003). Moreover, speculations of TZDs-
altered mitochondrial oxidative metabolism and ROS production leading to carcinogenesis 
warrants serious considerations (Scatena et al., 2008). Remarkably, cytotoxic concentrations 
of Pr-MPO did not trigger ROS/RNS formation; and our dose response assay revealed that 
this compound may even have an antioxidant function (Figure 56-57). This ows perhaps to 
the presence of a lanthanide in the structure of Pr-MPO, because lanthanides are reportedly 
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able to suppress iron uptake and inhibit ROS production as reviewed in our introduction 
(Kostova, 2005). Generally, not only would the clinical use of Pr-MPO evade the pleiotropic 
detrimental effects of uncontrolled ROS production, this compound also provides a useful 
tool for studying PPARγ biology without the confounding effects of receptor-independent 
ROS generation.  
 
5.2 Recapitulating antitumor effects of Pr-MPO in different pre-clinical 
models: relevance for human cancer  
Encouraged by the promising findings obtained with cultured human cancer cell lines, we 
sought to establish the antineoplastic potential of Pr-MPO in translational models. Earlier in 
this study, we observed that Raji and Jurkat lymphoma cell lines overexpressed PPARγ 
receptor relative to normal PBMCs, rendering them susceptible to Pr-MPO’s lethal effects 
(Figure 16D). Clinical samples of malignant lymphoma derived from patient biopsies (n = 3) 
confirmed these important findings, demonstrating potent cytotoxicity of Pr-MPO in PPARγ-
expressing clinical lymphoma cells (Figure60), unlike its marginal effect on normal PBMCs 
at the same concentrations (Figure 16D). Substantiating our data obtained from cell lines 
(Figure 45A-B), Pr-MPO exhibited tumor-selective activity in clinical samples with specific 
induction of autophagy in malignant lymphoma cells but not in PBMCs (Figure 61). Taken 
together, our translational model based on patient samples of malignant lymphoma 
recapitulated the key findings in transformed cell lines, reiterating the clinical potential of Pr-
MPO as a cancer-specific chemotherapeutic agent.  
 
Furthering our work in cultured cell lines and clinical samples, our colleagues in the 
laboratory assessed the antitumor effects of Pr-MPO treatment in vivo. Previously, a HT29 
colorectal xenograft study conducted by Choi et al. showed that 15mg/kg dose of pioglitazone 
induced rather than suppressed tumor growth (Choi et al., 2008). It was not addressed in that 
study if pioglitazone-promoted tumorigenic effect is PPARγ-dependent, or rather a PPARγ-
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off target adverse event. In contrast, others have shown that in vivo oral administration of 
200mg/kg troglitazone exerted antitumor effect on transplanted human colon carcinoma in 
nude mice (Sarraf et al., 1998). In our present study, both tested doses of Pr-MPO (100µg and 
200µg/mouse) inhibited HCT116 tumor growth, with 200µg Pr-MPO/mouse demonstrating 
greater efficacy (Appendix A). Almost 80% reduction in tumor volume was attained with 
intraperitoneal administration of Pr-MPO 200µg/mouse (approximately 13mg/kg, 
corresponding to 75µM, IC50 for HCT116, Figure 16B). Modulation of PPARγ target genes in 
Pr-MPO-treated tumors suggests that PPARγ is functionally activated in response to the novel 
compound (figure 63), corroborating in vitro receptor activation by Pr-MPO in HCT116 cell 





Figure 65: Pr-MPO, a potent activator of PPARγ, induces a variant paradigm of cell 




The development of PPARγ agonists has witnessed a conspicuous shift towards non-TZD-
related compounds in a bid to overcome the multitude of problems associated with this class 
of agents. In this study, we have identified a novel and potent small-molecule activator of 
PPARγ, namely, Pr-MPO. The presence of praseodymium, a lanthanide metal, in the 
coordination complex of Pr-MPO confers this compound a unique structure that is distinct 
from the TZDs. It is now known that structurally unrelated activator compounds can bind 
PPARγ receptor in different ways, triggering differential cofactor displacement and 
recruitment, thus eliciting dissimilar in vitro and in vivo effects. Indeed, relative to classical 
TZDs and naturally-occurring ligand 15d-PGJ2, Pr-MPO is remarkably more potent and its 
efficacy is unaffected by circulating lipids and serum. Importantly, Pr-MPO does not induce 
ROS/RNS production, which is wantonly stimulated by 15d-PGJ2 and TZDs in a PPARγ-
unregulated manner that was found to be detrimental to low-PPARγ-expressing normal 
tissues.  
 
Significantly, the identification of Pr-MPO also presents an invaluable tool for the studies of 
PPARγ-regulated physiological pathways without the confounding effects of ROS/RNS 
inevitably associated with TZDs and 15d-PGJ2 treatment. With the use of Pr-MPO in this 
study, we examined previously unreported physiological effects of PPARγ activation in a 
cancer model. Our data demonstrate potent tumoricidal activity of Pr-MPO in a variety of 
PPARγ-overexpressing cancer cells, with minimal effects on normal cells harboring low 
PPARγ expression. Contrary to previous reports demonstrating apoptosis and cell-cycle arrest 
as lethal mechanisms mediated by PPARγ agonists, we observed that apoptotic characteristics 
occurred only as accompanying features of Pr-MPO-induced cancer cell death. Further 
investigations yielded clear evidence to show that autophagy is required and responsible for 
cellular demise in the wake of Pr-MPO treatment. As with several other published drug 
models, autophagy in our model is independent and upstream of apoptosis, and inhibition of 
autophagy abolishes apoptotic features such as PARP cleavage. Our findings thus exemplify 
the intricate crosstalk between autophagy and apoptosis, reiterating the concept of autophagy 
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as a legitimate mechanism of cell kill. Moreover, the ability of Pr-MPO, a potent PPARγ 
activator, to induce autophagic cell death hinted at a potential regulatory link between PPARγ 
activation and autophagy induction. In this respect, ours is the first model showing PPARγ as 
a critical determinant for drug-induced autophagic response. Furthering this, our study 
outlined a mechanism by which PPARγ activation regulates autophagy by transcriptionally 
up- or down-regulating a panel of effector genes. In particular, BNIP3, MnSOD and NHE-1 
were identified as PPARγ transcriptional targets critical for Pr-MPO-induced autophagic cell 
death. These findings pave the way for future requisite work focused on deciphering the exact 
molecular basis by which PPARγ-regulated BNIP3, MnSOD and NHE-1 dictate autophagic 
response.  
 
Taken together, our findings from a combination of neuroblastoma, lymphoma, breast 
carcinoma and colorectal carcinoma models suggest the strong possibility that clinical 
benefits of Pr-MPO treatment would not be restricted to one but several PPARγ-expressing 
cancer types. In view of the clinical and experimental value of this compound, Pr-MPO 
represents an attractive prototypical lead compound, based on which improved or enhanced 
PPARγ agonists may be synthesized. In particular, the discovery of Pr-MPO-induced 
autophagic cell death that is Bax-, Bcl-2-, and caspase-independent indicate that this 
compound could be therapeutically useful in cancers defective in the canonical signaling 
pathways leading to apoptosis. In addition to demonstrating clinical benefit as a single-agent, 
Pr-MPO might also be a valuable adjuvant in combination therapies, sensitizing cells to 
classical PCD via autophagic induction. By establishing a functional link between PPARγ 
activation and autophagy induction, this pilot study lays the foundation for future studies 
deciphering Pr-MPO-induced death pathway, the understanding of which is fundamental for 
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Appendix A: Pr-MPO exerts potent antitumor effect in vivo. 
(A) Experimental design of xenograft model: nude mouse (nu/nu, female, 5- to 6-week-old) 
was injected subcutaneously in the left dorsal flank with 5 x 10
6
 HCT116 cells. When the 
tumors reached around 50mm
3
, the mice received either vehicle (water) or Pr-MPO treatment 
at a dosage of 100 or 200µg/mouse intraperitoneally. Injections were repeated as indicated 
above. (B) Average tumor volume of vehicle-treated versus 100µg or 200µg Pr-MPO-treated 
nude mice throughout the course of study. **, p < 0.05 compared with average tumor volume 
of vehicle control group at the end of the study (day 16). (C) At the end of the 16-day 
treatment, the nude mice were killed and the tumors formed were removed. Xenograft tumors 






Appendix B: Inhibition of PPARα by MK886 fails to protect SHEP-1 cells from Pr-
MPO-induced cell death. 
SHEP-1 cells were preincubated with MK886 0 or 3µM for 2h before treatment with Pr-MPO 
5µM for 24h. Cell viability was determined by MTT assay and expressed as % of untreated 







Appendix C: Pr-MPO induces phosphorylation of JNK and ERK kinases.  
SHEP-1 cells were treated with Pr-MPO at 0, 5, or 10µM for indicated durations. Total cell 
lysates were subjected to Western blotting for detection of phosphorylated-JNK (p-JNK), 
total JNK, phosphorylated-ERK (p-ERK) and total ERK. β-actin was included as a loading 





Appendix D: Pr-MPO does not affect the expression level of phosphorylated-PPARγ in 
SHSY5Y.  
SHSY5Y cells were treated with Pr-MPO at 0, 5, or 10µM for indicated durations. Total cell 
lysates were subjected to Western blotting for detection of phosphorylated-PPARγ (p-PPARγ) 
and total PPARγ protein levels. β-actin was included as a loading control.  
 
 
 
 
 
 
